The New York State Cancer Registry
Facility Reporting Manual

2022 - Edition

The New York State Department of Health
Table of Contents

ACKNOWLEDGEMENT
PART ONE – OVERVIEW
PART TWO – CONFIDENTIALITY
PART THREE - REPORTABLE CONDITIONS AND TERMINOLOGY
PART FOUR - DATA ITEMS AND DESCRIPTIONS
PART FIVE - CASEFINDING
PART SIX - DEATH CERTIFICATE ONLY AND DEATH CLEARANCE LISTS
PART SEVEN – QUALITY ASSURANCE
PART EIGHT – ELECTRONIC REPORTING
APPENDIX A - NYS PUBLIC HEALTH LAW
APPENDIX B – HIPAA INFORMATION
ACKNOWLEDGEMENT

We wish to acknowledge the Centers for Disease Control and Prevention's (CDC) National Program of Cancer Registries (NPCR) and the National Cancer Institute’s (NCI) Surveillance Epidemiology and End Results program (SEER) for their support. Production of this Reporting Manual was supported in part by a cooperative agreement awarded to the New York State Department of Health by the NPCR and a contract with SEER. Its contents are solely the responsibility of the New York State Department of Health and do not necessarily represent the official views of the CDC or NCI.
Page Left Blank Intentionally
New York State Cancer Registry Reporting Manual

Part One – Overview

1.1 WHAT IS THE NEW YORK STATE CANCER REGISTRY? .......................... 1
1.2 WHY REPORT TO THE NYSCR? ................................................................. 1
1.3 WHO REPORTS? ............................................................................................. 2
1.4 RECIPROCAL AGREEMENTS ....................................................................... 3
1.5 WHAT INFORMATION IS COLLECTED ABOUT PATIENTS WITH CANCER? .... 3
1.6 HOW ARE THE CANCER CASE REPORTS SENT AND PROCESSED? .......... 4
   1.6.1 Flow of data from reporting facilities through the NYSCR .................. 5
1.7 WHAT IS DEATH INFORMATION PROCESSING? ........................................ 6
1.8 FILE RETENTION ........................................................................................... 6
1.9 ARE THERE OTHER MEASURES OF QUALITY APPLIED TO THE CANCER
    REGISTRY? .................................................................................................... 7
1.10 UNDER WHAT CIRCUMSTANCES IS INFORMATION CORRECTED OR
    CHANGED? ........................................................................................................ 7
   1.10.1 What to Change .................................................................................... 8
   1.10.2 When to Submit Changes ..................................................................... 8
   1.10.3 Quality Control .................................................................................... 8
1.11 ARE THERE NATIONAL CANCER DATA OR DATA FROM OTHER STATES TO
    COMPARE WITH NEW YORK? ..................................................................... 8
1.12 WHAT IS THE DIFFERENCE BETWEEN THE NYSCR AND THE HOSPITAL
    DISCHARGE FILES (SPARCS)? ................................................................. 9
1.13 WHAT DOES THE NYSCR DO TO PROTECT PRIVACY? ......................... 9
1.14 WHAT KINDS OF DATA DOES THE NYSCR RELEASE? ......................... 10
1.1 WHAT IS THE NEW YORK STATE CANCER REGISTRY?

The New York State Cancer Registry (NYSCR) collects and processes information on cancer cases in New York State. In addition, the NYSCR produces reports on cancer incidence and mortality statewide and in each county, by gender and anatomic site (i.e., breast, lung, colon, prostate, etc.). Because of its comprehensive database of information on cancer cases in New York, the NYSCR serves as an important resource for residents, health care professionals and researchers.

One of the oldest cancer registries in the country, the NYSCR has been collecting information on patients with cancer for more than 65 years. The first state law requiring the reporting of cancer cases diagnosed in New York State, excluding New York City, was passed in 1940. In 1972, the law was amended to include the reporting of information on cancer patients diagnosed in New York City. Evaluation of reporting patterns over time indicates that 1976 is the first year that is considered complete enough to use for the analysis of statewide cancer trends.

In 1995, the NYSCR began receiving additional funding from the Centers for Disease Control and Prevention (CDC) under the federal Cancer Registries Amendment Act. These funds enabled the Registry to make many improvements in the collection and processing of data. Since then, the Registry has increased the number of data elements collected on each cancer patient, consistent with the standards of the National Program of Cancer Registries (NPCR). In September 1996, all Registry data from 1979 to that time were converted into a new database for processing and storage.

In 2018 the NYSCR was selected to become a National Cancer Institute-funded Surveillance, Epidemiology, and End Results (SEER) Registry. SEER’s data are extensively used by researchers, clinicians, public health entities and others. As a part of the SEER Program the information collected by the NYSCR will be included in this comprehensive program’s database and thus available for such important research. Moreover, New York’s data will also be included in SEER’s incidence, mortality, and survival publications.

1.2 WHY REPORT TO THE NYSCR?

The NYSCR is a population-based cancer incidence registry responsible for the collection of demographic, diagnostic and treatment information on all patients diagnosed with and/or treated for cancer at hospitals, laboratories, and other health care facilities throughout New York State. Submission of data is mandated under section 2401 (Appendix A) of the NYS Public Health Law.

According to the Public Health Law, the person in charge of every reporting facility shall immediately, but not later than one hundred eighty days, give notice of every case of cancer or malignant disease coming under the care of the institution to the NYS Department of Health Cancer Registry. For a complete listing of reportable conditions refer to Part 3: Reportable Conditions of this manual.

NOTE: Registrars are encouraged to obtain the most accurate and complete information for each case. Therefore, in most instances, the NYS Cancer Registry will not accept any
The NYSCR collects a wide variety of information that can be used for research and public health planning and evaluation. The first objective of the Registry is to monitor cancer levels to detect potential public health risks. The Registry also responds to concerns of New Yorkers who perceive that their community may have an elevated level of cancer. Because Registry data are population-based, they can be used to monitor cancer incidence patterns in New York State. Data collected by the Registry are used:

- to determine cancer rates and trends;
- to prepare health policy and planning;
- for research in epidemiological studies (including case-control studies);
- for evaluation of cancer control interventions;
- to identify and target high-risk populations; and
- to respond to public concerns regarding perceived excesses of cancer in population-based settings.

The NYSCR also plays an important role in research to identify the causes of cancer. Researchers have used data collected by the Registry to identify cancer patients who could be interviewed about possible exposures they had prior to being diagnosed with cancer. These responses can be compared to interview responses of people without cancer to determine whether they had different exposures. One study of this kind, conducted with Registry data, found a possible association between alcohol consumption and breast cancer. Researchers can also use Registry data to determine whether groups of people with specific exposures, for example, those working in certain occupations, are more likely to develop cancer than people who do not have these exposures.

1.3 **WHO REPORTS?**

In accordance with the NYS Public Health Law every physician, dentist and other health care provider shall give notice immediately, but no later than one hundred eighty days, of every case of cancer or other malignant disease coming under his or her care, to the NYS Department of Health Cancer Registry. This includes all:

- Hospitals
- Diagnostic and Treatment Centers;
- Radiation Treatment Centers;
- Ambulatory Surgery Centers;
- Nursing Homes;
- Clinics;
- Laboratories; and
- Managed Care Organizations.

A complete copy of section 2401 of the NYS Public Health Law is available in Appendix A.
1.4 RECIPROCAL AGREEMENTS

In order that cancer-reporting in New York State be as complete as possible, the NYSCR has established formal agreements with several states, including all neighboring states, to exchange information regarding cancer patients.

1.5 WHAT INFORMATION IS COLLECTED ABOUT PATIENTS WITH CANCER?

When the NYSCR initially began collecting data, only minimal information about the patient and tumor was collected. Over time, the volume of cancer reports has increased, along with the amount of data collected for each report. Essentially, data collected by the Registry can be divided into two major categories: information pertaining to the disease process and information about the patient. Regarding the disease process, the Registry collects data on the:

- anatomic site of the tumor;
- cell type/histology of the cancer
- stage at diagnosis; and
- type of treatment rendered.

If a patient is diagnosed with more than one type of cancer, this same information is collected for each unique tumor.

The Registry also collects specific socio-demographic information on every patient diagnosed with cancer, consisting of, but not limited to:

- age;
- sex;
- ethnicity;
- race;
- residence; and
- place of birth.

Information regarding the date and cause of death of individuals diagnosed with cancer is also stored on the Registry’s database.

The Registry includes reports of all malignant cancers, except selected skin cancers. Malignant cancers include those with both invasive and in situ behavior. In situ cancers are very early cancers, while invasive cancers have more potential to spread or metastasize to other parts of the body. The Registry also collects data on brain and nervous system tumors classified as benign or which have an uncertain behavior. Benign tumors are growths that do not have the potential to metastasize beyond the tissue where they originated. (See Part 3: Reportable Conditions of this manual for a detailed list of reportable conditions and terminology.)
1.6 **HOW ARE THE CANCER CASE REPORTS SENT AND PROCESSED?**

The NYS Department of Health (DOH) and the NYSCR utilize the Health Commerce System (HCS), a secure Intranet site, for all data-reporting. The Registry offers, to interested facilities, a software application called SEER*Abs at no charge for electronic reporting purposes. In addition to the enhanced Windows format, SEER*Abs contains the most recent North American Association of Central Cancer Registries (NAACCR) file format.

Facilities are required to electronically transmit cancer cases to the NYSCR via the HCS at least once a month. If the facility has nothing to report for a particular month, the person(s) responsible for submitting cancer data must contact his/her Field Representative and inform them of that fact in writing.

Once received at the Registry, cancer reports are processed utilizing a combination of automated and manual protocols before they can be used for data analysis. One of the primary strengths of the NYSCR is multiple-source reporting for diagnosed cases. Approximately three reports are received for each primary tumor diagnosed. All incoming reports are electronically matched against records on file for patients diagnosed during the past 30+ years in New York State. About six percent of all cancers are second primaries (new cancers occurring among those patients who have been previously diagnosed with cancer). For some sites, such as oral cavity and pharynx, the number of multiple primaries in an individual may be quite high. Registry staff must review all tumor reports that match to reports already on the database to determine whether the new report represents a new primary cancer, or one that was previously reported. The diagram on the following page illustrates the various steps of NYSCR data processing.
1.6.1 Flow of data from reporting facilities through the NYSCR

Data Abstracted by Healthcare Facilities

Correct Errors

Transmit Data to NYSCR

Notify Reporting Source Regarding Errors

Run Edits

Link Data to NYSCR Database

Existing Tumor (Patient)

Consolidate Tumor (Patient) Information

New Tumor (Patient)

Create New Case Record

Run In-house (NYSCR) Edits

Update NYSCR Database

Reports for Facilities, Researchers and Public
In a process known as “geocoding”, address information is used to assign a census tract and, in New York City, health districts. Much of the geocoding process is automated; however, approximately 15 percent of New York State addresses must be manually geocoded by NYSCR staff. There are several kinds of addresses that cannot be coded by the computer. These include addresses with incomplete information on the record, mailing addresses not identified by street name (e.g., P.O. Boxes, rural routes, apartment buildings) and addresses located on newly created streets or those that run between several towns or counties.

The field services staff monitor the number of cases submitted by each facility and the total number of cancer cases for a given diagnosis year. Although facilities are required to submit cases within six months of diagnosis or first contact with the patient, some case reports are not received until after a year or more has passed. The Registry continues to work to improve the timeliness of facility reporting. When most of the data for a given year are received and processed, then death information processing begins.

1.7 WHAT IS DEATH INFORMATION PROCESSING?

When the NYS DOH receives death certificates, an underlying cause of death is assigned based on the entire list of primary and secondary diagnoses. Any mention of cancer on the death certificate is also recorded regardless of whether the person died as a direct result of the cancer. All records of people who die from cancer or with a co-morbidity of cancer are cross-referenced with the NYSCR database. If no match is identified, or if the cancer site on the death certificate differs from that recorded in the NYSCR database, follow-back is initiated by contacting the facility where the death occurred and requesting any additional information they may have. This is an important process, as year of diagnosis, stage at diagnosis, histology and many other important pieces of information are not included on a death certificate. Of all tumors recorded at the Registry, approximately 3 percent are reported from death certificates for which no additional information is available. This is typically attributed to deaths which in a non-hospital setting or out of state. In some cases, the deceased had been diagnosed and treated for cancer at a facility other than the one in which he or she passed away and further information cannot be found. These cases are called “death certificate only cases,” (DCOs). Further information is provided in Part 6: Death Certificate Only and Death Clearance Lists.

1.8 FILE RETENTION

There is no statute governing how long cancer case files must be kept by reporting facilities; however, retention for at least five years is strongly recommended by the NYSCR. As with most cancer data software, SEER*Abs contains a backup function and backup is strongly recommended following any data entry. SEER*Abs users can direct questions regarding file backup to their Field Representative, while commercial software users should contact their software vendor or someone from their facility’s information technology services for assistance.
1.9 ARE THERE OTHER MEASURES OF QUALITY APPLIED TO THE CANCER REGISTRY?

Three indicators commonly measure the quality of cancer reporting:
- The percentage of cases reported by DCO;
- The percentage of cases confirmed microscopically; and
- The percentage of cases with non-specific diagnoses.

The number of DCO cases gives an indication of the completeness of cancer registration. The number of microscopically confirmed cases and the number with non-specific diagnoses indicate the accuracy of diagnostic information. These measures are related to the overall quality of data and indicate potential for improved reporting from individual facilities. A high percent of cases without microscopic confirmation or with non-specific diagnoses indicates that either (1) there was inadequate medical record abstracting and reporting, or (2) the diagnostic work-ups at the facility may not have been as complete as they could have been. The latter sometimes occurs following a clinical diagnosis of cancer in those patients whose work-ups may be compromised due to various co-morbid conditions.

Measures of data quality vary considerably among cancer sites. They are affected by many factors including available methods of screening and early detection, survival associated with a particular site/histology and age group primarily affected.

In addition to these measures of completeness and diagnostic quality, other factors affect the analysis and interpretation of cancer registry data. While almost all cancer cases reported to the Registry have information about gender, age and county of residence, additional data important for research or program planning may be less complete, such as race, ethnicity, and stage at diagnosis.

1.10 UNDER WHAT CIRCUMSTANCES IS INFORMATION CORRECTED OR CHANGED?

The change/correction procedure ensures that the most accurate information is available to users of NYSCR data by enabling reporting facilities to provide updated or corrected information to the NYSCR after the original case has been transmitted.

Example: At the time a case is reported to the NYSCR, the primary site is unknown (C809). On a subsequent admission several months later, the primary site is documented as upper lobe of the left lung (C341). An update should be submitted to revise the primary site, laterality and any other information that may now be available. Central Registry staff will update this information on the patient’s consolidated abstract in the NYSCR database.

Example: A case is received at the NYSCR that states the patient’s primary site is a cervical lymph node (C770) and the histology is adenocarcinoma (8140). Because a lymph node is a secondary (metastatic) site of an adenocarcinoma, the facility is contacted to request further review of the patient’s medical record to determine the correct primary site of this malignancy.

Example: A case is reported to the Registry before radiation treatment is started and/or completed. Update and resubmit the abstract to the NYSCR with updated radiation treatment information.
A representative of the NYSCR may contact a reporting facility when questionable and/or inconsistent information is received. In addition to correcting information in the facility’s database, corrected information must be relayed to a NYSCR representative as soon as possible. Registrars are encouraged to obtain the most accurate and complete information for each case.

1.10.1 What to Change

Change required data items when incorrect or unknown information was initially reported, and more specific/accurate information is subsequently available.

Examples:
- Update diagnostic information (e.g., diagnosis date, primary site, histology) if initially submitted information if found to be incorrect.
- Change staging information as indicated in specific staging manuals (i.e., SEER Summary Stage, AJCC TNM Stage) if additional information becomes available.
- Update 1st Course of Treatment information if initially submitted with incorrect codes or unknown values and more accurate information becomes available.
- Change service type information, as well as other applicable fields, if a patient subsequently presents to the facility following submission as a “lab only” case.
- Submit any applicable changes to the patient’s name (e.g., incorrect spelling on original abstract, name change due to marital status).

Do Not submit changes to update address changes or admission/discharge dates when the patient is re-admitted.

NOTE: Provide text in the “Remarks” field regarding any change(s), to assist NYSCR staff identify the most accurate information.

1.10.2 When to Submit Changes

When possible changes and/or corrections should be made within ten (10) days of the original submission date.

1.10.3 Quality Control

Reporting facilities should have quality control measures in place to make sure cancer data reported to the NYSCR are complete, accurate and timely. Please refer to Part 8 - Quality Assessment.

1.11 ARE THERE NATIONAL CANCER DATA OR DATA FROM OTHER STATES TO COMPARE WITH NEW YORK?

The U.S. Congress passed the Cancer Registries Amendment Act in 1992, which authorized creation of the NPCR by the CDC. The NYSCR has received support from the NPCR since 1996, which has enabled the NYSCR to achieve ‘gold’ status for the quality and completeness of its cancer data. Through ongoing collaboration with the SEER program, the NPCR provides nationwide, regional, and state-based cancer incidence and mortality data published in the United States Cancer Statistics and in the

The NYSCR Reporting Manual – Part One – Overview

Revised January 2022
The NYSCR is a member of the North American Association of Central Cancer Registries (NAACCR), which sets data standards and best practices for population-based registries. Thanks to the initiation of federal funding for cancer registries, the NAACCR membership now includes central registries in all fifty states, the District of Columbia, Puerto Rico, Guam, and the Canadian provinces. NAACCR compiles and publishes Cancer in North America and associated data products.

When the NYSCR updated its database in 1996, it adopted the SEER and NAACCR standards for coding data. One major change in the collection and coding of multiple primary tumors was important for the interpretation of cancer incidence statistics. For cancer cases diagnosed prior to 1996, the NYSCR used the International Agency for Research on Cancer (IARC) rule for counting primary tumors, which allows only one primary per site per person per lifetime. Thus, the Cancer Registry would count only one breast cancer or one lung cancer per person. SEER coding rules allow for multiple primary cancers in an anatomic site, based on histology, length of time between tumors and the pathologist's determination as to whether a second cancer represents a second primary or a recurrence. According to data from the SEER program, approximately 5% of breast cancers, for example, are second primary cancers among women previously diagnosed with breast cancer. Because all data for cancers diagnosed prior to 1996 were coded using IARC rules, New York data for some sites of cancer are not directly comparable to SEER or NAACCR data. The extent of the effect for each cancer site is dependent upon site-specific probability of multiple primaries. Beginning with cases diagnosed in 1996, New York State's data are comparable to both SEER and NAACCR data. SEER data, currently represent approximately 35% of the U.S. population.

1.12 WHAT IS THE DIFFERENCE BETWEEN THE NYSCR AND THE HOSPITAL DISCHARGE FILES (SPARCS)?

The Statewide Planning and Research Cooperative System (SPARCS) maintains a database of all hospital discharges occurring in New York State. This is a valuable source of information regarding treatment, cost, and patterns of care as they relate to cancer. Cancer patients may be admitted to the hospital numerous times over the course of their treatment and recovery. Often, a cancer patient is seen at several different healthcare facilities over the course of several years. The NYSCR counts the number of primary tumors, not the number of hospital admissions. Reports from different healthcare facilities and different years are matched to the database so that an accurate count of the number of primary tumors can be made. This is not possible with the SPARCS data, since discharge files do not contain important clinical information required to determine whether a cancer diagnosis represents a new primary tumor or recurrence of a previously reported primary tumor. Many data elements critical to studying cancer – such as stage at diagnosis, histology, behavior, and laterality – are not available in the discharge files.

1.13 WHAT DOES THE NYSCR DO TO PROTECT PRIVACY?

All information reported to the NYSCR is considered confidential. Strict policies and procedures are in place to protect every patient’s privacy. Access to NYSCR offices is

Revised January 2022
restricted. All employees are trained in handling confidential information. Specific policies govern the release of data to outside investigators. All research studies involving data with patient identifiers must be reviewed and approved by the NYS DOH Institutional Review Board (IRB), which protects every patient's right to privacy. Data release policies also govern the release of de-identified, individual-level data involving small geographic areas. Statistics for areas smaller than the county level are only released when there are enough cases in the area to guard against revealing confidential information about an individual. When there are fewer than six cases of a particular type of cancer in small area, (e.g., four cases of bladder cancer), then the exact number of cases is not revealed. Rather, the table which displays the number of cases for the small area will indicate "fewer than six cases".

1.14 WHAT KINDS OF DATA DOES THE NYSCR RELEASE?

The NYSCR publishes Cancer Incidence and Mortality in New York State annually. This report provides statewide figures for the number of cancer cases, cancer deaths and the age-adjusted rates by county, primary site, gender, race, and year of diagnosis for the most recent five-year period, as well as the proportion of cases diagnosed at an early stage. Five years of data are combined, since the number of cases and rates for single years may vary considerably, particularly for most of the counties outside metropolitan areas and cities. Cancer Incidence and Mortality in New York State also provides data for New York State, New York City and New York State excluding New York City. Periodically, special reports are released. These include more detailed data than are available in the annual publication. For additional information on special reports produced by the NYSCR, visit the NYSCR website.

Researchers often request data to evaluate a public health intervention or to test a hypothesis. Staff in the analytic unit of the NYSCR respond to special requests for cancer data.
New York State Cancer Registry Reporting Manual

Part Two – Confidentiality

2.1 DEFINITION ............................................................................................................1
2.2 LEGAL AND ETHICAL ASPECTS ...........................................................................1
  2.2.1 Why Safeguard Confidentiality? ......................................................................1
  2.2.2 The Public Health Law ..................................................................................1
  2.2.3 The Health Insurance Portability and Accountability Act of 1996 (HIPAA) ........2
2.3 POLICIES AND PROCEDURES .........................................................................2
  2.3.1 Confidentiality Pledge .................................................................................2
2.4 DATA SECURITY ..................................................................................................3
  2.4.1 Paper records ...............................................................................................3
  2.4.2 Electronic records ..........................................................................................3
2.5 PROCEDURES FOR RELEASE OF CONFIDENTIAL CANCER
PATIENT INFORMATION ..............................................................................................4
2.1 DEFINITION

Confidential is defined by Webster's Dictionary as: private, secret; entrusted with confidence; containing information whose unauthorized disclosure could be prejudicial.

2.2 LEGAL AND ETHICAL ASPECTS

2.2.1 Why Safeguard Confidentiality?

Cancer data are highly confidential and one of the most important responsibilities of cancer registry professionals is to safeguard the privacy of cancer patient information. Improper disclosure of protected health information could result in emotional, psychological, and financial harm to both patients and their families. The standard of confidentiality maintained by cancer registries is similar to that of the doctor-patient relationship and it extends indefinitely – even after the patient is deceased.

2.2.2 The Public Health Law

New York State Public Health Law provides the NYSCR with the legislative authority to collect confidential cancer information. As previously noted in Section 1 of this manual, section 2401 states:

Every physician, dentist and other health care provider shall give notice immediately but not later than one hundred eighty days of every case of cancer or other malignant disease coming under his or her care, to the department, except as otherwise provided.

The NYS DOH has also instituted stringent regulations to ensure maximum confidentiality of records received. New York Codes, Rules and Regulations (NYCRR) protect the confidentiality of all cancer case information received by the NYSCR. Title 101.31 of the NYCRR states:

The identity of any person contained in a report of cancer made pursuant to the provisions of Section 2401 of the Public Health Law, or cancer data collected for other specific research studies, shall not be disclosed except to governmental or government-sponsored research projects for the purpose of scientific studies and research when the State Commissioner of Health determines that substantial knowledge may be gained by such disclosure leading toward the reduction of morbidity and mortality. The recipient shall limit the use of such information to the specific study or research purpose for which such disclosure is made, shall not further disclose such information, and shall satisfy the State Commissioner of Health that the confidentiality of the patient's identity will be maintained.

Additionally, Department regulation Subpart 50-1 through 50-4 governs the storage, access and disposal of patient information and requires the development of unit specific protocols to ensure confidentiality of personal health related information.
2.2.3 The Health Insurance Portability and Accountability Act (HIPAA)

Federal regulations [see 45 C.F.R. s164.512] authorize disclosure without patient consent in certain circumstances, including the following:

*Disclosure is permitted to a public health authority authorized by law to access information to prevent/control disease, injury, disability (e.g., disease reporting, vital statistics reporting, public health surveillance, public health investigations, public health interventions and partner notification).*

Under the HIPAA a ‘Public Health Authority’ refers to “an agency or authority of the United States, a State or territory, a political subdivision of a State or territory, an Indian tribe, or a person or entity acting under a grant of authority from or contract with such public agency, including the employees or agents of such public agency or its contractors or persons or entities to whom it has granted authority, that is responsible for public health matters as part of its official mandate.”¹ “…Such agencies are authorized by law to collect or receive such information for the purposes of preventing or controlling disease, injury, vital events such as birth or death and the conduct of public health surveillance, public health investigations and public health interventions.”² *Central Cancer Registries* are considered public health authorities because their duties are mandated by state laws.

¹ C.F.R. 164.501
² C.F.R. 164.512

Cancer reporting and surveillance are required by New York State law. Public health reporting under the authority of New York State law is specifically exempted from HIPAA preemption, per 45 C.F.R. § 160.203(c). Access to patient medical records relating to the diagnosis and treatment of cancer by the NYSCR has been determined to be the minimum necessary for protected health information for the stated purpose in compliance with 45 C.F.R. s164.502. It is not necessary to complete a Business Associate Agreement before providing the NYSCR with the requested personally identifiable information. The requested information is required to conduct public health surveillance and will remain confidential. See Appendix B for more information regarding HIPAA.

2.3 POLICIES AND PROCEDURES

Anyone, whose position requires access to cancer data, whether at the NYSCR or a reporting facility, is responsible for ensuring confidentiality is continually maintained. Reporting facilities are urged to consider implementing the following policies and procedures if they are not already in place.

2.3.1 Confidentiality Pledge/Agreement

It is strongly recommended that anyone with access to confidential patient information first sign a *Confidentiality Pledge/Agreement*. This pledge/agreement should clearly state the expectations of the facility regarding the signatory’s handling of confidential information as well as potential penalties for violating terms of the agreement. Additionally, this requirement should extend beyond employees of the facility to any consultants, contractors, auditors, etc. A sample confidentiality statement is available at the end of this section (Part 2).
2.4 **DATA SECURITY**

Every measure must be taken to ensure that confidentiality of all medical records is protected. This includes Electronic Medical Records (EMRs). Anyone requiring access to confidential patient information should be required to sign a confidentiality pledge before authorization is approved.

The following additional guidelines are offered to Health Information Management personnel to maintain security of confidential patient information whether stored on paper or electronically.

2.4.1 **Paper records**

Central storage sites containing confidential patient files must be always secured. A chain of custody should be maintained on every record removed from the central storage site, citing the name and department of the individual removing the record, along with the date and time of removal and return.

Individuals who sign out records must ensure that those records remain secure while in their possession.

2.4.2 **Electronic records**

If not already in place, strict security procedures must be instituted, preventing any unauthorized access to EMRs. Confidential medical information, which is abstracted and entered onto an EMR, must be done so only by authorized personnel. Each authorized user should be assigned a personal access identification and password. This ID and password must never be shared with others. Access to confidential medical data should be limited to those individuals and/or agencies with a legitimate use for such data. As previously mentioned, NYS Public Health Law provides for the transmission of confidential cancer data to the NYSCR.

Upon termination of employment for any reason, facilities must remove any ID/password from their system, which may provide access for the former employee to confidential patient data.
2.5 PROCEDURES FOR RELEASE OF CONFIDENTIAL CANCER PATIENT INFORMATION

Telephone: If a caller is not immediately known, the identity of the caller must be confirmed before any information is released.

Facsimile: When transmitting confidential information via fax, the following guidelines should be implemented to ensure that the information is received by an authorized party only:

1. Transmit data only to a fax machine that is located within a secure area, offering limited access.
2. Verify that the appropriate individual is present before transmitting confidential data.
3. Accompany each fax transmission with a cover sheet, which includes a notice of confidentiality.

Example: The documents accompanying this facsimile contain confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual(s) or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any unauthorized party and is required to destroy the information after its stated purpose has been fulfilled, unless otherwise required by law.

If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this facsimile in error, please notify the sender immediately to arrange for return of these documents.

4. Verify that the intended recipient has received the faxed information.

Electronic Mail: Common e-mail should never be used to transmit confidential patient information. If someone wishes to send confidential data electronically, s/he should use the Secure File Transfer Utility (SFT) on the NYS DOH Health Commerce System (HCS). An HCS account is necessary to access and transmit information via the SFT. This system allows for secure transmission of files up to 2 GB. Assistance using the SFT is available from your Field Representative.

Regular Mail: All confidential patient information sent to the NYSCR via postal mail, or other couriers, must be prominently marked “confidential”. Use of registered or express mail is recommended. This allows the sender to track the package, as well as confirm receipt. Use of reinforced envelopes/packaging is also strongly recommended.
2.6 SAMPLE CONFIDENTIALITY PLEDGE

I understand and accept the responsibility of maintaining the confidentiality of all data and information collected and processed by ___________ (Facility Name) ___________.

I also understand my role in ensuring the right to privacy of persons and institutions cooperating with the cancer registry data collection activities.

I understand that ___________ (Facility Name) ___________ has policies that protect the patient’s right to consideration of privacy regarding his or her medical and personal information.

I understand that I must not reveal any confidential information to anyone except those individuals authorized to receive such information, such as another staff member or the original reporting source.

I also understand that failure to adhere to this policy may result in disciplinary action up to and including dismissal.

I have read and understand the ___________ (Facility Name) ___________ confidentiality policy and procedures and pledge to act in accordance with these policies and procedures.

Name (Please print): ___________________________________________________________
Signature: ___________________________ Date: __________

Witness Name (Please print): __________________________________________________
Signature: ___________________________ Date: __________
Page Left Blank Intentionally
New York State Cancer Registry Reporting Manual

Part Three - Reportable Conditions and Terminology

3.1 INTRODUCTION ................................................................................................... 1
3.2 RULES FOR REPORTING ................................................................................... 2
  3.2.1 Active Cancer ................................................................................................ 2
    3.2.1.1 Consult-Only Cases .............................................................................. 2
    3.2.1.2 Transient Care .................................................................................... 3
    3.2.1.3 Palliative / Terminal Care ................................................................. 3
    3.2.1.4 Autopsy/Death Certificate Only Cases ............................................... 3
    3.2.1.5 Clinical Cases ..................................................................................... 3
    3.2.1.6 Neoplasms of Brain and Central Nervous System (See 3.3) .............. 3
    3.2.1.7 Leukemia in Remission ..................................................................... 4
    3.2.1.8 Mucoepidermoid Sites ...................................................................... 4
      3.2.1.8.1 Reportable Lip Cases ................................................................  4
      3.2.1.8.2 Reportable Anal Cases ................................................................ 4
      3.2.1.8.3 Reportable Basal Cell Carcinomas .......................................... 4
      3.2.1.8.4 Reportable Squamous Cell Carcinomas .................................. 5
  3.2.2 First-Seen Rule ............................................................................................ 5
  3.2.3 Infusion Ports/Sleeve Placements/Fiducial Markers ...................................... 5
  3.2.4 MammoSite Radiation Therapy ................................................................... 5
  3.2.5 Behavior Code ............................................................................................. 5
    3.2.5.1 Behavior Code 2 (In Situ) Terms That Are Reportable ...................... 6
    3.2.5.2 Behavior Code 2 (In Situ) Terms That Are Not Reportable ............... 6
  3.2.6 Key Words and Conditions ....................................................................... 6
  3.2.7 Terms That May Not Sound Malignant but ARE Reportable ....................... 7
3.3 REPORTABLE BENIGN, BORDERLINE AND MALIGNANT INTRACRANIAL
  AND CENTRAL NERVOUS SYSTEM TUMORS ................................................... 8
  3.3.1 Anatomic Sites ............................................................................................ 8
  3.3.2 Histology/Morphology Terms .................................................................... 9
3.4 WHAT IS NOT REPORTABLE TO THE NYSCR ................................................. 11
  3.4.1 History of .................................................................................................. 11
  3.4.2 Recurrence ............................................................................................... 11
  3.4.3 Readmitted Patients ............................................................................... 11
  3.4.4 Basal and Squamous Cell Cancer of Skin .............................................. 11
  3.4.5 “Evolving” Melanoma ............................................................................. 11
  3.4.6 High Grade/Severe Dysplasia .................................................................. 11
3.5 GUIDELINES FOR INTERPRETATION OF EQUIVOCAL DIAGNOSTIC
  TERMINOLOGY .................................................................................................. 12
  3.5.1 Ambiguous Terminology that Constitute a Diagnosis.............................. 12
  3.5.2 Ambiguous Terms That Do Not Constitute A Diagnosis ......................... 12
  3.5.3 Coding reference priority ....................................................................... 12
3.6 RULES FOR DETERMINING MULTIPLE PRIMARIES FOR SOLID TUMORS ... 13
3.7 RULES FOR DETERMINING MULTIPLE PRIMARIES FOR HEMATOPOIETIC
  AND LYMPHOID NEOPLASMS ........................................................................ 13
3.8 CASEFINDING LISTS FOR ICD-9-CM CODES ................................................ 13
3.9 CASEFINDING LIST FOR ICD-10-CM CODES ................................................ 15
3.10 REPORTABLE TERMS LIST .......................................................................... 23

The NYSCR Reporting Manual – Part Three – Reportable Conditions and Terminology
Revised January 2022
Page Left Blank Intentionally
3.1 INTRODUCTION

In general, the following types of cases ARE reportable:

- Each form of in situ (behavior code 2) cancer, EXCEPT for the following:
  - All types carcinoma in situ of the cervix uteri (including adenocarcinoma in situ)
  - CIN III (cervical intraepithelial neoplasia, grade three)
  - All types of carcinoma in situ of the prostate
  - PIN III (prostatic intraepithelial neoplasia, grade three)
  - In situ lymphomas

- Each form of malignant (behavior code 3) cancer, EXCEPT skin of non-mucoepidermoid sites (C440-C449) with any of the following histologies:
  - Malignant neoplasm (8000-8005)
  - Epithelial carcinoma (8010-8046)
  - Papillary and squamous cell carcinoma (8050-8084)
  - Squamous intraepithelial neoplasia III (SIN III) (8077) of skin sites coded to C44_
  - Basal cell carcinoma (8090-8110)

- All Primary Central Nervous System tumors, regardless of behavior, with the following ICD-O topography codes:
  - Meninges, C70_
  - Brain, C71_
  - Spinal cord, cranial nerves, and other parts of CNS, C72_
  - Pituitary gland, craniopharyngeal duct and pineal glands, C751 – C753
  - Nerve roots for the following sites: C470, C473, C475, C476

- Borderline ovarian tumors
  - Serous cystadenoma, borderline malignancy 8442/1
  - Serous tumor of low malignant potential 8442/1
  - Atypical proliferating serous tumor 8442/1
  - Papillary cystadenoma, borderline malignancy 8451/1
  - Serous papillary cystic tumor of borderline malignancy 8462/1
  - Papillary serous cystadenoma, borderline malignancy 8462/1
  - Papillary serous tumor of low malignant potential 8462/1
  - Atypical proliferative papillary serous tumor 8462/1
  - Serous surface papillary tumor of borderline malignancy 8463/1
  - Atypical proliferative mucinous tumor 8472/1
  - Mucinous cystic tumor of borderline malignancy 8472/1
  - Mucinous cystadenoma, borderline malignancy 8472/1
  - Mucinous tumor, NOS, of low malignant potential 8472/1
  - Pseudomucinous cystadenoma, borderline malignancy 8472/1
  - Papillary mucinous cystadenoma, borderline malignancy 8473/1
  - Papillary pseudomucinous cystadenoma, borderline 8473/1
  - Papillary mucinous tumor of low malignant potential 8473/1
  - Seromucinous borderline tumor of the ovary 8474/1
  - malignancy
3.2 RULES FOR REPORTING

3.2.1 Active Cancer

Any person diagnosed with active cancer, EXCEPT basal and squamous cell cancers of skin, after January 1950 must be reported to the NYSCCR. Active cancer is defined as requiring therapy or management of the cancer or recurrence of the cancer. If a patient is diagnosed with or treated for metastatic cancer at your facility, report the PRIMARY SITE the first time the patient is seen at your facility for that cancer.

If ANY type of cancer-related service or management is provided for the patient at your facility, the case IS reportable.

Example: A patient is diagnosed at another facility but seen at your facility for planned breast reconstruction, which is part of the first course of treatment.

Example: A patient is diagnosed at another facility with melanoma and is seen at your facility for wide excision. This is reportable even if the pathology results from the wide excision are negative.

Patients seen at your facility for a reason completely unrelated to an active case of cancer are NOT reportable.

Example: A patient is treated for a broken leg. The patient also has a secondary diagnosis of breast cancer. The patient is not treated for breast cancer while at your facility.

Autopsy/death certificate cases are exceptions. See section 3.2.1.4 for more information.

Active cancer includes:

3.2.1.1 Consult-Only Cases

Report consultation only services provided by your facility to establish or confirm a diagnosis of or a treatment plan for active cancer.

Examples of reportable consult-only cases:

- A biopsy is done elsewhere, and the specimen (including electronically transmitted microscopic images) is sent to your facility. The patient never enters your facility; however, your facility’s pathologist diagnoses a reportable cancer in a pathology report. These cases are referred to as “Lab Only Cases.” This category also includes specimens sent to your facility, which test positive for malignancy using immunohistochemistry testing and lab test (ex. ER/PR testing, HER2/neu testing). If the patient returns to your facility for treatment the case must be updated with the correct service type and any additional demographic/treatment information and resubmitted.

- An outpatient CT scan of the chest reads, “probable carcinoma of the right lung.” The clinical impression is confirmed at your facility and is reported back to the referring facility or physician.
• A patient comes to your facility for a second opinion, where staff physicians order diagnostic tests that support the original diagnosis and treatment plan. The patient returns to the referring institution for treatment.
• The patient does not have treatment at the hospital, but the MD presented the patient with treatment options. The patient does not return (service type “16”).

Note: Consult-only services for a patient whose primary residence is NOT in the United States are NOT reportable to the NYSCR.

3.2.1.2 Transient Care

Report cancer cases when patients receive transient care at your facility to avoid interrupting a course of therapy started elsewhere.

Examples of reportable transient care:
• A patient from out of state is visiting relatives in the area. The oncology department at your facility administers the scheduled chemotherapy.
• Due to equipment failure, an institution refers a patient to your facility for radiation therapy. Your facility administers treatment until the equipment is repaired.

3.2.1.3 Palliative / Terminal Care

Report cases for patients with active cancer, admitted to your facility for the purpose of receiving supportive care, palliative care, pain management and/or hospice services.

3.2.1.4 Autopsy/Death Certificate Only Cases

This refers to an incidental finding of cancer at autopsy where there was no suspicion of cancer before the autopsy. To avoid Death Certificate Only (DCO) follow-back cases later, facilities should establish a mechanism to review death certificates for the presence of cancer diagnoses. See Part 6 for more information on DCO cases.

3.2.1.5 Clinical Cases

Report clinical cases. Clinical cases are non-histologically confirmed cancer diagnoses, based exclusively on the physician’s clinical interpretation. The medical history and physical examination section of a medical record often ends with the physician’s impression of the diagnosis, but the impression MUST be substantiated by the discharge summary or other supporting documentation. Do NOT report “rule out” only cases. See Section 3.5.1 for a list of ambiguous terms that constitute a reportable cancer diagnosis.

3.2.1.6 Neoplasms of the Central Nervous System (CNS) (See 3.3)

Report All PRIMARY central nervous system tumors and/or neoplasms with any of the following ICD-O topography codes:
• Meninges, C70_
• Brain, C71_
• Spinal cord, cranial nerves, and other parts of CNS, C72_
• Pituitary and pineal glands, C71 – C753
• Nerve roots for the following sites: C470, C473, C475, C476
3.2.1.7 **Leukemia in Remission**

Leukemia in remission is reportable if the patient receives treatment while at your facility. Cases in which the disease is *no longer active* should only be reported if the patient is still receiving cancer-directed therapy.

**Example:** A patient diagnosed six months ago with acute myelocytic leukemia is now in remission and on a maintenance dose of chemotherapy. The patient was admitted for evaluation of neutropenia following the last course of chemotherapy. If this is the first admission to your facility, this patient should be reported because cancer-directed treatment (e.g., chemotherapy) is being administered.

3.2.1.8 **Mucoepidermoid Sites**

Mucoepidermoid sites include the vulva (i.e., labia, vaginal opening, clitoris, and clitoral hood), vagina, penis, scrotum and portions of the lip and anus.

3.2.1.8.1 **Reportable Lip Cases**

The codes for the mucoepidermoid portions of the lip are C000-C009. These include the inner mucosal surface of the lip, the vermillion surface of the lip (i.e., the pinkish colored area where lipstick is applied) and the vermillion border of the lip. Report all malignancies involving these sites.

Basal cell carcinomas do NOT arise in the mucoepidermoid portion of the lip and anus. They can only arise in the skin of these two sites and are therefore NOT REPORTABLE.

3.2.1.8.2 **Reportable Anal Cases**

C210 is the code that includes the mucoepidermoid portion of the anus called the anoderm. The anoderm is the lining of the anal canal immediately inferior to the dentate line and extending for about 1.5 cm to the anal verge. It is devoid of hair and sebaceous and sweat glands; therefore, it is NOT true skin. Report all malignancies involving this site.

Basal cell carcinomas do NOT arise in the mucoepidermoid portion of the lip and anus. They can only arise in the skin of these two sites and are therefore NOT REPORTABLE.

3.2.1.8.3 **Reportable Basal Cell Carcinomas**

Basal cell carcinomas ARE reportable when they arise in the:

- Vulva \( (C51\_) \)
- Vagina \( (C529) \)
- Penis \( (C60\_) \)
- Scrotum \( (C632) \)

Basal cell carcinomas do NOT arise in the mucoepidermoid portion of the lip and anus. They can only arise in the skin of these two sites and are therefore NOT REPORTABLE.
3.2.1.8.4 **Reportable Squamous Cell Carcinomas**

Squamous cell carcinomas ARE reportable when they arise in the mucoepidermoid sites of the:
- Vulva (C51_)
- Vagina (C529)
- Penis (C60_)
- Scrotum (C632)
- Lip (C00_)
- Anus (C210)

### 3.2.2 First-Seen Rule

Submit a report on every patient first diagnosed or treated at your facility. If first seen with a cancer recurrence or metastatic disease, report the information from the INITIAL diagnosis of the PRIMARY site (i.e., not metastatic site[s]). Report a patient again ONLY if the patient is diagnosed with another primary cancer. Create a new abstract for every new primary of each patient.

### 3.2.3 Infusion Ports/Sleeve Placements/Fiducial Markers

Report patients who come to your facility for insertion of an infusion port (e.g., mediport, infusaport, port-a-cath, or chemotherapy port), when the record states the device will be used to provide central access for chemotherapy for a reportable cancer at a treating facility. These cases are reportable even if the patient is to receive their subsequent chemotherapy at another facility. Patients who are seen for sleeve placements and insertion of fiducial markers for subsequent radiation therapy are also reportable. It is understood that the patient's medical record may contain minimal information related to his/her diagnosis.

Service Type for these cases should be coded as “18 Port/Cath” and Class of Case as “31: Initial diagnosis and all first course treatment elsewhere AND reporting facility provided in-transit care.”

### 3.2.4 MammoSite Radiation Therapy

Report patients who come to your facility for the insertion of a MammoSite balloon catheter. The MammoSite Radiation Therapy System utilizes a specialized balloon catheter to deliver brachytherapy directly to the site of a lumpectomy, following a diagnosis of malignancy. These cases are reportable even if the patient is to receive their subsequent radiation therapy at another facility. It is understood that the patient’s medical record may contain minimal information related to her/his diagnosis.

### 3.2.5 Behavior Code

Patients diagnosed with a behavior code of 2 (in situ) or 3 (malignant) as defined in the International Classification of Disease for Oncology, Third Edition (ICD-O-3) and subsequent updates, including the 2021 and 2022 ICD-O-3.2 Updates must be reported, except as otherwise noted.
3.2.5.1 Behavior Code 2 (In Situ) Terms That Are Reportable

Synonymous terms for behavior code 2 (in situ) that ARE reportable to the NYSCR (except for basal and squamous cell carcinomas of the SKIN) include:

- AIN III (anal intraepithelial neoplasia) (C210-C211)
- Clark level 1 for melanoma (limited to epithelium)
- Confined to epithelium
- DIN III (ductal intraepithelial neoplasia)
- Early or evolving melanoma in situ, or any other early or evolving melanoma (As of 01/01/2021)
- High grade biliary intraepithelial neoplasia (BilIN III) of the gallbladder (C239)
- Intraductal
- Intraepidermal, NOS
- Intraepithelial, NOS
- Involvement up to but not including the basement membrane
- Lentigo maligna (C44_) AKA, Hutchinson melanotic freckle, NOS (C44_)
- LIN III (Laryngeal Intraepithelial Neoplasia, grade III) (C32_)
- Lobular carcinoma in situ (LCIS) of breast
- Lobular neoplasia grade III (LIN III) (C50_)
- Non-infiltrating
- Non-invasive
- No stromal invasion
- PanIN III (Pancreatic Intraepithelial Neoplasia, grade III) (C25_)
- PeIN III (Penile intraepithelial neoplasia, grade III) (C60_)
- SIN III (Squamous Intraepithelial Neoplasia, grade III)
- Squamous dysplasia, high grade
- Squamous intraepithelial neoplasia/neoplasm, grade II (Excluding Cervix)
- VAIN III (vaginal intraepithelial neoplasia, grade III)
- VIN III (vulvar intraepithelial neoplasia, grade III)

3.2.5.2 Behavior Code 2 (In Situ) Terms That Are Not Reportable

Synonymous terms for behavior code 2 (in situ) that are NOT reportable to the NYSCR include:

- Bowen disease of SKIN
- CIN III (cervical intraepithelial neoplasia, grade III)
- PIN III (prostatic intraepithelial neoplasia, grade III)

3.2.6 Key Words and Conditions

Reportable conditions are defined in terms of key words and other specified conditions. The most comprehensive source for determining reportability is the International Classification of Diseases for Oncology, Third Edition (ICD-O-3), and the 2021 and 2022 ICD-O-3.2 Updates, published by the World Health Organization (WHO). The ICD-O presents definitive information related to site, morphology, behavior, synonyms, codes, and rules. Section 3.8 of this manual contains a list of MOST of the terms that are reportable to the NYSCR.
### 3.2.7 Terms That May Not Sound Malignant but ARE Reportable

The following is a non-inclusive list of terms that may not sound malignant but ARE reportable to the NYSCR.

<table>
<thead>
<tr>
<th>Condition</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acute myelofibrosis</td>
<td>Malignant (except malignant hypertension)</td>
</tr>
<tr>
<td>Acute panmyelosis</td>
<td>Mature teratoma of the testes</td>
</tr>
<tr>
<td>Acute progressive histiocytosis X</td>
<td>Melanoma</td>
</tr>
<tr>
<td>Adamantinoma</td>
<td>Meningioma</td>
</tr>
<tr>
<td>Agnogenic myeloid metaplasia</td>
<td>Merkel cell tumor (skin)</td>
</tr>
<tr>
<td>Alpha heavy chain disease</td>
<td>Mesothelioma</td>
</tr>
<tr>
<td>Anal intraepithelial neoplasia (AIN III)</td>
<td>Mixed mesodermal tumor</td>
</tr>
<tr>
<td>Akin tumor</td>
<td>Multiple myeloma</td>
</tr>
<tr>
<td>Astrocytoma</td>
<td>Mycosis fungoides</td>
</tr>
<tr>
<td>Atypical carcinoid</td>
<td>Myelofibrosis, acute</td>
</tr>
<tr>
<td>Blastoma</td>
<td>Neoplasm, malignant</td>
</tr>
<tr>
<td>Carcinoma in situ (except for cervix)</td>
<td>Non-invasive mucinous cystic neoplasm (MCN) of the pancreas with high grade dysplasia</td>
</tr>
<tr>
<td>CASTLE</td>
<td>Oligodendroglioma</td>
</tr>
<tr>
<td>Dysgerminoma</td>
<td>Paget disease (breast)</td>
</tr>
<tr>
<td>Ependymoma</td>
<td>Paget disease, extra-mammary</td>
</tr>
<tr>
<td>Ewing tumor (bone)</td>
<td>Pagetoid reticulosis</td>
</tr>
<tr>
<td>Franklin disease</td>
<td>PanIN (Pancreatic Intraepithelial Neoplasm grade III)</td>
</tr>
<tr>
<td>Gamma heavy chain disease</td>
<td>Peripheral neuroectodermal tumor</td>
</tr>
<tr>
<td>Generalized Langerhans cell histiocytosis</td>
<td>Phyllodes tumor, malignant (breast)</td>
</tr>
<tr>
<td>Glioma</td>
<td>Pinealoma</td>
</tr>
<tr>
<td>Heavy chain disease</td>
<td>Plasmacytoma</td>
</tr>
<tr>
<td>Hepatoma</td>
<td>Primitive neuroectodermal tumor</td>
</tr>
<tr>
<td>Hodgkin disease</td>
<td>Sarcoma</td>
</tr>
<tr>
<td>Hyperesinophilic syndrome</td>
<td>Seminoma</td>
</tr>
<tr>
<td>Hypernephroma</td>
<td>SETTLE</td>
</tr>
<tr>
<td>Immunoproliferative small intestinal disease</td>
<td>Sezary disease</td>
</tr>
<tr>
<td>Intratubular germ cell neoplasia</td>
<td>Therapy related myelodysplastic syndrome</td>
</tr>
<tr>
<td>Kaposi sarcoma</td>
<td>Thymoma (nearly all thymomas are reportable as of 01/01/2021)</td>
</tr>
<tr>
<td>Klatskin tumor</td>
<td>Vaginal intraepithelial neoplasia (VAIN III)</td>
</tr>
<tr>
<td>Krukenberg tumor</td>
<td>Vulvar intraepithelial neoplasia (VIN III)</td>
</tr>
<tr>
<td>Letterer-Siwe disease</td>
<td>Waldenstrom macroglobulinemia</td>
</tr>
<tr>
<td>Leukemia</td>
<td></td>
</tr>
<tr>
<td>Leukemic reticuloendotheliosis</td>
<td></td>
</tr>
<tr>
<td>Linitis plastica</td>
<td></td>
</tr>
<tr>
<td>Lymphoma</td>
<td></td>
</tr>
<tr>
<td>Lymphoproliferative disorder (C44_)</td>
<td></td>
</tr>
</tbody>
</table>
3.3 REPORTABLE BENIGN, BORDERLINE AND MALIGNANT INTRACRANIAL AND CENTRAL NERVOUS SYSTEM TUMORS

3.3.1 Anatomic Sites

Report the following anatomic sites for PRIMARY intracranial and central nervous system (CNS) tumors and/or neoplasms, REGARDLESS of behavior.

<table>
<thead>
<tr>
<th>Anatomic Site</th>
<th>Anatomic Site</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abducens nerve</td>
<td>Falx, NOS</td>
</tr>
<tr>
<td>Accessory nerve, NOS</td>
<td>Filum terminale</td>
</tr>
<tr>
<td>Acoustic nerve</td>
<td>Fourth ventricle, NOS</td>
</tr>
<tr>
<td>Anterior cranial fossa</td>
<td>Frontal lobe</td>
</tr>
<tr>
<td>Arachnoid, NOS</td>
<td>Frontal pole</td>
</tr>
<tr>
<td>Basal ganglia</td>
<td>Globus pallidus</td>
</tr>
<tr>
<td>Basis pedunculi</td>
<td>Glossopharyngeal nerve</td>
</tr>
<tr>
<td>Brain, NOS</td>
<td>Hippocampus</td>
</tr>
<tr>
<td>Brain stem</td>
<td>Hypoglossal nerve</td>
</tr>
<tr>
<td>Cauda equina</td>
<td>Hypophysis</td>
</tr>
<tr>
<td>Central nervous system</td>
<td>Infratentorial brain, NOS</td>
</tr>
<tr>
<td>Central white matter</td>
<td>Insula</td>
</tr>
<tr>
<td>Cerebellopontine angle</td>
<td>Internal capsule</td>
</tr>
<tr>
<td>Cerebellum, NOS</td>
<td>Intracranial arachnoid</td>
</tr>
<tr>
<td>Cerebral cortex</td>
<td>Intracranial meninges</td>
</tr>
<tr>
<td>Cerebral hemisphere</td>
<td>Intracranial site</td>
</tr>
<tr>
<td>Cerebral meninges</td>
<td>Island of Reil</td>
</tr>
<tr>
<td>Cerebral peduncle</td>
<td>Lateral ventricle, NOS</td>
</tr>
<tr>
<td>Cerebral ventricle</td>
<td>Lumbar cord</td>
</tr>
<tr>
<td>Cerebral white matter</td>
<td>Medulla oblongata</td>
</tr>
<tr>
<td>Cerebrum</td>
<td>Meninges, NOS</td>
</tr>
<tr>
<td>Cervical cord</td>
<td>Midbrain</td>
</tr>
<tr>
<td>Choroid plexus, NOS</td>
<td>Middle cranial fossa</td>
</tr>
<tr>
<td>Choroid plexus of fourth ventricle</td>
<td>Nervous system, NOS</td>
</tr>
<tr>
<td>Choroid plexus of lateral ventricle</td>
<td>Occipital lobe</td>
</tr>
<tr>
<td>Choroid plexus of third ventricle</td>
<td>Occipital pole</td>
</tr>
<tr>
<td>Conus medullaris</td>
<td>Oculomotor nerve</td>
</tr>
<tr>
<td>Corpus callosum</td>
<td>Olfactory nerve</td>
</tr>
<tr>
<td>Corpus striatum</td>
<td>Olive</td>
</tr>
<tr>
<td>Cranial dura mater</td>
<td>Operculum</td>
</tr>
<tr>
<td>Cranial fossa, NOS</td>
<td>Optic chiasm</td>
</tr>
<tr>
<td>Cranial meninges</td>
<td>Optic nerve</td>
</tr>
<tr>
<td>Cranial nerve, NOS</td>
<td>Optic tract</td>
</tr>
<tr>
<td>Cranial pia mater</td>
<td>Other parts of brain</td>
</tr>
<tr>
<td>Craniopharyngeal duct</td>
<td>Overlapping lesion of brain</td>
</tr>
<tr>
<td>Dura, NOS</td>
<td>Overlapping lesion of brain and central nervous system</td>
</tr>
<tr>
<td>Dura mater, NOS</td>
<td>Pallium</td>
</tr>
<tr>
<td>Ependymal</td>
<td>Parasellar</td>
</tr>
<tr>
<td>Epidural</td>
<td>Parietal lobe</td>
</tr>
<tr>
<td>Extradural</td>
<td>Pia mater, NOS</td>
</tr>
<tr>
<td>Facial nerve</td>
<td>Pineal gland</td>
</tr>
<tr>
<td>Falx cerebelli</td>
<td></td>
</tr>
<tr>
<td>Falx cerebri</td>
<td></td>
</tr>
<tr>
<td>Pituitary fossa</td>
<td>Spinal pia mater</td>
</tr>
<tr>
<td>---------------------------------</td>
<td>-----------------------------------</td>
</tr>
<tr>
<td>Pituitary gland</td>
<td>Suprasellar</td>
</tr>
<tr>
<td>Pituitary, NOS</td>
<td>Supratentorial brain, NOS</td>
</tr>
<tr>
<td>Pons</td>
<td>Tapetum</td>
</tr>
<tr>
<td>Posterior cranial fossa</td>
<td>Temporal lobe</td>
</tr>
<tr>
<td>Putamen</td>
<td>Tentorium cerebelli</td>
</tr>
<tr>
<td>Pyramid</td>
<td>Tentorium, NOS</td>
</tr>
<tr>
<td>Rathke pouch</td>
<td>Thalamus</td>
</tr>
<tr>
<td>Rhinencephalon</td>
<td>Third ventricle, NOS</td>
</tr>
<tr>
<td>Sacral cord</td>
<td>Thoracic cord</td>
</tr>
<tr>
<td>Sella turcica</td>
<td>Trigeminal nerve</td>
</tr>
<tr>
<td>Spinal accessory nerve</td>
<td>Trochlear nerve</td>
</tr>
<tr>
<td>Spinal arachnoid</td>
<td>Uncus</td>
</tr>
<tr>
<td>Spinal cord</td>
<td>Vagus nerve</td>
</tr>
<tr>
<td>Spinal dura mater</td>
<td>Ventricle, NOS</td>
</tr>
<tr>
<td>Spinal meninges</td>
<td>Vermis of cerebellum</td>
</tr>
<tr>
<td>Spinal nerve root</td>
<td></td>
</tr>
</tbody>
</table>

### 3.3.2 Histology/Morphology Terms

Report the following histology/morphology terms for PRIMARY intracranial and central nervous system (CNS) tumors/neoplasms, REGARDLESS of BEHAVIOR.

<table>
<thead>
<tr>
<th>Acoustic neuroma</th>
<th>Diffuse meningiomatosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acidophil adenoma</td>
<td>Dysembryoplastic neuroepithelial tumor</td>
</tr>
<tr>
<td>Adenoma, NOS</td>
<td>Dysplastic gangliocytoma of cerebellum</td>
</tr>
<tr>
<td>Angioblastic meningioma</td>
<td>(D=Lhemitte-Duclos)</td>
</tr>
<tr>
<td>Angioblastoma</td>
<td>Endotheliomatous meningioma</td>
</tr>
<tr>
<td>Angiocentric immunoproliferative</td>
<td>Ependymoma</td>
</tr>
<tr>
<td>Lesion</td>
<td>Epithelioid hemangioendothelioma, NOS</td>
</tr>
<tr>
<td>Angiocentric glioma</td>
<td>Extra-adrenal paranglioma, NOS</td>
</tr>
<tr>
<td>Angiolipoma, NOS</td>
<td>Extraventricular neurocytoma</td>
</tr>
<tr>
<td>Angiomatous meningioma</td>
<td>Fibroblastic meningioma</td>
</tr>
<tr>
<td>Atypical choroid plexus papilloma</td>
<td>Fibroma, NOS</td>
</tr>
<tr>
<td>Atypical fibrous histiocytoma</td>
<td>Fibrous histiocytoma, NOS</td>
</tr>
<tr>
<td>Atypical fibroxanthoma</td>
<td>Fibrous meningioma</td>
</tr>
<tr>
<td>Atypical meningioma</td>
<td>Fibroxanthoma, NOS</td>
</tr>
<tr>
<td>Basophil adenoma</td>
<td>Follicular Adenoma</td>
</tr>
<tr>
<td>Capillary Hemangioma</td>
<td>Gangliocytoma</td>
</tr>
<tr>
<td>Cavernous Hemangioma</td>
<td>Ganglioglioma</td>
</tr>
<tr>
<td>Central neurocytoma</td>
<td>Ganglioneuroma</td>
</tr>
<tr>
<td>Cerebellar neurocytoma</td>
<td>Glioneuroma</td>
</tr>
<tr>
<td>Cerebellar liponeurocytoma</td>
<td>Granular cell tumor, NOS</td>
</tr>
<tr>
<td>Chordoid glioma of third ventricle</td>
<td>Hemangioblastic meningioma</td>
</tr>
<tr>
<td>Choroid plexus papilloma, NOS</td>
<td>Hemangioblastoma</td>
</tr>
<tr>
<td>Chromophobe adenoma</td>
<td>Hemangioma</td>
</tr>
<tr>
<td>Craniopharyngioma</td>
<td>Hemangioendothelioma, benign</td>
</tr>
<tr>
<td>Dermoid cyst, NOS</td>
<td>Hemangiopericytic meningioma</td>
</tr>
<tr>
<td>Desmoplastic infantile astrocytoma and ganglioglioma</td>
<td>Hemangiopericytoma, benign</td>
</tr>
<tr>
<td>Diffuse astrocytoma, IDH mutant</td>
<td>Hemangiopericytoma, NOS</td>
</tr>
<tr>
<td></td>
<td>Hurthle cell adenoma</td>
</tr>
</tbody>
</table>
Hurthle cell tumor
Lipoma
Lymphoproliferative disease, NOS
Melanocytic Schwannoma
Meningioma, NOS
Meningiomas, NOS
Meningotheliomatous meningioma
Mesenchymoma, benign
Mesenchymoma, NOS
Microfollicular adenoma
Mixed acidophil-basophil adenoma
Mixed cell adenoma
Mixed meningioma
Monomorphic adenoma
Mucoid cell adenoma
Multinodular and vasculating neuronal tumor (MVNT)
Multiple meningiomas
Multiple neurofibromatosis
Myxopapillary ependymoma
Neoplasm, benign
Neoplasm, uncertain whether benign or malignant
Neurilemmoma, NOS
Neurinoma
Neuroastrocytoma
Neurocytoma
Neurofibroma, NOS
Neurofibromatosis, NOS
Neurothekeoma
Neuro, NOS
Oligodendroglioma IDH mutant and 1p/19q-codeleted
Oncoytic adenoma
Oncocytoma
Oxyphilic adenoma
Papillary adenoma, NOS
Papillary ependymoma
Papillary glioneuronal tumor
Papillary meningioma
Paraganglioma, NOS
Perineuroma
Pigmented Schwannoma
Pilocytic/juvenile astrocytoma
Pinealoma
Pineoblastoma
Pineocytoma
Pituicytoma
Pleomorphic xanthroastrocytoma
Plexiform neurofibroma
Plexiform neuroma
Prolactinoma
Psammomatous meningioma
Rathke pouch tumor
Recklinghausen disease (except of Bone)
Rhabdomyoma, NOS
Rosette-forming glioneuronal tumor
Schwannoma, NOS
Solitary fibrous tumor
Soft tissue tumor, benign
Spindle cell oncocytoma
Subependymal astrocytoma
Subependymal giant cell astrocytoma
Subependymal glioma
Subependymoma
Syncytial meningioma
Teratoma, NOS
Teratoma, benign
Transitional meningioma
Tumor, benign
Tumor cells, benign
Tumor cells, uncertain whether benign or malignant
Tumorlet(s)
Tumor, uncertain whether benign or malignant
Von Recklinghausen disease (except of Bone)
Xanthofibroma
3.4 WHAT IS NOT REPORTABLE TO THE NYSCR

3.4.1 History of

Do NOT report patients with a history of malignancy who are clinically free of disease.

If a patient with a history of breast cancer receives Tamoxifen therapy, report the case only if the breast cancer was the reason for admission (i.e., principal diagnosis).

**Exception:** When a history of malignancy case appears on a DCO list, follow it back to the NYSCR. The reason a case appears on a DCO list is because the patient and/or tumor associated with that patient was not reported at the time of the original diagnosis. It is likely that the facility reconciling the DCO case will have limited documentation about the tumor and that numerous data fields will be coded as "unknown". For more information on DCO cases, see Part 6.

3.4.2 Recurrence

A recurrent diagnosis is the SAME cancer arising in or from the SAME primary site where it appeared earlier and when it is NOT considered by the physician to be a new primary cancer. Do report a recurrent diagnosis if this is the first time seen at your facility. Report information related to the INITIAL diagnosis and ORIGINAL primary site for a case that is first seen at your facility with a recurrent cancer or metastatic disease. Do NOT report a recurrent diagnosis if you have previously reported the primary cancer.

3.4.3 Readmitted Patients

Do NOT report readmitted patients if you have previously reported that primary. If a patient is readmitted to your facility and new or additional metastatic sites are diagnosed and/or treated, the case is NOT reportable provided your facility previously has reported the ORIGINAL primary cancer. Review records of readmitted patients to determine if a NEW primary has been diagnosed. Report each new primary separately.

3.4.4 Basal and Squamous Cell Cancer of Skin

Basal and squamous cell cancer originating in SKIN (i.e., non-mucoepidermoid sites), is NOT reportable, regardless of stage at diagnosis.

3.4.5 “Evolving” Melanoma

Evolving melanoma and evolving melanoma in situ are not reportable when diagnosed prior to January 1, 2021. As of January 1, 2021, early or evolving melanoma in situ, or any other early or evolving melanoma, is reportable.

3.4.6 High Grade/Severe Dysplasia

High grade dysplasia is not reportable. Some pathologists use the terms “high grade/severe dysplasia” interchangeably with “carcinoma in situ". High grade dysplasia should only be reported as carcinoma in situ when your facility’s pathologist verifies s/he considers them to be the same. When reporting such cases, document the histology as carcinoma in situ and include a comment that the behavior was confirmed with the pathologist.
3.5 **GUIDELINES FOR INTERPRETATION OF EQUIVOCAL DIAGNOSTIC TERMINOLOGY**

### 3.5.1 Ambiguous Terminology that Constitute a Diagnosis

Terms listed below ARE reportable. These terms are NOT to be used when determining multiple primaries. The Solid Tumor Rules manual contains a separate list of ambiguous terms:

<table>
<thead>
<tr>
<th>Term</th>
<th>Reportable Term</th>
</tr>
</thead>
<tbody>
<tr>
<td>Apparent(ly)</td>
<td>Most likely</td>
</tr>
<tr>
<td>Appears</td>
<td>Presumed</td>
</tr>
<tr>
<td>Comparable with</td>
<td>Probable</td>
</tr>
<tr>
<td>Compatible with</td>
<td>Suspect(ed)</td>
</tr>
<tr>
<td>Consistent with</td>
<td>Suspicious (for)</td>
</tr>
<tr>
<td>Favor(s)</td>
<td>Typical (of)</td>
</tr>
<tr>
<td>Malignant appearing</td>
<td></td>
</tr>
</tbody>
</table>

**Exception:** If a CYTOLOGY is identified only with one or more of the above ambiguous terms, do not interpret this as a diagnosis of cancer. Report the case only if the cytology findings are supported by a positive biopsy or a physician’s clinical impression of cancer confirms the cytology findings. The date of diagnosis is the date the cancer is confirmed.

Report cases that use the words on the list or an equivalent word such as “favored” rather than “favor(s).” Do not substitute synonyms such as “supposed” for presumed or “equal” for comparable. Do not substitute “likely” for “most likely.”

When a RADIOLOGY report mentions a “suspicious mass”, BUT there is no other documentation or mention of the mass in the medical record, do NOT report this case. The report is useful however, for casefinding, indicating the need to search for additional information to support the observation on the imaging report.

### 3.5.2 Ambiguous Terms That Do Not Constitute A Diagnosis

Terms listed below are NOT considered diagnostic of cancer without additional information. If a phrase such as “strongly suggestive,” “highly worrisome,” or “very possible” is used, disregard the modifying phrase (i.e., “strongly,” “highly,” “very”), and refer to the primary term (i.e., “suggestive,” “worrisome,” “possible”) to determine involvement.

<table>
<thead>
<tr>
<th>Term</th>
<th>Reportable Term</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cannot be ruled out</td>
<td>Questionable</td>
</tr>
<tr>
<td>Equivocal</td>
<td>Rule-out</td>
</tr>
<tr>
<td>Possible</td>
<td>Suggests</td>
</tr>
<tr>
<td>Potentially malignant</td>
<td>Worrisome</td>
</tr>
</tbody>
</table>
3.6 RULES FOR DETERMINING MULTIPLE PRIMARIES AND HISTOLOGIES FOR SOLID TUMORS

The NYSCR follows SEER Solid Tumor Rules (STRs) for determining multiple primaries and histologies for all solid tumors, except lymphomas. The current structure was revised with cases diagnosed January 1, 2021. Specific rules are outlined for Head and Neck, Colon (incl. Rectosigmoid and Rectum), Lung, Cutaneous Melanoma, Breast, Kidney, Urinary Sites (i.e., Renal Pelvis, Ureter and Bladder), Non-malignant CNS, and Malignant CNS and peripheral Nerves. One additional set of rules, last updated 1/1/2007, currently addresses all Other Sites not included in one of the site-specific rule sets. A .pdf copy of the STRs manual is available on the SEER website.

3.7 RULES FOR DETERMINING MULTIPLE PRIMARIES FOR HEMATOPOIETIC AND LYMPHOID NEOPLASMS

The NYSCR also follows SEER rules for determining multiple primaries for hematopoietic and lymphoid neoplasms. The current structure was implemented with cases diagnosed January 1, 2010. The rules set consists of both an online electronic database and manual, available via the SEER Hematopoietic Project website. While the manual can be downloaded in a .pdf format, the database is not available offline.

3.8 CASEFINDING LISTS FOR ICD-9-CM CODES

Use the following list as a guide for identifying cases that MAY be reportable to the NYSCR. Thoroughly review all available medical information to determine reportability.

<table>
<thead>
<tr>
<th>ICD-9-CM Codes</th>
<th>Diagnosis (in preferred ICD-O-3 terminology)</th>
</tr>
</thead>
<tbody>
<tr>
<td>042</td>
<td>AIDS (review cases for AIDS-related malignancies)</td>
</tr>
<tr>
<td>140.0 - 208.92</td>
<td>Malignant neoplasms</td>
</tr>
<tr>
<td>203.1</td>
<td>Plasma cell leukemia (9733/3)</td>
</tr>
<tr>
<td>205.1</td>
<td>Chronic neutrophilic leukemia (9963/3)</td>
</tr>
<tr>
<td>209.00 – 209.36</td>
<td>Malignant carcinoid/neuroendocrine tumors and Markel cell carcinoma</td>
</tr>
<tr>
<td>209.70-209.79</td>
<td>Secondary neuroendocrine tumors</td>
</tr>
<tr>
<td>210.0 - 229.9</td>
<td>Benign neoplasms</td>
</tr>
<tr>
<td>230.0 - 234.9</td>
<td>Carcinoma in situ</td>
</tr>
<tr>
<td>235.0 - 238.9</td>
<td>Neoplasms of uncertain behavior</td>
</tr>
<tr>
<td>237.73</td>
<td>Third Type-Schwannomatosis</td>
</tr>
<tr>
<td>237.79</td>
<td>Neurofibromatosis, other</td>
</tr>
<tr>
<td>238.4</td>
<td>Polycythemia vera (9950/3)</td>
</tr>
<tr>
<td>238.6</td>
<td>Solitary plasmacytoma (9731/3)</td>
</tr>
<tr>
<td>238.6</td>
<td>Extramedullary plasmacytoma (9734/3)</td>
</tr>
<tr>
<td>238.71</td>
<td>Essential thrombocytopenia (9962/3)</td>
</tr>
<tr>
<td>238.72</td>
<td>Refractory cytopenia with multilineage dysplasia (9985/3)</td>
</tr>
<tr>
<td>238.71</td>
<td>Refractory anemia (9980/3)</td>
</tr>
<tr>
<td>238.72</td>
<td>Refractory anemia with ringed sideroblasts (9982/3)</td>
</tr>
<tr>
<td>238.73</td>
<td>High grade myelodysplastic syndrome lesions</td>
</tr>
<tr>
<td>238.72</td>
<td>Refractory anemia with excess blasts (9983/3)</td>
</tr>
<tr>
<td>238.72</td>
<td>Refractory anemia with excess blasts in transformation (9984/3)</td>
</tr>
<tr>
<td>238.74</td>
<td>Myelodysplastic syndrome with 5q- syndrome (9987/3)</td>
</tr>
<tr>
<td>238.75</td>
<td>Therapy-related myelodysplastic syndrome (9987/3)</td>
</tr>
<tr>
<td>ICD-9-CM Codes</td>
<td>Diagnosis (in preferred ICD-O-3 terminology)</td>
</tr>
<tr>
<td>---------------</td>
<td>---------------------------------------------</td>
</tr>
<tr>
<td>238.76</td>
<td>Myelosclerosis with myeloid metaplasia (9961/3)</td>
</tr>
<tr>
<td>238.77</td>
<td>Post-transplant lymphoproliferative disorder (9987/3)</td>
</tr>
<tr>
<td>238.79</td>
<td>Chronic myeloproliferative disease (9960/3)</td>
</tr>
<tr>
<td>239.0 - 239.9</td>
<td>Neoplasms of unspecified behavior</td>
</tr>
<tr>
<td>259.2</td>
<td>Carcinoid Syndrome</td>
</tr>
<tr>
<td>273.2</td>
<td>Gamma heavy chain disease; Franklin disease</td>
</tr>
<tr>
<td>273.3</td>
<td>Waldenstrom macroglobulinemia</td>
</tr>
<tr>
<td>273.9</td>
<td>Unspecified disorder of immune mechanism (screen for potential 273.3 miscodes)</td>
</tr>
<tr>
<td>288.3</td>
<td>Hypereosinophilic syndrome (9964/3)</td>
</tr>
<tr>
<td>289.6</td>
<td>Familial Polycythemia (per SEER, synonym for Polycythemia vera (9950/3) )</td>
</tr>
<tr>
<td>289.83</td>
<td>Acute myelofibrosis (9931/3)</td>
</tr>
<tr>
<td>748.1</td>
<td>Astrocytoma, astrogliaoma, astroblastoma of nose</td>
</tr>
<tr>
<td>789.51</td>
<td>Malignant Ascites</td>
</tr>
<tr>
<td>V07.39</td>
<td>Other prophylactic chemotherapy (screen carefully for miscoded malignancies)</td>
</tr>
<tr>
<td>V10.0 - V10.9</td>
<td>Personal history of malignancy (review these for recurrences, subsequent primaries and/or subsequent treatment)</td>
</tr>
<tr>
<td>V50.41</td>
<td>Prophylactic organ removal, breast</td>
</tr>
<tr>
<td>V50.42</td>
<td>Prophylactic organ removal, ovary</td>
</tr>
<tr>
<td>V50.49</td>
<td>Prophylactic organ removal, other</td>
</tr>
<tr>
<td>V58.0</td>
<td>Admission for radiotherapy</td>
</tr>
<tr>
<td>V58.11</td>
<td>Admission for chemotherapy</td>
</tr>
<tr>
<td>V58.12</td>
<td>Admission for immunotherapy for neoplastic condition</td>
</tr>
<tr>
<td>V66.1</td>
<td>Convalescence following radiotherapy</td>
</tr>
<tr>
<td>V66.2</td>
<td>Convalescence following chemotherapy</td>
</tr>
<tr>
<td>V67.1</td>
<td>Radiation therapy follow-up</td>
</tr>
<tr>
<td>V67.2</td>
<td>Chemotherapy follow-up</td>
</tr>
<tr>
<td>V71.1</td>
<td>Observation for suspected malignant neoplasm</td>
</tr>
<tr>
<td>V76.0 - V76.9</td>
<td>Special screening for malignant neoplasm</td>
</tr>
</tbody>
</table>

Refer to ICD-O-3 for inclusive listing of morphology terms.
3.9  CASEFINDING LIST FOR ICD-10-CM CODES

Use the following list as a guide for identifying cases that MAY be reportable to the NYSCR. Thoroughly review all available medical information to determine reportability.

<table>
<thead>
<tr>
<th>ICD-10-CM Codes</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>B20</td>
<td>Human immunodeficiency virus [HIV] disease with other diseases</td>
</tr>
<tr>
<td></td>
<td>Note: Excludes HIV with malignancy (B21), see reportable list</td>
</tr>
<tr>
<td>B97.33, B97.34, B97.35</td>
<td>Human T-cell lymphotropic virus, (type I [HTLV-1], type II [HTLV-II], type 2 [HIV 2]) as the cause of diseases classified elsewhere</td>
</tr>
<tr>
<td>B97.7</td>
<td>Papillomavirus as the cause of diseases classified elsewhere</td>
</tr>
<tr>
<td>C00._ - C43.<em>, C4A.</em>, C45._ - C48.<em>, C49.</em> - C96._</td>
<td>Malignant neoplasms (excluding category C44 and C49.A), stated or presumed to be primary (of specified site) and certain specified histologies</td>
</tr>
<tr>
<td></td>
<td>NEW for FY2018: C96.20 Malignant mast cell neoplasm, unspecified</td>
</tr>
<tr>
<td></td>
<td>C96.21 Aggressive systemic mastocytosis</td>
</tr>
<tr>
<td></td>
<td>C96.22 Mast cell sarcoma</td>
</tr>
<tr>
<td></td>
<td>C96.29 Other malignant cell neoplasm</td>
</tr>
<tr>
<td>C44.00, C44.09</td>
<td>Unspecified/other malignant neoplasm of skin of lip</td>
</tr>
<tr>
<td>C44.01, C44.02</td>
<td>Basal/squamous cell carcinoma of skin of lip</td>
</tr>
<tr>
<td>C44.10_, C44.19_</td>
<td>Unspecified/other malignant neoplasm of skin of eyelid</td>
</tr>
<tr>
<td>C44.13_</td>
<td>Sebaceous cell carcinoma of skin of eyelid, including canthus</td>
</tr>
<tr>
<td></td>
<td>Note: Effective 10/1/2018</td>
</tr>
<tr>
<td>C44.20_, C44.29_</td>
<td>Unspecified/other malignant neoplasm skin of ear and external auricular canal</td>
</tr>
<tr>
<td>C44.21_, C44.22_</td>
<td>Basal/squamous cell carcinoma of skin of ear and external auricular canal</td>
</tr>
<tr>
<td>C44.30_, C44.39_</td>
<td>Unspecified/other malignant neoplasm of skin of other/unspecified parts of face</td>
</tr>
<tr>
<td>C44.31_, C44.32_</td>
<td>Basal/squamous cell carcinoma of skin of other and unspecified parts of face</td>
</tr>
<tr>
<td>C44.40, C44.49</td>
<td>Unspecified/other malignant neoplasm of skin of scalp &amp; neck</td>
</tr>
<tr>
<td>C44.50_, C44.59_</td>
<td>Unspecified/other malignant neoplasm of skin of trunk</td>
</tr>
<tr>
<td>C44.60_, C44.69_</td>
<td>Unspecified/other malignant neoplasm of skin of upper limb, including shoulder</td>
</tr>
<tr>
<td>C44.70_, C44.79_</td>
<td>Unspecified/other malignant neoplasm of skin of lower limb, including hip</td>
</tr>
<tr>
<td>C44.80, C44.89</td>
<td>Unspecified/other malignant neoplasm of skin of overlapping sites of skin</td>
</tr>
<tr>
<td>C44.90, C44.99</td>
<td>Unspecified/other malignant neoplasm of skin of unspecified sites of skin</td>
</tr>
<tr>
<td>ICD-10-CM Codes</td>
<td>Description</td>
</tr>
<tr>
<td>-----------------</td>
<td>-------------</td>
</tr>
</tbody>
</table>
| C49.A           | Gastrointestinal Stromal Tumors  
Note: As of 1/1/2021 forward. Gastrointestinal Stromal Tumor, NOS (GIST, NOS) is considered malignant (/3), unless stated to be benign. |
| D00._ – D09._   | In-situ neoplasms (Note: Carcinoma in situ of the cervix (CIN III-8077/2) and Prostatic Intraepithelial Carcinoma (PIN III-8148/2) are not reportable). |
| D3A._           | Benign carcinoid tumors |
| D10._ – D31._,  | Benign neoplasms (see “must collect” list for reportable benign neoplasms)  
D33._, D34, D35.0,  
D35.1, D35.5, D35.9, D36._  
Note: Screen for incorrectly coded malignancies or reportable by agreement tumors |
| D18.01          | Lymphangioma, any site (Note: Includes Lymphangiomas of Brain, Other parts of nervous system and endocrine glands, which are reportable) |
| D18.02          | Hemangioma of intracranial structures and any site |
| D32._           | Benign neoplasm of meninges (cerebral, spinal, and unspecified) |
| D33._           | Benign neoplasm of brain and other parts of central nervous system |
| D35.2 - D35.4   | Benign neoplasm of pituitary gland, craniopharyngeal duct and pineal gland |
| D37._ – D41._   | Neoplasms of uncertain or unknown behavior (see “must collect” list for reportable neoplasms of uncertain or unknown behavior)  
Note: Screen for incorrectly coded malignancies or reportable by agreement tumors |
| D42._, D43._    | Neoplasm of uncertain or unknown behavior of meninges, brain, CNS |
| D44.0 – D44.2,  | Neoplasm of uncertain or unknown behavior of other endocrine glands  
D44.6 – D44.9    
Note: Screen for incorrectly coded malignancies or reportable by agreement tumors |
| D44.3 – D44.5   | Neoplasm of uncertain or unknown behavior of pituitary gland, craniopharyngeal duct and pineal gland |
| D45             | Polycythemia vera (9950/3)  
ICD-10-CM Coding instruction note: Excludes familial polycythemia (C75.0), secondary polycythemia (D75.1) |
| D46._           | Myelodysplastic syndromes (9980, 9982, 9983, 9985, 9986, 9989, 9991, 9992) |
| D47.0           | Histiocytic and mast cell tumors of uncertain behavior |
| D47.02          | Systemic mastocytosis |
| D47.01          | Cutaneous mastocytosis (9740/1)  
Note: Effective 10/1/2017 |
<table>
<thead>
<tr>
<th>ICD-10-CM Codes</th>
<th>Description</th>
</tr>
</thead>
</table>
| D47.09          | Other mast cell neoplasms of uncertain behavior  
Note: Effective 10/1/2017 |
| D47.1           | Chronic myeloproliferative disease (9963/3) |
| D47.2           | Monoclonal gammopathy  
Note: Screen for incorrectly coded Waldenstrom macroglobulinemia |
| D47.3           | Essential (hemorrhagic) thrombocytopenia (9962/3)  
*Includes: Essential thrombocytosis, idiopathic hemorrhagic thrombocytopenia* |
| D47.4           | Osteomyelofibrosis (9961/3)  
*Includes: Chronic idiopathic myelofibrosis  
Myelofibrosis (idiopathic) (with myeloid metaplasia)  
Myelosclerosis (megakaryocytic) with myeloid metaplasia  
Secondary myelofibrosis in myeloproliferative disease* |
| D47.Z_          | Neoplasm of uncertain behavior of lymphoid, hematopoietic, and related tissue, unspecified (9960/3, 9970/1, 9971/3, 9931/3) |
| D47.Z2          | Castleman disease |
| D47.9           | Neoplasm of uncertain behavior of lymphoid, hematopoietic, and related tissue, unspecified (9970/1, 9931/3) |
| D48._           | Neoplasm of uncertain behavior of other and unspecified sites |
| D49.6, D49.7    | Neoplasm of unspecified behavior of brain, endocrine glands, and other CNS |
| D49.0 – D49.9   | Neoplasm of unspecified behavior (except for D49.6 and D49.7) |
| D61.1           | Drug-induced aplastic anemia (also known as “aplastic anemia due to antineoplastic chemotherapy”)  
*ICD-10-CM Coding instruction note: Use additional code for adverse effect, if applicable, to identify drug* |
| D61.18          | Pancytopenia |
| D61.810         | Antineoplastic chemotherapy induced pancytopenia |
| D61.82          | Myelophthisis  
*ICD-10-CM Coding instruction: Code first the underlying disorder, such as: malignant neoplasm of breast (C50._)* |
| D63.0           | Anemia in neoplastic disease  
*ICD-10-CM Coding instruction: Code first neoplasm (C00-C49)* |
| D64.81          | Anemia due to antineoplastic chemotherapy |
| D69.49, D69.59, D69.6 | Other thrombocytopenia  
Note: Screen for incorrectly coded thrombocytopenia |
| D70.1           | Agranulocytosis secondary to cancer chemotherapy  
*ICD-10-CM Coding instruction: Code also underlying neoplasm* |
<table>
<thead>
<tr>
<th>ICD-10-CM Codes</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>D72.1</td>
<td>Eosinophilia <em>(Note: Code for eosinophilia (9964/3). Not every case of eosinophilia is a malignancy. Reportable Diagnosis is &quot;Hypereosinophilic syndrome.&quot;</em>)</td>
</tr>
<tr>
<td>D72.110</td>
<td>Idiopathic hypereosinophilic syndrome [HES]</td>
</tr>
<tr>
<td>D72.111</td>
<td>Lymphocytic variant hypereosinophilic syndrome [LHES]</td>
</tr>
<tr>
<td>D72.118</td>
<td>Other hypereosinophilic syndrome</td>
</tr>
<tr>
<td>D72.119</td>
<td>Hypereosinophilic syndrome [HES], unspecified</td>
</tr>
<tr>
<td>D75.81</td>
<td>Myelofibrosis <em>(note: this is not primary myelofibrosis [9961/3] ICD-10-CM Coding instruction note: Code first the underlying disorder, such as: malignant neoplasm of breast (C50_)</em></td>
</tr>
<tr>
<td>D76._</td>
<td>Other specified diseases with participation of lymphoreticular and reticulohistiocytic tissue</td>
</tr>
<tr>
<td>D89.0, D89.1</td>
<td>Other disorders involving the immune mechanism, not elsewhere classified <em>(Note: Review for miscodes)</em></td>
</tr>
<tr>
<td>D89.4</td>
<td>Mast cell activation syndrome and related disorders <em>(Note: Review for miscodes)</em></td>
</tr>
<tr>
<td>E08</td>
<td>Diabetes mellitus due to underlying condition <em>(ICD-10-CM Coding instruction note: Code first the underlying condition, such as: malignant neoplasm (C00-C96)</em></td>
</tr>
<tr>
<td>E31.2_</td>
<td>Multiple endocrine neoplasia [MEN] syndromes <em>(ICD-10-CM Coding instruction: Code also any associated malignancies and other conditions associated with the syndromes)</em></td>
</tr>
<tr>
<td>E34.0</td>
<td>Carcinoid syndrome <em>(ICD-10-CM Coding instruction: May be used as an additional code to identify functional activity associated with a carcinoid tumor)</em></td>
</tr>
<tr>
<td>E83.52</td>
<td>Hypercalcemia</td>
</tr>
<tr>
<td>E88.09</td>
<td>Other disorders of plasma-protein metabolism, not elsewhere classified</td>
</tr>
<tr>
<td>E88.3</td>
<td>Tumor lysis syndrome (following antineoplastic chemotherapy)</td>
</tr>
<tr>
<td>G13.0</td>
<td>Paraneoplastic neuromyopathy and neuropathy <em>(ICD-10-CM Coding instruction note: Code first underlying neoplasm (C00-D49)</em></td>
</tr>
<tr>
<td>G13.1</td>
<td>Other systemic atrophy primarily affecting central nervous system in neoplastic disease <em>(ICD-10-CM Coding instruction note: Code first underlying neoplasm (C00-D49)</em></td>
</tr>
<tr>
<td>G32.8</td>
<td>Other specified degenerative disorders of nervous system in diseases classified elsewhere <em>(ICD-10-CM Coding instruction note: Code first underlying disease, such as: cerebral degeneration (due to) neoplasm (C00-D49)</em></td>
</tr>
<tr>
<td>ICD-10-CM Codes</td>
<td>Description</td>
</tr>
<tr>
<td>----------------</td>
<td>-----------------------------------------------------------------------------</td>
</tr>
<tr>
<td>G53</td>
<td>Cranial nerve disorders in diseases classified elsewhere</td>
</tr>
<tr>
<td>G55</td>
<td>Nerve root and plexus compressions in diseases classified elsewhere</td>
</tr>
<tr>
<td>G63</td>
<td>Polyneuropathy in diseases classified elsewhere</td>
</tr>
<tr>
<td>G73.1</td>
<td>Lambert-Eaton syndrome in neoplastic disease</td>
</tr>
<tr>
<td>G89.3</td>
<td>Neoplasm related pain (acute) (chronic)</td>
</tr>
<tr>
<td>G99.2</td>
<td>Myelopathy in diseases classified elsewhere</td>
</tr>
<tr>
<td>H47.42</td>
<td>Disorders of optic chiasm in (due to) neoplasm</td>
</tr>
<tr>
<td>H47.52_</td>
<td>Disorders of visual pathways in (due to) neoplasm</td>
</tr>
<tr>
<td>H47.63_</td>
<td>Disorders of visual cortex in (due to) neoplasm</td>
</tr>
<tr>
<td>J34.81</td>
<td>Nasal mucositis (ulcerative)</td>
</tr>
<tr>
<td>J91.0</td>
<td>Malignant pleural effusion</td>
</tr>
<tr>
<td>J93.12</td>
<td>Secondary spontaneous pneumothorax</td>
</tr>
<tr>
<td>K12.31</td>
<td>Oral mucositis (ulcerative) due to antineoplastic therapy</td>
</tr>
<tr>
<td>K12.33</td>
<td>Oral mucositis (ulcerative) due to radiation</td>
</tr>
<tr>
<td>K22.711</td>
<td>Barrett’s esophagus with high grade dysplasia</td>
</tr>
<tr>
<td>K62.7</td>
<td>Radiation proctitis</td>
</tr>
<tr>
<td>K62.82</td>
<td>Dysplasia of anus (AIN I and AIN II)</td>
</tr>
<tr>
<td>K92.81</td>
<td>Gastrointestinal mucositis (ulcerated) (due to antineoplastic therapy)</td>
</tr>
<tr>
<td>M36.0</td>
<td>Dermato(poly)myositis in neoplastic disease</td>
</tr>
<tr>
<td>M36.1</td>
<td>Arthropathy in neoplastic disease</td>
</tr>
<tr>
<td>M84.5_</td>
<td>Pathologic fracture in neoplastic disease</td>
</tr>
</tbody>
</table>

The NYSCR Reporting Manual – Part Three – Reportable Conditions and Terminology
Revised January 2022
<table>
<thead>
<tr>
<th>ICD-10-CM Codes</th>
<th>Description</th>
</tr>
</thead>
</table>
| M90.6_          | Osteitis deformans in neoplastic disease  
*ICD-10-CM Coding instruction: Code first the neoplasm (C40._, C41._)* |
| N42.3           | Dysplasia of prostate (PIN I and PIN II) |
| N76.81          | Mucositis (ulcerative) of vagina and vulva |
| N87._           | Dysplasia of cervix uteri (CIN I and CIN II) |
| N89.0, N89.1, N89.3 | Vaginal dysplasia (VIN I and VIN II) |
| N90.0, N90.1, N90.3 | Vulvar dysplasia (VAIN I and VAIN II) |
| O01._           | Hydatidiform mole  
*Note: Benign tumor that can become malignant. If malignant, report as Choriocarcinoma (9100/3,) malignancy code in the C00- C97 range* |
| O9A.1_          | Malignant neoplasm complicating pregnancy, childbirth, and the puerperium (conditions in C00-C96)  
*ICD-10-CM Coding instruction: Use additional code to identify neoplasm* |
| Q85.0_          | Neurofibromatosis (nonmalignant) (9540/1)  
*Note: Neurofibromatosis is not cancer. These tumors can be precursors to acoustic neuromas, which are reportable* |
| R18.0           | Malignant ascites  
*ICD-10-CM Coding instruction: Code first malignancy, such as: Malignant neoplasm of ovary (C56_), secondary malignant neoplasm of retroperitoneum and peritoneum (C78.6)* |
| R53.0           | Neoplastic (malignant) related fatigue  
*ICD-10-CM Coding instruction: Code first associated neoplasm* |
| R59._           | Enlarged lymph nodes |
| R85.6_          | Abnormal findings on cytological and histological examination of digestive organs  
*Note: see "must collect" list for R85.614* |
| R85.614         | Cytologic evidence of malignancy on smear of anus |
| R87.61_, R87.62_ | Abnormal findings on cytological/histological examination of female genital organs  
*Note: see "must collect" list for R87.614 and R87.624* |
<p>| R87.614         | Cytologic evidence of malignancy on smear of cervix |
| R87.624         | Cytologic evidence of malignancy on smear of vagina |
| R92._           | Abnormal findings on diagnostic imaging of breast |
| R97._           | Abnormal tumor markers |
| T38.6_          | Poisoning by antigenadotropins, antiestrogens, antiandrogens, not elsewhere classified |
| T38.8_, T38.9_  | Poisoning by hormones and their synthetic substitutes |
| T45.1_          | Poisoning by adverse effect of and under dosing of antineoplastic and immunosuppressive drugs |</p>
<table>
<thead>
<tr>
<th>ICD-10-CM Codes</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>T45.8, T45.9</td>
<td>Poisoning by primary systemic and hematological agent, unspecified</td>
</tr>
<tr>
<td>T66</td>
<td>Unspecified effects of radiation</td>
</tr>
<tr>
<td>T80.1</td>
<td>Vascular complications following infusion, transfusion, and therapeutic injection</td>
</tr>
<tr>
<td>T80.2</td>
<td>Infections following infusion, transfusion, and therapeutic injection</td>
</tr>
<tr>
<td>T80.810</td>
<td>Extravasation of vesicant antineoplastic chemotherapy</td>
</tr>
<tr>
<td>T80.818</td>
<td>Extravasation of other vesicant agent</td>
</tr>
</tbody>
</table>
| T86.0         | Complications of bone marrow transplant  
*ICD-10-CM Coding instruction: Use addition code to identify other transplant complications, such as: malignancy associated with organ transplant (C80.2) or post-transplant lymphoproliferative disorders (PTLD) (D47.Z1)* |
| Y63.2         | Overdose of radiation given during therapy |
| Y84.2         | Radiological procedure and radiotherapy as the cause of abnormal reaction of the patient, or of later complication, without mention of misadventure at the time of the procedure |
| Z03.89        | Encounter for observation for other suspected diseases and conditions ruled out |
| Z08           | Encounter for follow-up examination after completed treatment for malignant neoplasm (medical surveillance following completed treatment)  
*ICD-10-CM Coding instruction: Use additional code to identify the personal history of malignant neoplasm (Z85._)* |
| Z12._         | Encounter for screening for malignant neoplasms |
| Z13.0         | Encounter for screening for diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism |
| Z15.0         | Genetic susceptibility to malignant neoplasm  
*ICD-10-CM Coding instruction: Code first, if applicable, any current malignant neoplasm (C00-C75, C81-C96); Use additional code, if applicable, for any personal history of malignant neoplasm (Z85._)* |
| Z17.0, Z17.1 | Estrogen receptor positive and negative status |
| Z40.0         | Encounter for prophylactic surgery for risk factors related to malignant neoplasms |
| Z42.1         | Encounter for breast reconstruction following mastectomy |
| Z45.2         | Encounter for Adjustment and Management of Vascular Access Device |
| Z48.3         | Aftercare following surgery for neoplasm  
*ICD-10-CM Coding instruction: Use additional code to identify the neoplasm* |
<p>| Z48.290       | Encounter for aftercare following bone marrow transplant |
| Z51.0         | Encounter for antineoplastic radiation therapy |
| Z51.1         | Encounter for antineoplastic chemotherapy and immunotherapy |
| Z51.5, Z51.89| Encounter for palliative care and other specified aftercare |</p>
<table>
<thead>
<tr>
<th>ICD-10-CM Codes</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Z79.81</td>
<td>Long term (current) use of agents affecting estrogen receptors and estrogen levels</td>
</tr>
<tr>
<td></td>
<td><strong>ICD-10-CM Coding instruction:</strong> Code first, if applicable, malignant neoplasm of breast (C50_), malignant neoplasm of prostate (C619)</td>
</tr>
<tr>
<td>Z80._</td>
<td>Family history of primary malignant neoplasm</td>
</tr>
<tr>
<td>Z85._</td>
<td>Personal history of malignant neoplasm</td>
</tr>
<tr>
<td>Z86.0_, Z86.01_, Z86.03</td>
<td>Personal history of in situ and benign neoplasms and neoplasms of uncertain behavior</td>
</tr>
<tr>
<td>Z92.21, Z29.23, Z92.25, Z92.3</td>
<td>Personal history of antineoplastic chemotherapy, estrogen therapy, immunosuppression therapy or irradiation (radiation)</td>
</tr>
<tr>
<td>Z94.81, Z94.84</td>
<td>Bone marrow and stem cell transplant status</td>
</tr>
</tbody>
</table>
3.10 REPORTABLE TERMS LIST

The following list identifies MOST of the NYSCR’s reportable terms. This list is not comprehensive. Refer to the footnotes at the bottom of each page for explanations of the various font types used in the list. The DEFINITIVE references are the 2022 Solid Tumor Rules, the Hematopoietic and Lymphoid Database and Manual and ICD-O, including the ICD-O-3.2 Updates.

### REPORTABLE LIST:

<table>
<thead>
<tr>
<th><strong>A</strong></th>
<th>Acidophil adenocarcinoma</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Acidophil adenoma</strong></td>
<td>Acidophil-basophil carcinoma, mixed</td>
</tr>
<tr>
<td>Acidophil carcinoma</td>
<td>Acinar adenocarcinoma</td>
</tr>
<tr>
<td>Acinar adenocarcinoma, Sarcomatoid (C619)</td>
<td>Acinar carcinoma</td>
</tr>
<tr>
<td>Acinar cell carcinoma</td>
<td>Acinar cell cystadenocarcinoma</td>
</tr>
<tr>
<td>Acinic cell adenocarcinoma</td>
<td><strong>Acoustic neuroma</strong></td>
</tr>
<tr>
<td>Acquired cystic disease-associated renal cell carcinoma (C649)</td>
<td>Acral lentiginous melanoma, malignant ACTH-producing tumor</td>
</tr>
<tr>
<td>Acute basophilic leukemia</td>
<td>Acute bilineal leukemia</td>
</tr>
<tr>
<td>Acute biphenotypic leukemia</td>
<td>Acute differentiated progressive histiocytosis</td>
</tr>
<tr>
<td>Acute erythremia [obs]</td>
<td>Acute erythremic myelosis [obs]</td>
</tr>
<tr>
<td>Acute erythroid leukemia</td>
<td>Acute granulocytic leukemia</td>
</tr>
<tr>
<td>Acute leukemia, NOS</td>
<td>Acute leukemia, Burkitt type [obs]</td>
</tr>
<tr>
<td>Acute lymphatic leukemia</td>
<td>Acute lymphoblastic leukemia, Burkitt type</td>
</tr>
<tr>
<td>Acute lymphoblastic leukemia, L2 type, NOS</td>
<td>Acute lymphoblastic leukemia, mature B-cell type</td>
</tr>
<tr>
<td>Acute myeloblastic leukemia, NOS</td>
<td>Acute lymphoblastic leukemia, NOS</td>
</tr>
<tr>
<td>Acute lymphoblastic leukemia, precursor-cell type</td>
<td>Acute lymphoblastic leukemia, precursor-cell type</td>
</tr>
<tr>
<td>Acute lymphocytic leukemia</td>
<td>Acute megakaryoblastic leukemia</td>
</tr>
<tr>
<td>Acute lymphoblastic leukemia-lymphoma, NOS</td>
<td>Acute mixed lineage leukemia</td>
</tr>
<tr>
<td>Acute lymphoid leukemia</td>
<td>Acute monoblastic leukemia</td>
</tr>
<tr>
<td>Acute myeloblastic leukemia</td>
<td>Acute monocytic leukemia</td>
</tr>
<tr>
<td>Acute myeloblastic leukemia</td>
<td>Acute myelocytic leukemia</td>
</tr>
<tr>
<td>Acute myeloblastic leukemia with maturation</td>
<td>Acute myeloid leukemia with abnormal marrow eosinophils (includes all variants)</td>
</tr>
<tr>
<td>Acute myeloid leukemia with BCR-ABL1</td>
<td>Acute myeloid leukemia with biallelic mutations of CEBPA</td>
</tr>
<tr>
<td>Acute myeloid leukemia with maturation</td>
<td>Acute myeloid leukemia with multilineage dysplasia</td>
</tr>
<tr>
<td>Acute myeloid leukemia with mutated NPM1</td>
<td>Acute myeloid leukemia with mutated RUNX1</td>
</tr>
<tr>
<td>Acute myeloid leukemia</td>
<td>Acute myeloid leukemia</td>
</tr>
<tr>
<td>(megakaryoblastic) with t(1;22)(p13;q13); RBM15-MKL1</td>
<td></td>
</tr>
</tbody>
</table>

Refer to ICD-O-3 for inclusive listing of morphology terms.

Asterisk (*): *Non-reportable if primary site is skin of non-mucoepidermoid anatomic site (ICD-O-3: C44_)

**Bold:** Indicates benign/borderline/uncertain tumors that are reportable if they occur intracranially or in the CNS

Underlined: Indicates a change in behavior OR a new ICD-O term, reportable with diagnoses made 1/1/2022 forward

**SMALL CAPS:** Indicates a change in behavior to non-reportable with diagnoses made 1/1/2022 forward

**BOLD SMALL CAPS:** Indicates a new term reportable with diagnoses made 1/1/2022 forward

The NYSCR Reporting Manual – Part Three – Reportable Conditions and Terminology

Revised January 2022
<table>
<thead>
<tr>
<th>Acute myeloid leukemia without maturation</th>
<th>Acute panmyelosis with myelofibrosis (C421)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acute myeloid leukemia, 11q23 abnormalities</td>
<td>Acute progressive histiocytosis X</td>
</tr>
<tr>
<td>Acute myeloid leukemia, AML1 (CBF-alpha) / ETO</td>
<td>Acute promyelocytic leukemia</td>
</tr>
<tr>
<td>Acute myeloid leukemia, CBF-beta/MYH11</td>
<td>Acute promyelocytic leukemia, PML/RAR-alpha</td>
</tr>
<tr>
<td>Acute myeloid leukemia, inv(16)(p13;q22)</td>
<td>Acute promyelocytic leukemia, t(15;17)(q22;q11-12)</td>
</tr>
<tr>
<td>Acute myeloid leukemia with inv(3)(p21q26.2) or t(3;3)(q21;q26.2); RPN1EV1</td>
<td>Adamantinoma, NOS</td>
</tr>
<tr>
<td>Acute myeloid leukemia, M6 type</td>
<td>Adamantinoma of long bones</td>
</tr>
<tr>
<td>Acute myeloid leukemia, minimal differentiation</td>
<td>Adenocarcinoma</td>
</tr>
<tr>
<td>Acute myeloid leukemia, MLL</td>
<td>Adenocarcinoma and epidermoid carcinoma mixed</td>
</tr>
<tr>
<td>Acute myeloid leukemia, NOS (FAB or WHO type, not specified)</td>
<td>Adenocarcinoma and squamous cell carcinoma, mixed</td>
</tr>
<tr>
<td>Acute myeloid leukemia, PML/RAR-alpha</td>
<td>Adenocarcinoma combined with other types of carcinoma</td>
</tr>
<tr>
<td>Acute myeloid leukemia, t(15;17)(q22;q11-12)</td>
<td><strong>ADENOCARCINOMA, HPV-ASSOCIATED</strong> C530-C531, C538-C539)</td>
</tr>
<tr>
<td>Acute myeloid leukemia, t(16;16)(p13;q11)</td>
<td>Adenocarcinoma in a polyp, NOS</td>
</tr>
<tr>
<td>Acute myeloid leukemia, t(8;21)(q22;q22)</td>
<td>Adenocarcinoma in a polypoid adenoma</td>
</tr>
<tr>
<td>Acute myeloid leukemia with BCR-ABL1</td>
<td>Adenocarcinoma in adenomatous polyp</td>
</tr>
<tr>
<td>Acute myeloid leukemia with biallelic mutations of CEBPA</td>
<td>Adenocarcinoma in adenomatous polyposis coli</td>
</tr>
<tr>
<td>Acute myeloid leukemia with mutated NPM1</td>
<td>Adenocarcinoma in multiple adenomatous polyps</td>
</tr>
<tr>
<td>Acute myeloid leukemia with mutated RUNX1</td>
<td><strong>ADENOCARCINOMA, HPV-INDEPENDENT, CLEAR CELL TYPE (C539)</strong></td>
</tr>
<tr>
<td>Acute myeloid leukemia with prior myelodysplastic syndrome</td>
<td><strong>ADENOCARCINOMA, HPV-INDEPENDENT, GASTRIC TYPE (C530-C531, C538-C539)</strong></td>
</tr>
<tr>
<td>Acute myeloid leukemia with t(6;9)(p23;q34) DEK-NUP214</td>
<td><strong>ADENOCARCINOMA, HPV-INDEPENDENT, MESONEPHRIC TYPE</strong></td>
</tr>
<tr>
<td>Acute myeloid leukemia without prior myelodysplastic syndrome</td>
<td><strong>ADENOCARCINOMA, HPV-INDEPENDENT, NOS C530-C531, C538-C539)</strong></td>
</tr>
<tr>
<td>Acute myelomonocytic leukemia</td>
<td>Adenocarcinoma in situ in a polyp, NOS</td>
</tr>
<tr>
<td>Acute myelomonocytic leukemia with abnormal eosinophils</td>
<td>Adenocarcinoma in situ in adenomatous polyp</td>
</tr>
<tr>
<td>Acute myelosclerosis</td>
<td>Adenocarcinoma in situ in polypoid adenoma</td>
</tr>
<tr>
<td>Acute non-lymphocytic leukemia</td>
<td>Adenocarcinoma in situ in tubular adenoma</td>
</tr>
<tr>
<td>Acute panmyelosis</td>
<td>Adenocarcinoma in situ in tubulovillous adenoma</td>
</tr>
<tr>
<td></td>
<td>Adenocarcinoma in situ in villous adenoma</td>
</tr>
</tbody>
</table>

Refer to ICD-O-3 for inclusive listing of morphology terms.

**Asterisk (\(*\):** *Non-reportable if primary site is skin of non-mucoepidermoid anatomic site (ICD-O-3: C44_)*

**Bold:** Indicates benign/borderline/uncertain tumors that are reportable if they occur intracranially or in the CNS

**Underlined:** Indicates a change in behavior OR a new ICD-O term, reportable with diagnoses made 1/1/2021 forward

**BOLD SMALL CAPS:** Indicates a change in behavior to reportable with diagnoses made 1/1/2022 forward

The NYSCR Reporting Manual – Part Three – Reportable Conditions and Terminology

Revised January 2022
Adenocarcinoma in situ, NOS
Adenocarcinoma in tubular adenoma
Adenocarcinoma in tubulovillous adenoma
Adenocarcinoma in villous adenoma
Adenocarcinoma of anal ducts (C211)
Adenocarcinoma of anal glands (C211)
Adenocarcinoma of rete ovarii (C569)
Adenocarcinoma with apocrine metaplasia
Adenocarcinoma with cartilaginous and osseous metaplasia
Adenocarcinoma with cartilaginous metaplasia
Adenocarcinoma with mixed subtypes
Adenocarcinoma with neuroendocrine differentiation
Adenocarcinoma with osseous metaplasia
Adenocarcinoma with spindle cell metaplasia
Adenocarcinoma with squamous metaplasia
Adenocarcinoma, cylindroid
Adenocarcinoma, diffuse type
Adenocarcinoma, endocervical type
Adenocarcinoma, intestinal type
Adenocarcinoma, NOS
Adenocarcinoma, pancreatobiliary-type (C241)
Adenocystic carcinoma
Adenoid basal carcinoma (C53_)
Adenoid cystic carcinoma
Adenoid squamous cell carcinoma*
**Adenoma, NOS**

**ADENOMATOUS POLYP, HIGH GRADE DYSPLASIA (C160 – C166, C168-C169, C170-C173, C178-C179)**

Adenomyoepithelioma with carcinoma (C50_)
Adenomyoepithelioma (C50_)
Adenosarcoma
Adenosquamous carcinoma
Adnexal carcinoma
Adnexal adenocarcinoma (C44 )
Adrenal cortical adenocarcinoma

---

Refer to ICD-O-3 for inclusive listing of morphology terms.

Asterisk (*): *Non-reportable if primary site is skin of non-mucoepidermoid anatomic site (ICD-O-3: C44_)
Bold: Indicates benign/borderline/uncertain tumors that are reportable if they occur intracranially or in the CNS
Underlined: Indicates a change in behavior OR a new ICD-O term, reportable with diagnoses made 1/1/2021 forward
**BOLD SMALL CAPS:** Indicates a change in behavior to reportable with diagnoses made 1/1/2021 forward

The NYSCR Reporting Manual – Part Three – Reportable Conditions and Terminology

Revised January 2022
<table>
<thead>
<tr>
<th>Term</th>
<th>Term</th>
<th>Term</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anaplastic large B-cell lymphoma</td>
<td>Anaplastic large cell lymphoma ALK-negative</td>
<td>Atypical chronic myeloid leukemia, Philadelphia chromosome (Ph1) negative</td>
</tr>
<tr>
<td>Anaplastic large cell lymphoma, CD30+</td>
<td>Anaplastic large cell lymphoma, NOS</td>
<td>Atypical fibrous histiocytoma</td>
</tr>
<tr>
<td>Anaplastic large cell lymphoma, T cell and Null cell type</td>
<td>Anaplastic oligodendroglioma, IDH-mutant and 1p/19q-codeleted (C71_)</td>
<td>Atypical fibroxanthoma</td>
</tr>
<tr>
<td>Anaplastic oligoastrocytoma (C71_)</td>
<td>Anaplastic pleomorphic xanthoastrocytoma (C71_)</td>
<td>Atypical medullary carcinoma (C50_)</td>
</tr>
<tr>
<td>Androblastoma, malignant</td>
<td>Androblastoma, malignant</td>
<td>Atypical meningioma</td>
</tr>
<tr>
<td><strong>Angioblastic meningioma</strong></td>
<td><strong>Angioblastic meningioma</strong></td>
<td><strong>Atypical proliferative mucinous tumor</strong></td>
</tr>
<tr>
<td><strong>Angioblastoma</strong></td>
<td><strong>Angioblastic meningioma</strong></td>
<td><strong>Atypical proliferative papillary serous tumor</strong></td>
</tr>
<tr>
<td><strong>Angiogenic glioma</strong></td>
<td><strong>Angiogenic glioma</strong></td>
<td><strong>Atypical proliferating serous tumor</strong></td>
</tr>
<tr>
<td>Angiocentric immunoproliferative lesion</td>
<td>Angiocentric T-cell lymphoma [obs]</td>
<td><strong>Atypical teratoid/rhabdoid tumor</strong></td>
</tr>
<tr>
<td>Angiocentric T-cell lymphoma [obs]</td>
<td>Angioendotheliomatosis</td>
<td>Atypical teratoid/rhabdoid tumor (C71_)</td>
</tr>
<tr>
<td>Angioimmunoblastic lymphoma</td>
<td>Angiominoblastic T-cell lymphoma</td>
<td></td>
</tr>
<tr>
<td><strong>Angioliroma, NOS</strong></td>
<td><strong>Angioliroma, NOS</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Angiomatous meningioma</strong></td>
<td><strong>Angiomatous meningioma</strong></td>
<td></td>
</tr>
<tr>
<td>Angiomyosarcoma</td>
<td>Angiomyosarcoma</td>
<td></td>
</tr>
<tr>
<td>Angiosarcoma</td>
<td>Angiotropic lymphoma</td>
<td></td>
</tr>
<tr>
<td><strong>Aortic body paranglioma (C755)</strong></td>
<td><strong>Aortic body paranglioma (C755)</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Aortic body tumor (C755)</strong></td>
<td><strong>Aortic body tumor (C755)</strong></td>
<td></td>
</tr>
<tr>
<td>Aorticopulmonary paranglioma (C755)</td>
<td>Aorticopulmonary paranglioma (C755)</td>
<td></td>
</tr>
<tr>
<td>Apocrine adenocarcinoma</td>
<td>Apocrine adenocarcinoma</td>
<td></td>
</tr>
<tr>
<td>Argentaffinoma, malignant</td>
<td>Argentaffinoma, malignant</td>
<td></td>
</tr>
<tr>
<td>Arrhenoblastoma, NOS</td>
<td>Arrhenoblastoma, NOS</td>
<td></td>
</tr>
<tr>
<td>Askin tumor</td>
<td>Askin tumor</td>
<td></td>
</tr>
<tr>
<td>Astroblastoma</td>
<td>Astroblastoma</td>
<td></td>
</tr>
<tr>
<td>Astrocytic glioma</td>
<td>Astrocytic glioma</td>
<td></td>
</tr>
<tr>
<td>Astrocytoma</td>
<td>Astrocytoma</td>
<td></td>
</tr>
<tr>
<td>Astrocytoma, anaplastic</td>
<td>Astrocytoma, anaplastic</td>
<td></td>
</tr>
<tr>
<td>Astrocytoma, low grade (C71_)</td>
<td>Astrocytoma, low grade (C71_)</td>
<td></td>
</tr>
<tr>
<td>Astroglia</td>
<td>Astroglia</td>
<td></td>
</tr>
<tr>
<td>Atypical carcinoid tumor</td>
<td>Atypical carcinoid tumor</td>
<td></td>
</tr>
<tr>
<td>Atypical choroid plexus papilloma</td>
<td>Atypical choroid plexus papilloma</td>
<td></td>
</tr>
<tr>
<td>Atypical chronic myeloid leukemia, BCR/ABL1 negative</td>
<td>Atypical chronic myeloid leukemia, BCR/ABL1 negative</td>
<td></td>
</tr>
</tbody>
</table>

Refer to ICD-O-3 for inclusive listing of morphology terms.

Asterisk (*): "Non-reportable if primary site is skin of non-mucoepidermoid anatomic site (ICD-O-3: C44_)

Bold: Indicates benign/borderline/uncertain tumors that are reportable if they occur intracranially or in the CNS

Underlined: Indicates a change in behavior OR a new ICD-O term, reportable with diagnoses made 1/1/2021 forward

BOLD SMALL CAPS: Indicates a change in behavior to reportable with diagnoses made 1/1/2022 forward

The NYSCR Reporting Manual – Part Three – Reportable Conditions and Terminology

Revised January 2022
| B-lymphoblastic leukemia/lymphoma, NOS | Bronchiolo-alveolar carcinoma, goblet cell type (C34_) |
| B-lymphoblastic leukemia/lymphoma with hyperdiploidy | Bronchiolo-alveolar carcinoma, indeterminate type (C34_) |
| B-lymphoblastic leukemia/lymphoma with hypodiploidy (hypodiploid ALL) | Bronchiolo-alveolar carcinoma, mixed mucinous and non-mucinous (C34_) |
| B-lymphoblastic leukemia/lymphoma with t(1;19)(q23;p13.3); E2A PBX1 (TCF3 PBX1) | Bronchiolo-alveolar carcinoma, mucinous (C34_) |
| B-lymphoblastic leukemia/lymphoma with t(5;14)(q31;q32); IL3-IGH | Bronchiolo-alveolar carcinoma, non-mucinous (C34_) |
| B-lymphoblastic leukemia/lymphoma, not otherwise specified | Bronchiolo-alveolar carcinoma, type II pneumocyte (C34_) |
| B-lymphocytic leukemia/lymphoma, BCR-ABL1-like | Bronchiolo-alveolar carcinoma, type II pneumocyte and goblet cell type (C34_) |
| BEDNAR TUMOR | Burkitt cell leukemia |
| Bellini duct carcinoma (C649) | Burkitt-like lymphoma |
| Beta cell adenoma (C254) | Burkitt lymphoma, NOS |
| Beta cell tumor, malignant | Burkitt tumor |
| Bile duct adenocarcinoma | Cancer* |
| Bile duct carcinoma | C cell carcinoma |
| Bile duct cystadenocarcinoma | C cell carcinoma (C739) |
| Biliary intraepithelial neoplasia III (8148/2) | C-ALL |
| Biliary intraepithelial neoplasia, high grade (8148/2) | Cancer* |
| Biphenotypic sinonasal sarcoma | Capillary hemangioma |
| Blast cell leukemia | Carcinofibroma |
| Blastaoma, NOS* | Carcinoid, NOS (including appendix, effective with 2015 diagnoses) |
| Blue nevus, malignant | Carcinoid tumor, argentaffin, malignant |
| Botryoid sarcoma | Carcinoid tumor, NOS (including appendix, effective with 2015 diagnoses) |
| Brenner tumor, malignant | Carcinoma in a polyp, NOS |
| Breast implant-associated anaplastic large cell lymphoma (C50_) | Carcinoma in adenomatous polyp |
| Bronchial adenoma, carcinoid | Carcinoma in pleomorphic adenoma |
| Bronchial adenoma, cylindroid | Carcinoma in situ in adenomatous polyp |
| Bronchial-associated lymphoid tissue lymphoma | Carcinoma in situ, NOS* |
| Bronchiolar adenocarcinoma | Carcinoma showing thymus-like differentiation |
| Bronchiolar carcinoma | Carcinoma showing thymus-like element |
| Bronchiolo-alveolar adenocarcinoma | Carcinoma simplex |
| Bronchiolo-alveolar carcinoma | Carcinoma with apocrine metaplasia |
| Bronchiolo-alveolar carcinoma, Clara cell (C34_) | Refer to ICD-O-3 for inclusive listing of morphology terms. |
| Bronchiolo-alveolar carcinoma, Clara cell and goblet cell type (C34_) | |

Asterisk (*): Non-reportable if primary site is skin of non-mucoepidermoid anatomic site (ICD-O-3: C44_)  
**Bold**: Indicates benign/borderline/uncertain tumors that are reportable if they occur intracranially or in the CNS  
Underlined: Indicates a change in behavior OR a new ICD-O term, reportable with diagnoses made 1/1/2021 forward  
**Bold Small Caps**: Indicates a change in behavior to reportable with diagnoses made 1/1/2022 forward
<table>
<thead>
<tr>
<th>Carcinoma with chondroid differentiation (C50_)</th>
<th>Chordoid glioma of third ventricle</th>
</tr>
</thead>
<tbody>
<tr>
<td>Carcinoma with neuroendocrine Differentiation</td>
<td>Chordoma</td>
</tr>
<tr>
<td>Carcinoma with osseous differentiation (C50_)</td>
<td>Choriocarcinoma combined with embryonal carcinoma</td>
</tr>
<tr>
<td>Carcinoma with osteoclast-like giant Cells</td>
<td>Choriocarcinoma combined with other germ cell elements</td>
</tr>
<tr>
<td>Carcinoma with other types mesenchymal differentiation (C50_)</td>
<td>Choriocarcinoma combined with teratoma</td>
</tr>
<tr>
<td>Carcinoma with productive fibrosis</td>
<td>Choriocarcinoma, NOS</td>
</tr>
<tr>
<td>Carcinoma, anaplastic*</td>
<td>Chorioepithelioma</td>
</tr>
<tr>
<td>Carcinoma, diffuse type</td>
<td>Choroid plexus carcinoma (C715)</td>
</tr>
<tr>
<td>Carcinoma, intestinal type</td>
<td>Choroid plexus papilloma, anaplastic</td>
</tr>
<tr>
<td>Carcinoma, NOS*</td>
<td>Choroid plexus papilloma, malignant</td>
</tr>
<tr>
<td>Carcinoma, undifferentiated*</td>
<td><strong>Choroid plexus papilloma, NOS</strong></td>
</tr>
<tr>
<td>Carcinosarcoma, embryonal</td>
<td>Chromaffin paraganglioma (C741)</td>
</tr>
<tr>
<td>Carcinosarcoma, NOS</td>
<td>Chromophobe adenocarcinoma</td>
</tr>
<tr>
<td>Carotid body paraganglioma (C754)</td>
<td><strong>Chromophobe adenoma</strong></td>
</tr>
<tr>
<td>Carotid body tumor (754)</td>
<td>Chromophobe carcinoma</td>
</tr>
<tr>
<td>CASTLE</td>
<td>Chromophobe cell renal carcinoma (C649)</td>
</tr>
<tr>
<td><strong>Cavernous angioma</strong></td>
<td>Chronic eosinophilic leukemia</td>
</tr>
<tr>
<td><strong>Cavernous hemangioma</strong></td>
<td>Chronic erythremia [obs]</td>
</tr>
<tr>
<td>CD30+ lymphoproliferative disorder</td>
<td>Chronic granulocytic leukemia</td>
</tr>
<tr>
<td>Cell adenocarcinoma, mixed</td>
<td>Chronic granulocytic leukemia, BCR/ABL</td>
</tr>
<tr>
<td>Cellular ependymoma (C71_)</td>
<td>Chronic granulocytic leukemia, Philadelphia chromosome (Ph1) positive</td>
</tr>
<tr>
<td>Central neuroblastoma (C71_)</td>
<td>Chronic granulocytic leukemia, T (9;22)(q34;q11)</td>
</tr>
<tr>
<td>Central neurocytoma</td>
<td>Chronic idiopathic myelofibrosis</td>
</tr>
<tr>
<td>Central osteosarcoma (C40, C41_)</td>
<td>Chronic leukemia, NOS [obs]</td>
</tr>
<tr>
<td>Central primitive neuroectodermal tumor, NOS (C71)</td>
<td>Chronic lymphatic leukemia</td>
</tr>
<tr>
<td>Cerebellar liponeurocytoma</td>
<td>Chronic lymphocytic leukemia</td>
</tr>
<tr>
<td>Cerebellar sarcoma, NOS</td>
<td>Chronic lymphocytic leukemia, B-cell type (includes all variants of BCLL)</td>
</tr>
<tr>
<td>Ceruminous adenocarcinoma</td>
<td>Chronic lymphoid leukemia</td>
</tr>
<tr>
<td>Ceruminous carcinoma</td>
<td>Chronic monocytic leukemia [obs]</td>
</tr>
<tr>
<td>Chemodectoma</td>
<td>Chronic myelocytic leukemia</td>
</tr>
<tr>
<td>Chloroma</td>
<td>Chronic myelomonocytic leukemia, NOS</td>
</tr>
<tr>
<td>Cholangiocarcinoma</td>
<td>Chronic myelogenous leukemia</td>
</tr>
<tr>
<td>Cholangiocarcinoma and hepatocellular carcinoma, combined</td>
<td>Chronic myelogenous leukemia, BCR/ABL1 positive</td>
</tr>
<tr>
<td>Chondroblastoid osteosarcoma</td>
<td>Chronic myelogenous leukemia, Philadelphia chromosome (Ph1) positive</td>
</tr>
<tr>
<td>Chondroblastoma, malignant</td>
<td><strong>Chondrosarcoma grade I</strong></td>
</tr>
<tr>
<td>Chondroid chordoma</td>
<td><strong>Chondrosarcoma grade II/III (grade 2/3)</strong></td>
</tr>
<tr>
<td><strong>Chondrosarcoma grade II/III (grade 2/3)</strong></td>
<td><strong>Chondrosarcoma grade II/III (grade 2/3)</strong></td>
</tr>
<tr>
<td>Chondrosarcoma, NOS</td>
<td><strong>Chondrosarcoma grade II/III (grade 2/3)</strong></td>
</tr>
</tbody>
</table>

Refer to ICD-O-3 for inclusive listing of morphology terms.

Asterisk (*): *Non-reportable if primary site is skin of non-mucoepidermoid anatomic site (ICD-O-3: C44_)

**Bold:** Indicates benign/borderline/uncertain tumors that are reportable if they occur intracranially or in the CNS

**Underlined:** Indicates a change in behavior OR a new ICD-O term, reportable with diagnoses made 1/1/2021 forward

**BOLD SMALL CAPS:** Indicates a change in behavior to reportable with diagnoses made 1/1/2022 forward

The NYSCR Reporting Manual – Part Three – Reportable Conditions and Terminology

Revised January 2022
Chronic myelogenous leukemia, t(9;22)(q34;q11)
Chronic myeloid leukemia
Chronic myelomonocytic leukemia
Chronic myelomonocytic leukemia in transformation [obs]
Chronic myelomonocytic leukemia, NOS
Chronic myelomonocytic leukemia, Type I
Chronic myelomonocytic leukemia, Type II
Chronic myeloproliferative disease, NOS
Chronic myeloproliferative disorder
Chronic neutrophilic leukemia
**CIC-REARRANGED SARCOMA**
Circumscribed arachnoidal cerebellar sarcoma
Classical Hodgkin lymphoma, lymphocyte depletion, diffuse fibrosis
Classical Hodgkin lymphoma, lymphocyte depletion, NOS
Classical Hodgkin lymphoma, lymphocyte depletion, reticular
Classical Hodgkin lymphoma, lymphocyte-rich
Classical Hodgkin lymphoma, mixed cellularity, NOS
Classical Hodgkin lymphoma, nodular sclerosis, cellular phase
Classical Hodgkin lymphoma, nodular sclerosis, grade 1
Classical Hodgkin lymphoma, nodular sclerosis, grade 2
Classical Hodgkin lymphoma, nodular sclerosis, NOS
Classic epithelioid sarcoma
Classic indolent Kaposi sarcoma
Clear cell adenocarcinofibroma (C569)
Clear cell adenocarcinoma, mesonephroid
Clear cell adenocarcinoma, NOS
Clear cell carcinoma
Clear cell chondrosarcoma (C40_, C41_)
Clear cell cystadenocarcinofibroma (C569)
Clear cell ependymoma (C71_)
Clear cell (glycogen-rich) urothelial carcinoma
Clear cell neuroendocrine tumor, non-functioning pancreatic
Clear cell sarcoma
Clear cell sarcoma of kidney
Clear cell sarcoma of tendons and aponeuroses
Cloacogenic carcinoma
CNS embryonal tumor with rhabdoid features (C71_)
Collecting duct carcinoma (C649)
Colloid adenocarcinoma
Colloid carcinoma
Combined carcinoid and adenocarcinoma
Combined hepatocellular carcinoma and Cholangiocarcinoma
Combined large cell neuroendocrine carcinoma
Combined small cell carcinoma
Combined small cell-adenocarcinoma
Combined small cell-squamous cell carcinoma
Comedocarcinoma, noninfiltrating
Comedocarcinoma, NOS
Common ALL
Common precursor B ALL
Composite carcinoid
Composite Hodgkin and non-Hodgkin lymphoma
Composite paraganglioma
Composite pheochromocytoma (C741)
Condylomatous carcinoma
Congenital fibrosarcoma
Congenital spindle cell rhabdomyosarcoma with VGLL2/NCOA2/CITED2 rearrangements
Conventional central osteosarcoma (C40_, C41_)

Refer to ICD-O-3 for inclusive listing of morphology terms.

**Asterisk (*)**: *Non-reportable if primary site is skin of non-mucoepidermoid anatomic site (ICD-O-3: C44_)
**Bold**: Indicates benign/borderline/uncertain tumors that are reportable if they occur intracranially or in the CNS
**Underlined**: Indicates a change in behavior OR a new ICD-O term, reportable with diagnoses made 1/1/2021 forward
**Small Caps**: Indicates a change in behavior to non-reportable with diagnoses made 1/1/2021 forward

**BOLD SMALL CAPS**: Indicates a change in behavior to reportable with diagnoses made 1/1/2022 forward

The NYSCR Reporting Manual – Part Three – Reportable Conditions and Terminology

Revised January 2022
### Desmoplastic infantile astrocytoma and ganglioglioma
- Desmoplastic medulloblastoma
- Desmoplastic melanoma, amelanotic (C44_)
- Desmoplastic melanoma, malignant
- Desmoplastic mesothelioma
- Desmoplastic nodular medulloblastoma (C716)
- Desmoplastic small round cell tumor
- Di Guglielmo disease [obs]
- Differentiated intraepithelial neoplasia
- Differentiated penile intraepithelial neoplasia (PeIN) (C60_)
- Differentiated vulvar intraepithelial neoplasia (VIN) (C51_)
- Diffuse astrocytoma (C71_)
- Diffuse astrocytoma, IDH-mutant (C71_)
- Diffuse astrocytoma, IDH-wildtype (C71_)
- Diffuse astrocytoma, low grade (C71_)
- Diffuse leptomeningeal glioneuronal tumor (C71_)
- Diffuse midline glioma, H3 K27M-mutant (C71_)

### Diffuse meningiomatosis
- Digital papillary adenocarcinoma (C44_)
- Diktyoma
- Diktyoma, malignant (C69_)
- DIN III (ductal intraepithelial neoplasia III) (C50_)
- Duct adenocarcinoma
- Duct carcinoma
- Duct carcinoma, desmoplastic type
- Duct cell carcinoma
- Ductal carcinoma
- Ductal carcinoma in situ, comedo type (C50_)
- Ductal carcinoma in situ, cribriform type (C50_)
- Ductal carcinoma in situ, micropapillary (C50_)
- Ductal carcinoma in situ, NOS (C50_)
- Ductal carcinoma in situ, papillary (C50_)

Refer to ICD-O-3 for inclusive listing of morphology terms.

**Asterisk (*)**: *Non-reportable if primary site is skin of non-mucoepidermoid anatomic site (ICD-O-3: C44_)
**Bold**: Indicates benign/borderline/uncertain tumors that are reportable if they occur intracranially or in the CNS
**Underlined**: Indicates a change in behavior OR a new ICD-O term, reportable with diagnoses made 1/1/2021 forward
**BOLD SMALL CAPS**: Indicates a change in behavior to reportable with diagnoses made 1/1/2022 forward

The NYSCR Reporting Manual – Part Three – Reportable Conditions and Terminology

Revised January 2022
Ductal carcinoma in situ, solid type (C50_)  
Ductal carcinoma, cribriform type (C50_)  
Ductal intraepithelial neoplasia III (DIN III) (C50_)  
**Dysembryoplastic neuroepithelial tumor**  
Dysgerminoma  
**Dysplastic gangliocytoma of cerebellum (D=Lhemitte-Duclos)**  

E  
**Early/Evolving invasive melanoma** (C44_)  
**Early/Evolving melanoma in situ** (C44_)  
EC-cell carcinoid  
Eccrine adenocarcinoma (C44_)  
Eccrine papillary adenocarcinoma (C44_)  
Eccrine poroma, malignant  
ECL cell carcinoid, malignant  
Ectomesenchymoma  
**Embryoma**  
Embryonal adenocarcinoma  
Embryonal carcinoma  
Embryonal carcinoma and teratoma, mixed  
Embryonal carcinoma, infantile  
Embryonal carcinoma, polyembryonal type  
Embryonal hepatoma  
Embryonal rhabdomyosarcoma  
Embryonal rhabdomyosarcoma, pleomorphic  
Embryonal sarcoma  
Embryonal teratoma  
Embryonal tumor with multi-layered rosettes C19MC-altered (C71_)  
Embryonal tumor with multi-layered rosettes, NOS (C71_)  
Embryonal tumor with rhabdoid features (C710)  
**Encapsulated follicular variant of papillary thyroid carcinoma, NOS (EFVPTC, NOS) (C739)**  

Refer to ICD-O-3 for inclusive listing of morphology terms.

**Asterisk (\(*\)):** Non-reportable if primary site is skin of non-mucoepidermoid anatomic site (ICD-O-3: C44_)

**Bold:** Indicates benign/borderline/uncertain tumors that are reportable if they occur intracranially or in the CNS

**Underlined:** Indicates a change in behavior OR a new ICD-O term, reportable with diagnoses made 1/1/2021 forward

**BOLD SMALL CAPS:** Indicates a change in behavior to reportable with diagnoses made 1/1/2022 forward

---

Revised January 2022
Ependymoma, anaplastic
Ependymoma, NOS
Ependymoma, RELA fusion-positive
Epidermoid carcinoma in situ with questionable stromal invasion*
Epidermoid carcinoma in situ, NOS*
Epidermoid carcinoma, keratinizing*
Epidermoid carcinoma, large cell, nonkeratinizing*
Epidermoid carcinoma, NOS*
Epidermoid carcinoma, small cell nonkeratinizing*
Epidermoid carcinoma, spindle cell*
Epithelial ependymoma
Epithelial tumor, malignant*
Epithelial-myoepithelial carcinoma
Epithelioid and spindle cell melanoma, mixed
Epithelioid cell melanoma
Epithelioid cell sarcoma
Epithelioid glioblastoma
Epithelioid hemangioendothelioma, malignant
Epithelioid hemangioendothelioma, NOS
Epithelioid leiomyosarcoma
Epithelioid malignant peripheral nerve sheath tumor
Epithelioid mesothelioma, NOS
Epithelioid MPNST
Epithelioid sarcoma
Epithelioid trophoblastic tumor
Epithelioma, malignant*
Epithelioma, NOS*
Erdhiem-Chester Disease
Erythremic myelosis, NOS
Erythroleukemia
Essential hemorrhagic thrombocytopenia
Essential thrombocythemia
Essential thrombocytosis
Esthesioneurublastoma
Esthesioneurocytoma
Esthesioneuroepithelioma
Ewing sarcoma
Ewing tumor

Extra-adrenal paragangioma, NOS
Extradural plasmacytoma
Extraventricular neurocytoma
F
FAB L1
FAB L2
FAB L3 [obs]
FAB M0
FAB M1
FAB M2, AML1(CBF-alpha)/ETO
FAB M2, NOS
FAB M2, t(8;21)(q22;q22)
FAB M3 (includes all variants)
FAB M4
FAB M4Eo
FAB M5 (includes all variants)
FAB M6
FAB M7
Fascial fibrosarcoma
Fetal adenocarcinoma
Fibrillary astrocytoma
Fibroblastic liposarcoma
Fibroblastic meningioma
Fibroblastic osteosarcoma
Fibroblastic reticular cell tumor
Fibrochondrosarcoma
Fibroepithelial basal cell carcinoma, Pinkus type*
Fibroepithelioma of Pinkus type*
Fibroepithelioma, NOS*
Fibroliposarcoma
Fibroma, NOS
Fibromatosis-like metaplastic carcinoma (C50_)
Fibromyxosarcoma
Fibrosarcoma, NOS
Fibrosarcoma, NOS
Fibrosarcomatous dermofibrosarcoma protuberans
Fibrous astrocytoma
Fibrous histiocytoma, malignant
Fibrous histiocytoma, NOS
Fibrous meningioma
Fibrous mesothelioma, malignant
Fibrous mesothelioma, NOS
Fibroxanthoma, malignant

Refer to ICD-O-3 for inclusive listing of morphology terms.

Asterisk (*): *Non-reportable if primary site is skin of non-mucoepidermoid anatomic site (ICD-O-3: C44_)
Bold: Indicates benign/borderline/uncertain tumors that are reportable if they occur intracranially or in the CNS
Underlined: Indicates a change in behavior OR a new ICD-O term, reportable with diagnoses made 1/1/2021 forward
Small Caps: Indicates a change in behavior to non-reportable with diagnoses made 1/1/2021 forward
Bold Small Caps: Indicates a change in behavior to reportable with diagnoses made 1/1/2022 forward

The NYSCR Reporting Manual – Part Three – Reportable Conditions and Terminology

Revised January 2022
<table>
<thead>
<tr>
<th><strong>Fibroxanthoma, NOS</strong></th>
<th>Gastrointestinal autonomic nerve tumor</th>
</tr>
</thead>
<tbody>
<tr>
<td>Follicular adenocarcinoma, moderately differentiated</td>
<td>Gastrointestinal pacemaker cell tumor</td>
</tr>
<tr>
<td>Follicular adenocarcinoma, NOS</td>
<td>Gastrointestinal stromal sarcoma</td>
</tr>
<tr>
<td>Follicular adenocarcinoma, trabecular</td>
<td>Gastrointestinal stromal tumor, NOS</td>
</tr>
<tr>
<td>Follicular adenocarcinoma, well differentiated</td>
<td>Gelatinous adenocarcinoma</td>
</tr>
<tr>
<td><strong>Follicular adenoma</strong></td>
<td>Gelatinous carcinoma</td>
</tr>
<tr>
<td>FOLLICULAR CARCINOMA, ENCAPSULATED (C739)</td>
<td>Gemistocytic astrocytoma</td>
</tr>
<tr>
<td>Follicular carcinoma, minimally invasive (C739)</td>
<td>Gemistocytoma</td>
</tr>
<tr>
<td>Follicular carcinoma, moderately differentiated</td>
<td>Generalized Langerhans cell histiocytosis</td>
</tr>
<tr>
<td>Follicular carcinoma, NOS</td>
<td>Germ cell tumor</td>
</tr>
<tr>
<td>Follicular carcinoma, oxyphilic cell (C739)</td>
<td>Germ cell tumor, mixed</td>
</tr>
<tr>
<td>Follicular carcinoma, trabecular</td>
<td>Germ cell tumor, nonseminomatous (C62_)</td>
</tr>
<tr>
<td>Follicular carcinoma, well differentiated</td>
<td>Germ cell tumors with associated hematological malignancy (C379)</td>
</tr>
<tr>
<td>Follicular dendritic cell sarcoma</td>
<td>Germinoma</td>
</tr>
<tr>
<td>Follicular dendritic cell tumor</td>
<td>Ghost cell odontogenic carcinoma</td>
</tr>
<tr>
<td>Follicular lymphoma, grade 1</td>
<td>Giant cell and spindle cell carcinoma*</td>
</tr>
<tr>
<td>Follicular lymphoma, grade 2</td>
<td>Giant cell carcinoma*</td>
</tr>
<tr>
<td>Follicular lymphoma, grade 3</td>
<td>Giant cell glioblastoma</td>
</tr>
<tr>
<td>Follicular lymphoma, NOS</td>
<td>Giant cell sarcoma (except of Bone)</td>
</tr>
<tr>
<td>Follicular thyroid carcinoma (FTC), encapsulated angioinvasive (C739)</td>
<td>Giant cell sarcoma of bone</td>
</tr>
<tr>
<td><strong>FOLLICULAR TUMOR OF UNCERTAIN MALIGNANT POTENTIAL (C730)</strong></td>
<td>Giant cell tumor of bone, malignant</td>
</tr>
<tr>
<td>Franklin disease</td>
<td>Giant cell tumor of tendon sheath, malignant (C49_)</td>
</tr>
<tr>
<td><strong>G</strong></td>
<td>GIST, NOS</td>
</tr>
<tr>
<td>G cell tumor, malignant</td>
<td>Glassy cell carcinoma</td>
</tr>
<tr>
<td>Gamma heavy chain disease</td>
<td>Glioblastoma, IDH-mutant</td>
</tr>
<tr>
<td><strong>Gangliocytoma</strong></td>
<td>Glioblastoma, IDH wildtype</td>
</tr>
<tr>
<td><strong>Ganglioglioma</strong></td>
<td>Glioblastoma multiforme</td>
</tr>
<tr>
<td>Ganglioglioma, anaplastic</td>
<td>Glioblastoma with sarcomatous component</td>
</tr>
<tr>
<td>Ganglioneuroblastoma</td>
<td>Glioblastoma, NOS</td>
</tr>
<tr>
<td><strong>Ganglioneuroma</strong></td>
<td>Glioma, malignant</td>
</tr>
<tr>
<td>GANT</td>
<td>Glioma, mixed</td>
</tr>
<tr>
<td>Gastrin cell tumor, malignant</td>
<td>Glioma, NOS (except Nasal glioma, not neoplastic)</td>
</tr>
<tr>
<td>Gastrinoma</td>
<td>Gliomatosis cerebri</td>
</tr>
<tr>
<td>Gastrinoma, malignant</td>
<td><strong>Glioneuroma</strong></td>
</tr>
<tr>
<td><strong>GASTROBLASTOMA (C160 – C169)</strong></td>
<td>Gliosarcoma</td>
</tr>
<tr>
<td></td>
<td>Glomangiosarcoma</td>
</tr>
<tr>
<td></td>
<td>Glomoid sarcoma</td>
</tr>
</tbody>
</table>

Refer to ICD-O-3 for inclusive listing of morphology terms.

Asterisk (*): *Non-reportable if primary site is skin of non-mucoepidermoid anatomic site (ICD-O-3: C44_)

**Bold**: Indicates benign/borderline/uncertain tumors that are reportable if they occur intracranially or in the CNS

**Underlined**: Indicates a change in behavior OR a new ICD-O term, reportable with diagnoses made 1/1/2021 forward

**BOLD SMALL CAPS**: Indicates a change in behavior to reportable with diagnoses made 1/1/2022 forward

The NYSCR Reporting Manual – Part Three – Reportable Conditions and Terminology

Revised January 2022
ICD-O-3 for inclusive listing of morphology terms.

Glomus jugulare tumor, NOS (C755)
Glomus tumor, malignant
Glucogonoma
Glucogonoma, malignant
Glycogen-rich carcinoma
Goblet cell adenocarcinoma
Goblet cell carcinoid
Granular cell carcinoma
Granular cell myoblastoma, malignant
Granular cell tumor, malignant
Granular cell tumor, NOS
Granulocytic leukemia, NOS
Granulocytic sarcoma
Granulosa cell carcinoma
Granulosa cell tumor, adult type (C569)
Granulosa cell tumor, malignant
Granulosa cell tumor, sarcomatoid (C569)
Grawitz tumor

Hairy cell leukemia
Hairy cell leukemia variant
Heavy chain disease
Heavy chain disease, NOS
Hemangioblastic meningioma
Hemangioblastoma
Hemangioendothelial sarcoma
Hemangioendothelioma, benign
Hemangioma, NOS
Hemangiopericytic meningioma
Hemangiopericytoma, benign
Hemangiopericytoma, malignant
Hemangiopericytoma, NOS
Hemangiosarcoma
Hepatoblastoma
Hepatocarcinoma
Hepatocellular and bile duct carcinoma, mixed
Hepatocellular carcinoma
Hepatocellular carcinoma, clear cell type (C220)
Hepatocellular carcinoma, fibrolamellar
Hepatocellular carcinoma, pleomorphic type (C220)
Hepatocellular carcinoma, sarcomatoid (C220)
Hepatocellular carcinoma, scirrhous (C220)
Hepatocellular carcinoma, spindle cell variant (C220)
Hepatolobangjoiocarcinoma
Hepatoid adenocarcinoma
Hepatoid carcinoma
Hepatoid yolk sac tumor
Hepatoma, malignant
Hepatoma, NOS
Hepatosplenic gamma-delta cell lymphoma
Hereditary leiomyomatosis & RCC-associated renal cell carcinoma (C649)
Hidradenocarcinoma (C44_)
HIGH GRADE APPENDICEAL MUCINOUS NEOPLASM (HAMN) (C181)
High grade intraurothelial neoplasia
High grade neuroendocrine carcinoma
High grade serous carcinoma
High grade surface osteosarcoma (C40_, C41_)
Histiocyte-rich large B-cell lymphoma
Histiocytic medullary reticulosis [obs]
Histiocytic sarcoma
Hodgkin disease, lymphocyte predominance, diffuse [obs]
Hodgkin disease, lymphocyte predominance, NOS [obs]
Hodgkin disease, lymphocytic depletion, diffuse fibrosis
Hodgkin disease, lymphocytic depletion, NOS
Hodgkin disease, lymphocytic depletion, reticular
Hodgkin disease, lymphocytic-histiocytic predominance [obs]
Hodgkin disease, lymphocytic predominance, diffuse

Refer to ICD-O-3 for inclusive listing of morphology terms.

Asterisk (*): *Non-reportable if primary site is skin of non-mucoepidermoid anatomic site (ICD-O-3: C44_)
Bold: Indicates benign/borderline/uncertain tumors that are reportable if they occur intracranially or in the CNS
Underlined: Indicates a change in behavior OR a new ICD-O term, reportable with diagnoses made 1/1/2021 forward
BOLD SMALL CAPS: Indicates a change in behavior to reportable with diagnoses made 1/1/2022 forward

The NYSCR Reporting Manual – Part Three – Reportable Conditions and Terminology
Revised January 2022
Refer to ICD-O-3 for inclusive listing of morphology terms.

Asterisk (*): *Non-reportable if primary site is skin of non-mucoepidermoid anatomic site (ICD-O-3: C44_)

Bold: Indicates benign/borderline/uncertain tumors that are reportable if they occur intracranially or in the CNS

Underlined: Indicates a change in behavior OR a new ICD-O term, reportable with diagnoses made 1/1/2021 forward

BOLD SMALL CAPS: Indicates a change in behavior to reportable with diagnoses made 1/1/2022 forward

The NYSCR Reporting Manual – Part Three – Reportable Conditions and Terminology

Revised January 2022
Infiltrating lobular carcinoma and ductal carcinoma in situ (C50_)
Infiltrating lobular mixed with other types of carcinoma (C50_)
Infiltrating papillary adenocarcinoma
Inflammatory adenocarcinoma
Inflammatory carcinoma
Inflammatory liposarcoma
Insular carcinoma (C739)
Insulinoma
Insulinoma, malignant
Interdigitating cell sarcoma
Interdigitating dendritic cell sarcoma
Interstitial cell tumor, malignant
Intestinal-type adenocarcinoma
**INTESTINAL-TYPE ADENOMA, HIGH GRADE**
(C160-C166, C168-C169, C170-C173, C178, C179)
Intestinal T-cell lymphoma
Intimal sarcoma
Intracortical osteosarcoma (C40_, C41_)
Intracyclic carcinoma, NOS
Intracyclic papillary adenocarcinoma
Intracyclic papillary neoplasm with associated invasive carcinoma
Intraductal adenocarcinoma, noninfiltrating, NOS
Intraductal and lobular carcinoma
Intraductal carcinoma and lobular carcinoma in situ
Intraductal carcinoma, clinging (C50_)
Intraductal carcinoma, noninfiltrating, NOS
Intraductal carcinoma, NOS
Intraductal carcinoma, solid type
Intraductal micropapillary carcinoma (C50_)
Intraductal oncocytic papillary neoplasm, NOS (C250-C254, C257-C259)
Intraductal oncocytic papillary neoplasm with associated invasive carcinoma (C250-C254, C257-C259)
Intraductal papillary adenocarcinoma with invasion

Intraductal papillary adenocarcinoma, NOS
Intraductal papillary carcinoma, NOS
Intraductal papillary mucinous carcinoma, invasive (C25_)
Intraductal papillary mucinous carcinoma, non-invasive (C25_)
Intraductal papillary mucinous neoplasm (IPMNs) with an associated invasive carcinoma (C25_)
Intraductal papillary mucinous neoplasm with high-grade displasia (C25_)
Intraductal papilloma with ductal carcinoma in situ (C50_)
Intraductal papilloma with lobular carcinoma in situ (C50_)
Intraductal tubulopapillary neoplasm (C25_)
Intraepidermal carcinoma, NOS*
Intraepithelial carcinoma, NOS*
Intraepithelial squamous cell carcinoma*
Intraosseous carcinoma
Intraosseous low grade osteosarcoma (C40_, C41_)
Intraosseous well differentiated osteosarcoma (C40_, C41_)
Intrapulmonary thymoma (C34_)
Intratubular germ cell neoplasia (C62_)
Intratubular malignant germ cells (C62_)
Intravascular B-cell lymphoma
Intravascular bronchial alveolar tumor (C34_) [obs]
Intravascular large B-cell lymphoma (C499)
Invasive carcinoma of no special type (C50_)
Invasive carcinoma, NST (C50_)
Invasive encapsulated follicular variant of papillary thyroid carcinoma (invasive EFVPTC) (C739)
Invasive lobular carcinoma (C50_)
Invasive lobular carcinoma, alveolar type (C50_)

Refer to ICD-O-3 for inclusive listing of morphology terms.

Asterisk (*): "Non-reportable if primary site is skin of non-mucoepidermoid anatomic site (ICD-O-3: C44_)
**Bold**: Indicates benign/borderline/uncertain tumors that are reportable if they occur intracranially or in the CNS
**Underlined**: Indicates a change in behavior OR a new ICD-O term, reportable with diagnoses made 1/1/2021 forward
**Bold SMALL CAPS**: Indicates a change in behavior to reportable with diagnoses made 1/1/2022 forward

The NYSCR Reporting Manual – Part Three – Reportable Conditions and Terminology

Revised January 2022
Refer to ICD-O-3 for inclusive listing of morphology terms.

Asterisk (*): *Non-reportable if primary site is skin of non-mucoepidermoid anatomic site (ICD-O-3: C44_)

Bold: Indicates benign/borderline/uncertain tumors that are reportable if they occur intracranially or in the CNS

Underlined: Indicates a change in behavior OR a new ICD-O term, reportable with diagnoses made 1/1/2021 forward

SMALL CAPS: Indicates a change in behavior to non-reportable with diagnoses made 1/1/2022 forward

BOLD SMALL CAPS: Indicates a change in behavior to reportable with diagnoses made 1/1/2022 forward
| Low grade adenosquamous carcinoma (C50_)
| **LOW GRADE APPENDICEAL MUCINOUS NEOPLASM (LAMN) (C181)**
| Low grade cribriform cystadenocarcinoma (LGCCC)
| Low grade central osteosarcoma
| Low grade fibromyxoid sarcoma
| Low grade intramedullary osteosarcoma
| Low grade myofibroblastic sarcoma
| Low grade serous carcinoma
| Lymphangiendothelial sarcoma
| Lymphangiendothelioma, malignant
| Lymphangiosarcoma
| Lymphoblastic leukemia, NOS
| Lymphoblastoma [obs]
| Lymphocytic leukemia, NOS
| Lymphoepithelial carcinoma*
| Lymphoepithelioid lymphoma
| Lymphoepithelioma*
| Lymphoepithelioma-like carcinoma
| Lymphoid leukemia, NOS
| Lymphoma, NOS
| Lymphomatoid granulomatosis, grade 3
| Lymphomatoid papulosis (C44_)
| **Lymphoproliferative disease, NOS**
| Lymphosarcoma cell leukemia [obs]
| Lymphosarcoma, diffuse [obs]
| Lymphosarcoma, NOS [obs]

**M**

M6A
M6B
Macroglobulinemia, Waldenstrom
Malignancy*
Malignant chondroid syringoma (C44_)
Malignant cystic nephroma (C649)
Malignant eccrine spiradenoma (C44_)
Malignant fibrous histiocytoma (MFH) of bone
Malignant giant cell tumor of soft parts
Malignant histiocytosis
Malignant lymphoma, centroblastic, diffuse
Malignant lymphoma, centroblastic, follicular

Refer to ICD-O-3 for inclusive listing of morphology terms.

**Asterisk (*)**: Non-reportable if primary site is skin of non-mucoepidermoid anatomic site (ICD-O-3: C44_)

**Bold**: Indicates benign/borderline/uncertain tumors that are reportable if they occur intracranially or in the CNS

**Underlined**: Indicates a change in behavior OR a new ICD-O term, reportable with diagnoses made 1/1/2021 forward

**BOLD SMALL CAPS**: Indicates a change in behavior to reportable with diagnoses made 1/1/2022 forward

Revised January 2022
Refer to ICD-O-3 for inclusive listing of morphology terms.

Asterisk (*): Non-reportable if primary site is skin of non-mucoepidermoid anatomic site (ICD-O-3: C44_)

Bold: Indicates benign/borderline/uncertain tumors that are reportable if they occur intracranially or in the CNS

Underlined: Indicates a change in behavior OR a new ICD-O term, reportable with diagnoses made 1/1/2021 forward

SMALL CAPS: Indicates a change in behavior to non-reportable with diagnoses made 1/1/2021 forward

BOLD SMALL CAPS: Indicates a change in behavior to reportable with diagnoses made 1/1/2022 forward
| Malignant melanoma in giant pigmented nevus | Mast cell tumor, NOS |
| Malignant melanoma in junctional nevus | Mastocytoma, malignant |
| Malignant melanoma in precancerous melanosis | Matrical carcinoma (C44_)* |
| Malignant melanoma, NOS | Mature T ALL |
| Malignant melanoma, regressing | Mature T-cell lymphoma, NOS |
| Malignant midline reticulosis [obs] | Mature teratoma of testis in adult |
| Malignant mucinous adenofibroma (C569) | Mediastinal large B-cell lymphoma (C383) |
| Malignant mucinous cystadenofibroma (C569) | Mediterranean lymphoma |
| Malignant multilocular cystic nephroma (C649) | Medullary adenocarcinoma |
| Malignant myelosclerosis [obs] | Medullary carcinoma with amyloid stroma (C739) |
| Malignant myoepithelioma | Medullary carcinoma with lymphoid stroma |
| Malignant peripheral nerve sheath tumor | Mediastinal large B-cell lymphoma (C383) |
| Malignant peripheral nerve sheath tumor with rhabdomyoblastic differentiation | Mediterranean lymphoma |
| Malignant perivascular epithelial cell tumor | Medullary adenocarcinoma |
| Malignant reticulosis, NOS [obs] | Medullary carcinoma with amyloid stroma (C739) |
| Malignant rhabdoid tumor | Medullary carcinoma with lymphoid stroma |
| Malignant Schwannoma with rhabdomyoblastic differentiation | Medullary carcinoma, NOS |
| Malignant serous adenofibroma (C569) | Medullary osteosarcoma (C40_, C41_) |
| Malignant serous cystadenofibroma (C569) | Medullary thyroid carcinoma (C739) |
| Malignant tenosynovial giant cell tumor (C49_) | Medulloblastoma |
| Malignant teratoma, anaplastic | Medulloblastoma, classic |
| Malignant teratoma, intermediate | Medulloblastoma, group 3 (C71_) |
| Malignant teratoma, trophoblastic | Medulloblastoma, group 4 (C71_) |
| Malignant teratoma, undifferentiated | Medulloblastoma, non-WNT/non-SHH (C71_) |
| Malignant tumor, clear cell type | Medulloblastoma, SHH-activated and TP53-mutant (C71_) |
| Malignant tumor, fusiform cell type* | Medulloblastoma, SHH-activated and TP53-wildtype (C71_) |
| Malignant tumor, giant cell type* | Medulloblastoma, WNT-activated (C71_) |
| Malignant tumor, small cell type* | Medulloepithelioma, NOS |
| Malignant tumor, spindle cell type* | Medullomyoblastoma |
| MALT lymphoma | Megakaryocytic leukemia |
| Mammary carcinoma, in situ (C50_) | Megakaryocytic myelosclerosis |
| Mantle cell lymphoma | Melanoma in situ |
| Mantle zone lymphoma | Melanoma, malignant of soft parts |
| Marginal zone B-cell lymphoma, NOS | Melanoma, NOS |
| Marginal zone lymphoma, NOS | Melanotic medulloblastoma (C716) |
| Mast cell leukemia (C421) | Melanotic MPNST |
| Mast cell sarcoma | Melanotic psammomatous MPNST |
| **Melanotic Schwannoma** | **Meningeal melanoma (C71_)** |
| Meningeal melanoma (C71_) | Meningeal melanomatosis (C709) |
| Meningeal sarcoma | Meningeal sarcomatosis |
| Meningeal sarcomatosis | Meningioma, anaplastic |
| Meningioma, anaplastic | Meningioma, malignant |

Refer to ICD-O-3 for inclusive listing of morphology terms.

Asterisk (*): *Non-reportable if primary site is skin of non-mucoepidermoid anatomic site (ICD-O-3: C44_*)

**Bold**: Indicates benign/borderline/uncertain tumors that are reportable if they occur intracranially or in the CNS

**Underlined**: Indicates a change in behavior OR a new ICD-O term, reportable with diagnoses made 1/1/2021 forward

**SMALL CAPS**: Indicates a change in behavior to non-reportable with diagnoses made 1/1/2021 forward

**BOLD SMALL CAPS**: Indicates a change in behavior to reportable with diagnoses made 1/1/2022 forward

The NYSCR Reporting Manual – Part Three – Reportable Conditions and Terminology

Revised January 2022
Meningioma, NOS
Meningiomatosis, NOS
Meningothelial meningioma
Meningothelial sarcoma
Merkel cell carcinoma
Merkel cell tumor
Mesenchymal chondrosarcoma
Mesenchymal tumor, malignant
**Mesenchymoma, benign**
Mesenchymoma, malignant
**Mesenchymoma, NOS**
Mesodermal mixed tumor
Mesonephric adenocarcinoma
Mesonephric-like adenocarcinoma
Mesonephroma, malignant
Mesonephroma, NOS
Mesothelioma, biphasic, NOS
Mesothelioma, malignant
Metaplastic carcinoma of no special type
(C50_)
Metaplastic carcinoma, NOS
Metaplastic carcinoma with chondroid differentiation (C50_)
Metaplastic carcinoma with osseous differentiation (C50_)
Metaplastic carcinoma with other types
Mesenchymal differentiation (C50_)
Metaplastic thymoma (C379)
Metatypical carcinoma*
Microcystic adnexal carcinoma (C44_)
Microcystic urothelial carcinoma
**Microfollicular adenoma**
**Microglioma (C71_) [obs]**
Micropapillary adenocarcinoma (C34_)
Micropapillary carcinoma, NOS
Micropapillary serous carcinoma (C569)
**Middle ear paraganglioma**
(C755)
Midline carcinoma of children and young adults with NUT rearrangement
Minimally invasive adenocarcinoma, mucinous (C34_)
Minimally invasive adenocarcinoma, non-mucinous (C34_)
Minimally invasive adenocarcinoma, NOS (C34_)
**MiT family translocation renal cell carcinoma (C649)**
**Mixed acidophil-basophil adenoma**
Mixed acidophil-basophil carcinoma
Mixed acinar ductal carcinoma
Mixed acinar-endocrine carcinoma
(C25_)
Mixed adenocarcinoma and epidermoid carcinoma
Mixed adenocarcinoma and squamous cell carcinoma
Mixed basal-squamous cell carcinoma*
Mixed carcinoid-adenocarcinoma
Mixed cell adenocarcinoma
**Mixed cell adenoma**
Mixed ductal-endocrine carcinoma (C25_)
Mixed embryonal carcinoma and teratoma
Mixed embryonal rhabdomyosarcoma and alveolar rhabdomyosarcoma
Mixed epithelioid and spindle cell melanoma
Mixed germ cell tumor
Mixed glioma
Mixed hepatocellular and bile duct carcinoma
Mixed invasive mucinous and non-mucinous adenocarcinoma (C34_)
Mixed islet cell and exocrine adenocarcinoma
Mixed liposarcoma
Mixed medullary-follicular carcinoma (C739)
Mixed medullary-papillary carcinoma (C739)
**Mixed meningioma**
Mixed mesenchymal sarcoma
Mixed mesodermal tumor, NOS
Mixed Mullerian tumor
Mixed pancreatic endocrine and exocrine tumor, malignant (C25_)
Mixed phenotype acute leukemia with t(9;22)(q34;q11.2); BCR-ABL1
Mixed phenotype acute leukemia with t(v;11q23); MLL rearranged

Refer to ICD-O-3 for inclusive listing of morphology terms.

**Asterisk (*)**: *Non-reportable if primary site is skin of non-mucoepidermoid anatomic site (ICD-O-3: C44_)
**Bold**: Indicates benign/borderline/uncertain tumors that are reportable if they occur intracranially or in the CNS
**Underlined**: Indicates a change in behavior OR a new ICD-O term, reportable with diagnoses made 1/1/2021 forward
**Bold Small Caps**: Indicates a change in behavior to reportable with diagnoses made 1/1/2022 forward

The NYSCR Reporting Manual – Part Three – Reportable Conditions and Terminology
Revised January 2022
Refer to ICD-O-3 for inclusive listing of morphology terms.

Asterisk (*): *Non-reportable if primary site is skin of non-mucoepidermoid anatomic site (ICD-O-3: C44_)

Bold: Indicates benign/borderline/uncertain tumors that are reportable if they occur intracranially or in the CNS

Underlined: Indicates a change in behavior OR a new ICD-O term, reportable with diagnoses made 1/1/2021 forward

SMALL CAPS: Indicates a change in behavior to non-reportable with diagnoses made 1/1/2022 forward

BOLD SMALL CAPS: Indicates a change in behavior to reportable with diagnoses made 1/1/2022 forward
Refer to ICD-O-3 for inclusive listing of morphology terms.

Asterisk (*): *Non-reportable if primary site is skin of non-mucoepidermoid anatomic site (ICD-O-3: C44_)

Bold: Indicates benign/borderline/uncertain tumors that are reportable if they occur intracranially or in the CNS

Underlined: Indicates a change in behavior OR a new ICD-O term, reportable with diagnoses made 1/1/2021 forward

**SMALL CAPS:** Indicates a change in behavior to non-reportable with diagnoses made 1/1/2021 forward

**BOLD SMALL CAPS:** Indicates a change in behavior to reportable with diagnoses made 1/1/2022 forward

The NYSCR Reporting Manual – Part Three – Reportable Conditions and Terminology

Revised January 2022
Nonlipid reticuloendotheliosis NOS
Non-lymphocytic leukemia, NOS
Non-small cell carcinoma (C34)
NUT carcinoma
NUT midline

Oat cell carcinoma*
Odontogenic carcinoma
Odontogenic carcinosarcoma
Odontogenic fibrosarcoma
Odontogenic sarcoma
Odontogenic tumor, malignant
Olfactory neuroblastoma
Olfactory neuroctytoma (C300)
Olfactory neuroepithelioma
Olfactory neurogenic tumor
Oligoastrocytoma, NOS
Oligodendroblastoma
Oligodendroglioma, anaplastic
Oligodendroglioma IDH mutant and 1p/19q-codeleted
Oligodendroglioma, NOS
Oncocytic adenocarcinoma
Oncocytic adenoma
Oncocytic carcinoma
Oncocytoma
Orchioblastoma
Ossifying fibromyxoid tumor, malignant (C49)
Osteoblastic sarcoma
Osteochondrosarcoma
Osteolastoma, malignant
Osteofibrosarcoma
Osteogenic sarcoma, NOS
Osteosarcoma in Paget disease of bone
Osteosarcoma, NOS
Oxyphilic adenocarcinoma
Oxyphilic adenoma

Paget disease, mammary
Pagetoid reticulosis
Pancoast tumor (a tumor in the apex of the chest with Horner syndrome)
Pancreatobiliary-type carcinoma (C241)
Pancreatoblastoma
PanIN III (Pancreatic Intraepithelial Neoplasia grade III)
Pancreatic endocrine tumor, nonfunctioning (254)
Pancreatic endocrine tumor, NOS (254)
Pancreatic neuroendocrine tumor
Pancreatic neuroendocrine tumor, nonfunctioning (254)
Papillary adenocarcinoma, follicular variant
Papillary adenocarcinoma, NOS
Papillary adenoma, NOS
Papillary and follicular adenocarcinoma
Papillary and follicular carcinoma
Papillary carcinoma in situ*
Papillary carcinoma of thyroid (C739)
Papillary carcinoma, columnar cell (C739)
Papillary carcinoma, diffuse sclerosing (C739)
Papillary carcinoma, encapsulated (C739)
Papillary carcinoma, follicular variant
Papillary carcinoma, NOS*
Papillary carcinoma, oxyphilic cell (C739)
Papillary carcinoma, tall cell (C739)
Papillary cystadenocarcinoma, NOS
Papillary cystadenocarcinoma, borderline malignancy
Papillary ependymoma
Papillary ependymoma
Papillary epidermoid carcinoma*
Papillary glioneuronal tumor
Papillary meningioma
Papillary meningioma
Papillary microcarcinoma (C739)
Papillary mucinous cystadenocarcinoma (569)

Refer to ICD-O-3 for inclusive listing of morphology terms.

Asterisk (*): *Non-reportable if primary site is skin of non-mucoepidermoid anatomic site (ICD-O-3: C44_)
Bold: Indicates benign/borderline/uncertain tumors that are reportable if they occur intracranially or in the CNS
Underlined: Indicates a change in behavior OR a new ICD-O term, reportable with diagnoses made 1/1/2021 forward
Small Caps: Indicates a change in behavior to non-reportable with diagnoses made 1/1/2022 forward

The NYSCR Reporting Manual – Part Three – Reportable Conditions and Terminology

Revised January 2022
Papillary mucinous cystadenoma, borderline malignancy
Papillary mucinous tumor of low malignant potential
**PAPILLARY NEOPLASM, PANCREATOBLIARY TYPE, WITH HIGH GRADE INTRAEPITHELIAL NEOPLASIA C241**
Papillary pseudomucinous Cystadenocarcinoma (C569)
**Papillary pseudomucinous cystadenoma, borderline Malignancy**
Papillary renal cell carcinoma (C649)
Papillary serous adenocarcinoma
Papillary serous cystadenocarcinoma
**Papillary serous cystadenoma, borderline malignancy**
Papillary serous tumor of low malignant potential
Papillary squamous cell carcinoma*
Papillary squamous cell carcinoma in situ
Papillary squamous cell carcinoma, non-invasive
Papillary transitional cell carcinoma
Papillary transitional cell carcinoma, non-invasive (C67_)
Papillary tumor of the pineal region
Papillary urothelial carcinoma (C67_)
Papillary urothelial carcinoma, non-invasive (C67_)
Papillary adenoma
Papilloecrine adenocarcinoma
Papillary urothelial carcinoma
Paraganglioma (C75.5)
Paraganglioma, malignant
Parasymptomatic paraganglioma (C75.5)
Parietal cell adenocarcinoma (C16_)
Parietal cell carcinoma (C16_)
Parosteal osteosarcoma (C40_, C41_)
PEComa, malignant
Penile intraepithelial neoplasia, Grade III (PeIN III)
Periductal stromal tumor, low grade (C50_)
Perineural MPNST
Perineural carcinoma, malignant

**Perineuroma**
Periosteal chondrosarcoma (C40_, C41_)
Periosteal fibrosarcoma
Periosteal osteosarcoma
Periosteal osteosarcoma (C40_, C41_)
Periosteal sarcoma, NOS
Peripheral neuroectodermal tumor
Peripheral primary neuroectodermal tumor, NOS
Peripheral T-cell lymphoma, AILD (Angioimmunoblastic Lymphadenopathy with Dysproteinemia)
Peripheral T-cell lymphoma, large cell
Peripheral T-cell lymphoma, pleomorphic medium and large cell
Peripheral T-cell lymphoma, pleomorphic medium and large cell
Peripheral T-cell lymphoma, pleomorphic small cell
Peripheral T-cell lymphoma, pleomorphic small cell
Perivascular epithelioid cell tumor, malignant
Pheochromoblastoma (C741)
Pheochromocytoma, NOS (C741)
Pheochromocytoma, malignant
Phosphaturic mesenchymal tumor, malignant
Phylloides tumor, malignant
Pigmented basal cell carcinoma*
**PIGMENTED DERMATOFIBROSARCOMA PROTUBERANS (C44_)**
**Pigmented Schwannoma**
Pilocytic astrocytoma (C71_)
Pilocytic/juvenile astrocytoma (C71_)
Piloid astrocytoma
**Piloid astrocytoma**
Pilomatrixoma, malignant (C44_)
Pilomatrixoma, malignant*
Pilomyxoid astrocytoma
Pineal parenchymal tumor of intermediate differentiation (C753)
Pinealoma

Refer to ICD-O-3 for inclusive listing of morphology terms.

Asterisk (*): Non-reportable if primary site is skin of non-mucoepidermoid anatomic site (ICD-O-3: C44_)
**Bold**: Indicates benign/borderline/uncertain tumors that are reportable if they occur intracranially or in the CNS
Underlined: Indicates a change in behavior OR a new ICD-O term, reportable with diagnoses made 1/1/2021 forward
**BOLD SMALL CAPS**: Indicates a change in behavior to reportable with diagnoses made 1/1/2022 forward

The NYSCR Reporting Manual – Part Three – Reportable Conditions and Terminology

Revised January 2022
Refer to ICD-O-3 for inclusive listing of morphology terms.

Asterisk (*): *Non-reportable if primary site is skin of non-mucoepidermoid anatomic site (ICD-O-3: C44_)

**Bold:** Indicates benign/borderline/uncertain tumors that are reportable if they occur intracranially or in the CNS

*Underline:* Indicates a change in behavior OR a new ICD-O term, reportable with diagnoses made 1/1/2021 forward

**Bold Small Caps:** Indicates a change in behavior to reportable with diagnoses made 1/1/2022 forward

---

<table>
<thead>
<tr>
<th>Pineoblastoma</th>
<th>Polymorphic post-transplant lymphoproliferative disorder</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pineocytoma</td>
<td>PPNET</td>
</tr>
<tr>
<td>Pinkus tumor</td>
<td>Pre-B ALL</td>
</tr>
<tr>
<td>PI-RADS 4 (C619)</td>
<td>Precancerous melanosis</td>
</tr>
<tr>
<td>PI-RADS 5 (C619)</td>
<td>Precursor B-cell lymphoblastic lymphoma, NOS</td>
</tr>
<tr>
<td>Pituitary blastoma</td>
<td>Precursor B-cell lymphoblastic lymphoma, NOS</td>
</tr>
<tr>
<td>Pituitary carcinoma, NOS (C751)</td>
<td>Precursor cell lymphoblastic leukemia, NOS</td>
</tr>
<tr>
<td>Plasma cell leukemia (C421)</td>
<td>Precursor cell lymphoblastic leukemia, not phenotyped</td>
</tr>
<tr>
<td>Plasma cell myeloma</td>
<td>Precursor T-cell lymphoblastic leukemia, NOS</td>
</tr>
<tr>
<td>Plasma tumor</td>
<td></td>
</tr>
<tr>
<td>Plasmablastic lymphoma</td>
<td></td>
</tr>
<tr>
<td>Plasmacytic leukemia (C421)</td>
<td></td>
</tr>
<tr>
<td>Plasmacytic lymphoma</td>
<td></td>
</tr>
<tr>
<td>Plasmacytoma of bone (C40_, C41_)</td>
<td></td>
</tr>
<tr>
<td>Plasmacyctoma, extramedullary (not occurring in bone)</td>
<td></td>
</tr>
<tr>
<td>Plasmacytoma, NOS</td>
<td></td>
</tr>
<tr>
<td>Pleomorphic carcinoma*</td>
<td></td>
</tr>
<tr>
<td>Pleomorphic cell sarcoma</td>
<td></td>
</tr>
<tr>
<td>Pleomorphic liposarcoma</td>
<td></td>
</tr>
<tr>
<td>Pleomorphic lobular carcinoma (C50_)</td>
<td></td>
</tr>
<tr>
<td>Pleomorphic lobular carcinoma in situ (C50_)</td>
<td></td>
</tr>
<tr>
<td>Pleomorphic rhabdomyosarcoma</td>
<td></td>
</tr>
<tr>
<td>Pleomorphic rhabdomyosarcoma, adult type</td>
<td></td>
</tr>
<tr>
<td>Pleomorphic xanthoastrocytoma</td>
<td></td>
</tr>
<tr>
<td>Pleuropulmonary blastoma</td>
<td></td>
</tr>
<tr>
<td><strong>Plexiform Neurofibroma</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Plexiform Neuroma</strong></td>
<td></td>
</tr>
<tr>
<td>PNEN, NOS</td>
<td></td>
</tr>
<tr>
<td>Pneumoblastoma</td>
<td></td>
</tr>
<tr>
<td>Polar spongioblastoma (C71_)</td>
<td></td>
</tr>
<tr>
<td>Polycythemia rubra vera</td>
<td></td>
</tr>
<tr>
<td>Polycythemia vera</td>
<td></td>
</tr>
<tr>
<td>Polyembryoma</td>
<td></td>
</tr>
<tr>
<td>Polygonal cell carcinoma*</td>
<td></td>
</tr>
<tr>
<td><strong>POLYMORPHIC POST TRANSPLANT LYMPHOPROLIFERATIVE DISORDER (PTLD)</strong></td>
<td></td>
</tr>
<tr>
<td>Polymorphic reticulosis [obs]</td>
<td></td>
</tr>
<tr>
<td>Polymorphous low grade adenocarcinoma</td>
<td></td>
</tr>
<tr>
<td>Polyvesicular vitelline tumor</td>
<td></td>
</tr>
<tr>
<td>Porocarcinoma (C44_)</td>
<td></td>
</tr>
</tbody>
</table>

**Pre-leukemia**

**Pre-leukemic syndrome**

**Pre-pre-B ALL**

**Pre-T ALL**

**Primary cutaneous anaplastic large cell lymphoma (C44_)**

**Primary cutaneous CD30+ large T-cell lymphoma (C44_)**

**PRIMARY CUTANEOUS CD30+ T CELL LYMPHOPROLIFERATIVE DISORDER (C44_)**

**PRIMARY CUTANEOUS CD4-POSITIVE SMALL/MEDIUM T-CELL LYMPHOMA (C44_)**

**Primary cutaneous follicle center lymphoma**

**Primary cutaneous gamma-delta T-cell lymphoma**

**Primary cutaneous neuroendocrine carcinoma (C44_)**

**Primary effusion lymphoma**

**Primary intraosseous carcinoma**

**Primary serous papillary carcinoma of peritoneum (C481)**

**Primitive neuroectodermal tumor**

**Primitive polar spongioblastoma (C71_) [obs]**

**Pro-B ALL**

**Prolactinoma**
Refer to ICD-O-3 for inclusive listing of morphology terms.

Asterisk (*): *Non-reportable if primary site is skin of non-mucoepidermoid anatomic site (ICD-O-3: C44_)

Bold: Indicates benign/borderline/uncertain tumors that are reportable if they occur intracranially or in the CNS

Underlined: Indicates a change in behavior OR a new ICD-O term, reportable with diagnoses made 1/1/2021 forward

SMALL CAPS: Indicates a change in behavior to non-reportable with diagnoses made 1/1/2021 forward

BOLD SMALL CAPS: Indicates a change in behavior to reportable with diagnoses made 1/1/2022 forward
Refer to ICD-O-3 for inclusive listing of morphology terms.

Asterisk (*): Non-reportable if primary site is skin of non-mucoepidermoid anatomic site (ICD-O-3: C44_)

Bold: Indicates benign/borderline/uncertain tumors that are reportable if they occur intracranially or in the CNS

Underlined: Indicates a change in behavior OR a new ICD-O term, reportable with diagnoses made 1/1/2021 forward

SMALL CAPS: Indicates a change in behavior to non-reportable with diagnoses made 1/1/2021 forward

BOLD SMALL CAPS: Indicates a change in behavior to reportable with diagnoses made 1/1/2022 forward

The NYSCR Reporting Manual – Part Three – Reportable Conditions and Terminology

Revised January 2022
Solid pseudopapillary neoplasm of Pancreas
Solitary fibrous tumor/Hemangiopericytoma
Solitary fibrous tumor/hemangiopericytoma Grade 1 (CNS) (C71_)
Solitary fibrous tumor/hemangiopericytoma Grade 2 (CNS) (C71_)
Solitary fibrous tumor/hemangiopericytoma Grade 3 (CNS) (C71_)
Solitary myeloma
Solitary plasmacytoma
Somatostatin cell tumor, malignant
Somatostatinoma
Somatostatinoma, malignant
Spermatocytic seminoma
Spermatocytoma
Spindle cell carcinoma*
Spindle cell melanoma
Spindle cell melanoma, type A
Spindle cell melanoma, type B
Spindle cell oncocytoma
Spindle cell rhabdomyosarcoma
Spindle cell sarcoma
Spindle epithelial tumor with thymus-like differentiation
Spindle epithelial tumor with thymus-like element
Spindled mesothelioma
Splenic lymphoma with villous lymphocytes (C422)
Splenic marginal zone B-cell lymphoma (C422)
Splenic marginal zone lymphoma, NOS (C422)
Spongioblastoma multiforme
Spongioblastoma polare
Spongioblastoma, NOS
Spongioneuroblastoma
Squamous transitional cell carcinoma (C53_)
Squamous carcinoma*
Squamous cell carcinoma, HPV-associated

Squamous cell carcinoma, HPV-independent
Squamous cell carcinoma, HPV-negative
Squamous cell carcinoma, HPV-positive
Squamous cell carcinoma in situ with questionable stromal invasion*
Squamous cell carcinoma in situ, NOS*
Squamous cell carcinoma with horn formation*
Squamous cell carcinoma, acantholytic*
Squamous cell carcinoma, clear cell type*
Squamous cell carcinoma, keratinizing, NOS*
Squamous cell carcinoma, large cell, keratinizing*
Squamous cell carcinoma, large cell, nonkeratinizing*
Squamous cell carcinoma, microinvasive*
Squamous cell carcinoma, nonkeratinizing, NOS*
Squamous cell carcinoma, NOS*
Squamous cell carcinoma, sarcomatoid*
Squamous cell carcinoma, small cell*
Squamous cell carcinoma, spindle cell*
Squamous cell epithelioma*
Squamous dysplasia, high grade
Squamous intraepithelial neoplasia/neoplasm, grade II (Excluding Cervix)
Squamous intraepithelial neoplasia, grade III, vulva, and vagina
Stem cell leukemia
Steroid cell tumor, malignant
Stromal endometriosis (C541)
Stromal myosis, NOS
Stromal myosis, NOS (C541)
Stromal sarcoma, NOS
Struma ovarii, malignant
Subacute granulocytic leukemia [obs]
Subacute leukemia, NOS [obs]
Subacute lymphatic leukemia [obs]
Subacute lymphocytic leukemia [obs]
Subacute lymphoid leukemia [obs]
Subacute monocytic leukemia [obs]

Refer to ICD-O-3 for inclusive listing of morphology terms.

Asterisk (*): *Non-reportable if primary site is skin of non-mucoepidermoid anatomic site (ICD-O-3: C44_)
Bold: Indicates benign/borderline/uncertain tumors that are reportable if they occur intracranially or in the CNS
Underlined: Indicates a change in behavior OR a new ICD-O term, reportable with diagnoses made 1/1/2021 forward
SMALL CAPS: Indicates a change in behavior to non-reportable with diagnoses made 1/1/2021 forward
BOLD SMALL CAPS: Indicates a change in behavior to reportable with diagnoses made 1/1/2022 forward

The NYSCR Reporting Manual – Part Three – Reportable Conditions and Terminology
Revised January 2022
Refer to ICD-O-3 for inclusive listing of morphology terms.

**Asterisk (*)**: *Non-reportable if primary site is skin of non-mucoepidermoid anatomic site (ICD-O-3: C44_)
**Bold**: Indicates benign/borderline/uncertain tumors that are reportable if they occur intracranially or in the CNS
**Underlined**: Indicates a change in behavior OR a new ICD-O term, reportable with diagnoses made 1/1/2021 forward
**SMALL CAPS**: Indicates a change in behavior to non-reportable with diagnoses made 1/1/2021 forward
**BOLD SMALL CAPS**: Indicates a change in behavior to reportable with diagnoses made 1/1/2022 forward

Subacute myelogenous leukemia [obs]
Subacute myeloid leukemia [obs]
Subcutaneous panniculitis-like T-cell lymphoma

Subependymal astrocytoma
Subependymal giant cell astrocytoma
Subependymal glioma
Subependymoma
Superficial spreading adenocarcinoma
Supratentorial PNET (C71_)
Sweat gland adenocarcinoma
Sweat gland carcinoma
Sweat gland tumor, malignant
Sympathicoblastoma

Syncytial meningioma
Synovial sarcoma, biphasic
Synovial sarcoma, epithelioid cell
Synovial sarcoma, monophasic fibrous
Synovial sarcoma, NOS
Synovial sarcoma, spindle cell
Synovioma, NOS
Synovioma, malignant
Syringomatous carcinoma (C44_)
Systemic EBV positive T-cell lymphoproliferative disease of childhood
Systemic tissue proliferative disease

T-cell lymphoma, NOS
T-cell /histiocyte-rich large B-cell lymphoma
T-cell rich large B-cell lymphoma
T/NK-cell lymphoma
Tanycytic ependymoma (C71_)
Tectal plate lipoma of brain
Telangiectatic osteosarcoma
Teratoblastoma, malignant
Teratocarcinoma
Teratoid medullopithelioma
Teratoma with malignant transformation

**Teratoma, benign**
Teratoma, malignant, NOS
Teratoma, mature, of testis in adult

**Teratoma, NOS**

Terminal duct adenocarcinoma

**Third type-schwannomatosis**
Thecoma, malignant
Therapy-related acute myeloid leukemia, NOS
Therapy-related acute myeloid leukemia and myelodysplastic syndrome, NOS
Therapy-related acute myeloid leukemia, alkylating agent related
Therapy-related acute myeloid leukemia, epipodophyllotoxin-related
Therapy-related myelodysplastic syndrome, NOS
Therapy-related myelodysplastic syndrome, alkylating agent related
Therapy-related myelodysplastic syndrome, epipodophyllotoxin-related
Therapy-related myelodysplastic syndrome, NOS
Thymic carcinoma (C379)
Thymic carcinoma with adenoid cystic carcinoma-like features (C379)
Thymic large B-cell lymphoma (C379)
Thymoma, atypical (C379)
Thymoma, atypical, malignant (C379)
Thymoma, cortical, malignant (C379)
Thymoma, epithelial (C379)
Thymoma, epithelial, malignant (C379)
Thymoma, lymphocyte-rich (C379)
Thymoma, lymphocyte-rich, malignant (C379)
Thymoma, lymphocytic (C379)
Thymoma, lymphocytic, malignant (C379)
Thymoma, malignant
Thymoma, medullary (C379)
Thymoma, medullary, malignant (C379)
Thymoma, mixed type (C379)
Thymoma, mixed type, malignant (C379)
Thymoma, NOS (C379)
Thymoma, organoid (C379)
Thymoma, organoid, malignant (C379)
Thymoma, predominantly cortical (C379)
Thymoma, predominantly cortical, malignant (C379)
Thymoma, spindle cell (C379)
Thymoma, spindle cell, malignant (C379)
Thymoma, type A (C379)
Thymoma, type A, malignant (C379)
Thymoma, type A, atypical variant (C379)
Thymoma, type AB (C379)
Thymoma, type AB, malignant (C379)
Thymoma, type B1 (C379)
Thymoma, type B1, malignant (C379)
Thymoma, type B2 (C379)
Thymoma, type B2, malignant (C379)
Thymoma, type B3 (C379)
Thymoma, type B3, malignant (C379)
Thymoma, type C (C379)
Tibial adamantinoma
TI-RADS 5 (C379)
Trabecular adenocarcinoma
T lymphoblastic leukemia/lymphoma
Trabecular carcinoma
Transitional carcinoma
Transitional cell carcinoma in situ
Transitional cell carcinoma, micropapillary (C67_)
Transitional cell carcinoma, NOS
Transitional cell carcinoma, sarcomatoid
Transitional cell carcinoma, spindle cell
**Transitional meningioma**
Transitional pineal tumor (C753)
Trichilemmal carcinoma (C44_)*
Trichilemmocarcinoma (C44_)*
Trophoblastic tumor, epithelioid
True histiocytic lymphoma [obs]
Tubular adenocarcinoma
Tubular carcinoma
Tubulocystic renal cell carcinoma (C649)
Tubulolobular carcinoma (C50_)
Tubulopapillary adenocarcinoma
**Tumor cells, benign**
Tumor cells, malignant*
**Tumor cells, uncertain whether benign or malignant**
Tumor malignant, NOS*
**Tumorlet(s)**
Typical carcinoid
T-zone lymphoma

Refer to ICD-O-3 for inclusive listing of morphology terms.

Asterisk (*): *Non-reportable if primary site is skin of non-mucoepidermoid anatomic site (ICD-O-3: C44_)
**Bold:** Indicates benign/borderline/uncertain tumors that are reportable if they occur intracranially or in the CNS
*Underlined:* Indicates a change in behavior OR a new ICD-O term, reportable with diagnoses made 1/1/2021 forward
**BOLD SMALL CAPS:** Indicates a change in behavior to reportable with diagnoses made 1/1/2022 forward
Wilms tumor
Wolffian duct carcinoma

X

Xanthofibroma

Y

Yolk sac tumor

Refer to ICD-O-3 for inclusive listing of morphology terms.

Asterisk (*): *Non-reportable if primary site is skin of non-mucoepidermoid anatomic site (ICD-O-3: C44_)
Bold: Indicates benign/borderline/uncertain tumors that are reportable if they occur intracranially or in the CNS
Underlined: Indicates a change in behavior OR a new ICD-O term, reportable with diagnoses made 1/1/2021 forward
SMALL CAPS: Indicates a change in behavior to non-reportable with diagnoses made 1/1/2021 forward
BOLD SMALL CAPS: Indicates a change in behavior to reportable with diagnoses made 1/1/2022 forward
New York State Cancer Registry Reporting Manual

Part Four - Data Items and Descriptions

This section of the manual has been reduced to those data items that are NYSCR specific. For information on all other required data items, refer to the Standards for Oncology Registry Entry (STORE) Manual v2022 and/or the SEER Program Coding and Staging Manual 2022. For a complete list of NYSCR Required Fields, contact your Field Rep at (518) 474-0971.

SERVICE TYPE
MANAGING PHYSICIAN FIRST NAME
MANAGING PHYSICIAN LAST NAME
MANAGING PHYSICIAN ADDRESS
MANAGING PHYSICIAN CITY
MANAGING PHYSICIAN STATE
MANAGING PHYSICIAN ZIP
MANAGING PHYSICIAN PHONE NUMBER
NYS TOBACCO HISTORY
PATH REPORT AVAILABLE
PARENT’S PHONE NUMBER
PATIENT CONTROL NUMBER
PFI (PERMANENT FACILITY IDENTIFIER) NUMBER

The NYSCR Reporting Manual – Part Four – Data Items and Descriptions

Revised January 2022
Page Left Blank Intentionally
SERVICE TYPE

Reporting Status: Required
Section: State Requested Items

<table>
<thead>
<tr>
<th>Alternate Name</th>
<th>Item #</th>
<th>Length</th>
<th>Source of Standard</th>
<th>Column #</th>
</tr>
</thead>
<tbody>
<tr>
<td>Source Within Facility</td>
<td>9522</td>
<td>2</td>
<td>NYSCR</td>
<td>3051-3052</td>
</tr>
</tbody>
</table>

Description
Code for the service type for the encounter being reported.

Codes
01 Inpatient
03 Laboratory – within facility
04 Clinic – within facility
05 Autopsy Only
06 DCO/followback, unreported tumor
08 Hospice
11 Radiation treatment only
12 DCO/followback, unreported tumor, no cancer workup
14 DCO/followback, reported tumor, DCO site correct
15 State, Territory, Country; Non NY
16 Consult Only, non-laboratory
17 Private medical practitioner, office visit
18 Port/Cath
19 DCO/followback, reported tumor, DCO site incorrect
20 Outpatient, non-surgical
21 Outpatient, surgical
23 Laboratory followback
24 ECC – Early Case Capture Childhood Submission
MANAGING PHYSICIAN FIRST NAME

Reporting Status: Required When Available
Section: State Requested Items

<table>
<thead>
<tr>
<th>Alternate Name</th>
<th>Item #</th>
<th>Length</th>
<th>Source of Standard</th>
<th>Column #</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>9540</td>
<td>40</td>
<td>NYSCR</td>
<td>3197-3236</td>
</tr>
</tbody>
</table>

Description
The first name of the patient’s managing physician.

Rationale
This information will be used as needed to follow up on cases with limited information.
MANAGING PHYSICIAN LAST NAME

Reporting Status: Required When Available
Section: State Requested Items

<table>
<thead>
<tr>
<th>Alternate Name</th>
<th>Item #</th>
<th>Length</th>
<th>Source of Standard</th>
<th>Column #</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>9541</td>
<td>40</td>
<td>NYSCR</td>
<td>3237-3276</td>
</tr>
</tbody>
</table>

Description
The last name of the patient's managing physician.

Rationale
This information will be used as needed to follow up on cases with limited information.
MANAGING PHYSICIAN ADDRESS

Reporting Status: Required When Available
Section: State Requested Items

<table>
<thead>
<tr>
<th>Alternate Name</th>
<th>Item #</th>
<th>Length</th>
<th>Source of Standard</th>
<th>Column #</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>9542</td>
<td>60</td>
<td>NYSCR</td>
<td>3277-3336</td>
</tr>
</tbody>
</table>

Description
The number and street address of the patient's managing physician.

Rationale
This information will be used as needed to follow up on cases with limited information.
MANAGING PHYSICIAN CITY

Reporting Status: Required When Available
Section: State Requested Items

<table>
<thead>
<tr>
<th>Alternate Name</th>
<th>Item #</th>
<th>Length</th>
<th>Source of Standard</th>
<th>Column #</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>9543</td>
<td>50</td>
<td>NYSCR</td>
<td>3337-3386</td>
</tr>
</tbody>
</table>

Description
The name of the city used in the mailing address of the patient's managing physician.

Rationale
This information will be used as needed to follow up on cases with limited information.
**MANAGING PHYSICIAN STATE**

**Reporting Status:** Required When Available  
**Section:** State Requested Items

<table>
<thead>
<tr>
<th>Alternate Name</th>
<th>Item #</th>
<th>Length</th>
<th>Source of Standard</th>
<th>Column #</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>9544</td>
<td>2</td>
<td>NYSCR</td>
<td>3387-3388</td>
</tr>
</tbody>
</table>

**Description**  
USPS abbreviation for the state used in the mailing address of the patient's managing physician.

**Rationale**  
This information will be used as needed to follow up on cases with limited information.
MANAGING PHYSICIAN ZIP

Reporting Status: Required When Available
Section: State Requested Items

<table>
<thead>
<tr>
<th>Alternate Name</th>
<th>Item #</th>
<th>Length</th>
<th>Source of Standard</th>
<th>Column #</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>9545</td>
<td>9</td>
<td>NYSCR</td>
<td>3389-3397</td>
</tr>
</tbody>
</table>

Description
Postal code used in the mailing address of the patient's managing physician.

Rationale
This information will be used as needed to follow up on cases with limited information.
MANAGING PHYSICIAN PHONE NUMBER

Reporting Status: Required When Available
Section: State Requested Items

<table>
<thead>
<tr>
<th>Alternate Name</th>
<th>Item #</th>
<th>Length</th>
<th>Source of Standard</th>
<th>Column #</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>9546</td>
<td>10</td>
<td>NYSCR</td>
<td>3398-3407</td>
</tr>
</tbody>
</table>

Description
The phone number (including area code) of the patient’s managing physician.

Rationale
This information will be used as needed to follow up on cases with limited information.
NYS TOBACCO HISTORY

Reporting Status: Required
Section: Special Use

<table>
<thead>
<tr>
<th>Alternate Name</th>
<th>Item #</th>
<th>Length</th>
<th>Source of Standard</th>
<th>Column #</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>9536</td>
<td>1</td>
<td>NYSCR</td>
<td>3195</td>
</tr>
</tbody>
</table>

**Description**
Assign a code that best describes the patient’s use of tobacco – current OR past. This field pertains specifically to tobacco use. Do not record any other smoking related history (e.g., e-cigarettes or “vaping” or marijuana use.

**Codes**
0    Never Used
1    Cigarette Smoker, Current
2    Cigar / Pipe Smoker, Current
3    Snuff / Chew / Smokeless, Current
4    Combination Use, Current
5    Previous Use
9    Unknown
PATH REPORT AVAILABLE

Reporting Status: Required (for Cases Diagnosed January 1, 2001 and Later)
Section: State Requested Items

<table>
<thead>
<tr>
<th>Alternate Name</th>
<th>Item #</th>
<th>Length</th>
<th>Source of Standard</th>
<th>Column #</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>9525</td>
<td>1</td>
<td>NYSCR</td>
<td>3084</td>
</tr>
</tbody>
</table>

Description
Indicates the availability of a pathology report.

Rationale
The field was added to enable the NYSCR to enforce the requirement of the field Text-DX Proc-Path (item #2570) when a pathology report is available to the abstractor. When this field is coded with a value of “1-Yes”, then the Text-DX Proc-Path field (not a state-specific field) will also be required. The field of “Path Report Available?” is not required for Lab Only Consult cases because the field of Text-DX Proc-Path is a required field for all Laboratory Only Consults.

Codes
0 No
1 Yes
**PARENT’S PHONE NUMBER**

**Reporting Status:** Required When Available  
**Section:** State Requested Items

<table>
<thead>
<tr>
<th>Alternate Name</th>
<th>Item #</th>
<th>Length</th>
<th>Source of Standard</th>
<th>Column #</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>9547</td>
<td>10</td>
<td>NYSCR</td>
<td>3408-3417</td>
</tr>
</tbody>
</table>

**Description**  
Phone number (including area code) of the patient's parent, legal guardian. Applies to all patients under 18 years of age.
PATIENT CONTROL NUMBER

Reporting Status: Required
Section: State Requested Items

<table>
<thead>
<tr>
<th>Alternate Name</th>
<th>Item #</th>
<th>Length</th>
<th>Source of Standard</th>
<th>Column #</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>9524</td>
<td>20</td>
<td>NYSCR</td>
<td>3064-3083</td>
</tr>
</tbody>
</table>

Patient’s admission number, account number, or laboratory identification number. This is usually a separate and unique number which differs from the medical record number.

Rationale
The “Patient Control Number” is a unique identifier assigned by your facility to the patient upon admission. The number is used by the facility to identify a patient’s particular period of hospitalization. It is useful in identifying a specific admission or transaction with the facility if additional information or clarification is needed at a future date.

Codes
If the patient control number is fewer than 20 characters, right-justify the characters and allow leading blanks.
**PFI (PERMANENT FACILITY IDENTIFIER) NUMBER**

**Reporting Status:** Required  
Section: State Requested Items

<table>
<thead>
<tr>
<th>Alternate Name</th>
<th>Item #</th>
<th>Length</th>
<th>Source of Standard</th>
<th>Column #</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>9523</td>
<td>11</td>
<td>NYSCR</td>
<td>3053-3063</td>
</tr>
</tbody>
</table>

**Description**  
A unique numerical identifier assigned to the physical location of the facility. Record your PFI number as assigned by the NYSCR.

**Rationale**  
A method of identifying a facility by location. This identifier remains constant regardless of facility status changes or transfers of ownership.

**Codes**  
Unique individual code as assigned by the NYSCR.
5.1 DEFINITION OF CASEFINDING ........................................................................... 1
5.2 CASEFINDING LIST FOR ICD-9-CM AND ICD-10-CM CODES ........................... 1
5.3 CASEFINDING PROCEDURES ............................................................................ 1
5.3.1 Hospital Departments Involved in Casefinding .............................................. 2
  5.3.1.1 Laboratory: Pathology, Cytology and Hematology ...................................... 2
  5.3.1.2 Diagnostic Radiology .................................................................................. 3
  5.3.1.3 Outpatient Services ................................................................................... 3
  5.3.1.4 Oncology-Related Services ....................................................................... 3
  5.3.1.5 Emergency Department ............................................................................ 3
  5.3.1.6 Health Information Management / Medical Records ............................... 3
  5.3.1.7 Staff Physicians' Offices .......................................................................... 4
  5.3.1.8 Long-Term Care Facility / Skilled Nursing Facility .................................. 4
  5.3.1.9 Hospice .................................................................................................... 4
5.4 QUALITY OF CASEFINDING / PERIODIC INTERNAL CASEFINDING AUDITS ..4
5.1 DEFINITION OF CASEFINDING

Casefinding is a systematic method of locating all eligible cases to be included in a cancer registry database. Although the hospital remains the primary source for most cases at the Central Registry, a number of non-hospital sources are critically important in accurately assessing cancer incidence. Comprehensive casefinding includes investigating all diagnostic and therapeutic services to look for active cancer cases. Casefinding identifies both new, previously unreported cancer cases, as well as those cases that have been identified elsewhere, and already entered into the registry.

5.2 CASEFINDING LIST FOR ICD-9-CM AND ICD-10-CM CODES

Refer to the casefinding lists included in sections 3.8 and 3.9 respectively.

5.3 CASEFINDING PROCEDURES

Registrars must rely on several sources of documentation to identify all cancer cases diagnosed and/or treated at a facility. More than one type of documentation is generally needed to capture all required information for each patient. Therefore, registrars must investigate every department or service area where a patient may be seen or treated within a facility, to identify eligible cases. Potential sources differ based on the facility type, size, services provided, etc. To ensure completeness, the task of casefinding should be limited to those familiar with the various reportable terms and conditions. Note that the American College of Surgeons (ACoS) and/or a particular facility’s cancer committee may require the registrar(s) to abstract certain diagnoses that are not reportable to the NYSCR.

Effective communication skills are essential in the casefinding process. Registrars will likely interact with other facility staff while researching and compiling information on eligible cases. The NYSCR recommends that registrars explain the purpose of their visits to various departments along with any requests for information, underscoring how accurate, timely and complete cancer data collection plays a significant role in the health of all New Yorkers. Cooperation of ancillary departments involved in cancer care is critical to achieving maximum casefinding results.

The need for open communication regarding cancer reporting extends not only to the registrar’s colleagues within their facility, but to the facility’s assigned NYSCR field representative. The NYSCR Field Representative serves as a liaison between the NYSCR and the reporting facility. Registrars are encouraged to contact their field rep. with any questions and/or concerns that may present. The NYSCR is committed to maintaining open communication with reporting facilities and encourages questions and feedback. Working together, facility registrars and NYSCR field staff can usually resolve most issues quickly and completely.
5.3.1 Hospital Departments Involved in Casefinding

The list below identifies services/departments where eligible cancer cases may be identified. Not all facilities offer every service or contain every department listed. Registrars should review their facility’s NYSDOH Operating Certificate for a complete list of all cancer related diagnostic and/or therapeutic services provided by the facility, both at their main campus, as well as at any satellite locations included on the Operating Certificate.

Each of the following services/departments is considered a potential source for eligible cancer cases:

- Laboratory Services (both on-site and contracted laboratory services):
  - Pathology (Including Autopsy Reports)
  - Cytology
  - Hematology
- Diagnostic Radiology
- Outpatient Services:
  - Clinics
  - Ambulatory Care Services
  - Outpatient Surgery
- Oncology-Related Services:
  - Chemotherapy
  - Radiation Therapy
- Emergency Department (ED/ER)
- Health Information Management / Medical Records (HIM)
- Staff Physician’s Offices
- Long-Term Care Facility/Skilled Nursing Facility
- Hospice and Other Palliative Care Services

5.3.1.1 Laboratory: Pathology (including autopsy reports), Cytology and Hematology

The laboratory department is generally the primary casefinding source for eligible cases to be included in the registry database. Personnel who are thoroughly knowledgeable in cancer case reporting must review every pathology report (including all bone marrow biopsies and autopsy reports), cytology reports and hematology reports. This may be accomplished manually, through an electronic report based on related diagnostic codes and terms or a combination of both means, with a combination of both means being recommended.

At some larger institutions the pathology department may be comprised of distinct subspecialties such as dermatopathology, EENT pathology, GYN pathology and/or pediatric bone marrow pathology. All areas must be reviewed for reportable cancer diagnoses.

Experience demonstrates that trained registry personnel perform the most complete and accurate screening of pathology reports. If someone outside the registry reviews the pathology reports, a registrar should audit the findings periodically, to ensure complete and accurate casefinding. See Part 8: Quality Assessment for further information.
5.3.1.2 Diagnostic Radiology

Registrars should regularly review reports from diagnostic radiology for eligible cancer diagnoses. In addition to routine x-rays, casefinding sources should include all specialized diagnostic imaging conducted by the facility, such as MRI, CT and PET scans, mammography, fluoroscopy, ultrasound, and nuclear medicine.

5.3.1.3 Outpatient Services

Casefinding should include review of surgery and clinic visit logs. Billing records may also be helpful, as these contain both the diagnoses and applicable ICD codes. Inpatient and outpatient Disease Indices are often available separately.

5.3.1.4 Oncology-Related Services

In addition to diagnostic radiology radiation therapy, along with chemotherapy services should be viewed as casefinding sources. Radiation therapy and chemotherapy appointment logs/books should be reviewed routinely to identify eligible cases. Additionally, regular, thorough review of transcription reports related to patient consultations, treatment and follow-up visits may identify reportable cases.

5.3.1.5 Emergency Department (ED/ER)

ED records are a casefinding source. Review ED logs and death certificates to capture and report eligible cases of patients who expire in the ED or are declared dead on arrival (DOA).

5.3.1.6 Health Information Management / Medical Records (HIM)

Another significant source of cancer casefinding is the HIM/Medical Records Department, especially through the Disease Index. Usually run periodically, The Medical Record Disease Index (MRDI) is a listing (either electronic or as a hard copy) in numerical order by ICD code or medical record number. The MRDI should contain the patient’s name, any reportable ICD diagnosis code(s), and medical record number. Additional information may include admission and/or discharge dates, physician’s name and/or license/ID number, length of stay and ICD codes for co-morbid diagnoses and/or CPT procedure codes. When requesting a MRDI, the cancer registrar should specify the reportable ICD cancer codes to identify pertinent inpatient and outpatient visits.

The value of the MRDI as a casefinding source cannot be overstated. Not every reportable case has a positive histological diagnosis at each facility. Frequently in fact, a case is histologically diagnosed at one facility, or in a physician’s office, and the patient is then seen at a different facility for treatment. These cases often can be identified through the MRDI.

Health Information Management/Medical Records Departments can also be a source of information associated with discharges, specifically discharges following a death (death log). Regular review of all hospital deaths reduces the likelihood of future DCO cases. See Part 6 – Death Certificate Only and Death Clearance Lists, for more information on DCOs.
5.3.1.7 Staff Physicians' Offices

A staff physician is any physician who is directly employed by the facility or any physician in private practice who has privileges to admit patients to and/or practice in that healthcare facility. When a facility employs a physician, the facility owns the medical records of patients seen by that physician. As a result, cancer registrars are responsible for reporting eligible cancer cases identified from these records.

5.3.1.8 Long-Term Care Facility / Skilled Nursing Facility

Long-term care facilities and/or skilled nursing facilities affiliated with a hospital are potential sources for casefinding. Routine review of these records should be performed to identify reportable cancer cases.

5.3.1.9 Hospice

If your facility maintains a hospice unit, monitor admissions for casefinding purposes. Report eligible cancer cases when a patient receives palliative and/or comfort care. To reduce the likelihood of future DCO cases, report active hospice cancer cases to the NYSCR whether patients were diagnosed and/or received any treatment at the facility.

5.4 QUALITY OF CASEFINDING / PERIODIC INTERNAL CASEFINDING AUDITS

The NYSCR strongly encourages all reporting facilities to conduct periodic internal casefinding checks, to ensure that every eligible cancer case is identified and reported. Registrars are encouraged to speak with their NYSCR field representative and to network with registrars from other facilities for ideas when developing their own system of internal review. Registrars should look for changes in services and/or staffing when significant fluctuations occur in the annual reporting caseload. Registrars are encouraged to address fluctuations in reporting totals with their NYSCR field representative as soon as they are noted. See Part 8 – Quality Assessment, for further information.
New York State Cancer Registry Reporting Manual

Part Six - Death Certificate Only and Death Clearance Lists

6.1 INTRODUCTION................................................................................................... 1
6.2 HOW A CASE BECOMES A DCO ........................................................................ 1
6.3 DCO LISTS AS COMPLETENESS INDICATORS..................................................... 2
6.4 METHODS FOR REDUCING DCO LISTS........................................................... 2
6.5 RECONCILIATION OF DCO LISTS.................................................................... 2
   6.5.1 Reportable Cases............................................................................................ 2
   6.5.2 “History Only” Cases.................................................................................... 3
   6.5.3 Non-Reportable Cases .................................................................................. 3
   6.5.4 Previously Reported Cases............................................................................. 3
   6.5.5 Patient Not in Database................................................................................ 3
   6.5.6 Medical Record Cannot Be Located.............................................................. 3
   6.5.7 Digital Storage ............................................................................................. 4
6.6 DEATH CLEARANCE LISTS (DCLS).................................................................. 4
Page Left Blank Intentionally
6.1 INTRODUCTION

The following section contains specific information pertaining to Death Certificate Only (DCO) and Death Clearance Lists.

A DCO is an incidence of cancer that is reported to the NYSCR via the office of Vital Statistics or from the Statewide Planning and Research Cooperative System (SPARCS), following mention of cancer or other malignant disease on a Death Certificate, which in turn cannot be matched with any cases stored in the NYSCR database. SPARCS reports are limited to those records associated with cancer-related admissions, however, in some instances the type of cancer identified on a SPARCS record differs from that listed on the death certificate. Occasionally, previously reported cases may appear on a facility’s DCO list. The circumstances which lead to this are discussed later in this section. DCO lists are transmitted to facilities on a yearly basis.

6.2 HOW A CASE BECOMES A DCO

The NYSCR receives a data file from Vital Statistics and SPARCS that contains information on every New York State death certificate with a diagnosis or co-morbidity attributed to cancer, as well as all cancer-related admissions for a given year. This file contains information related to the underlying cause of death, any contributing causes, the date of death, where death was declared and various bits of demographic information (e.g., name, social security number, address). A computerized program at the NYSCR attempts to match the information on the Vital Statistics and SPARCS file to those already in the Registry’s database to determine whether a potentially reportable tumor, mentioned on a death certificate can be matched to a previously recorded tumor.

Potentially reportable cases which do not link automatically to a previously reported patient in the database are given to members of the Registry’s Medical Coding Staff via an internal software program. The medical coders must then determine whether the Vital Statistics or SPARCS case matches any patient in the NYSCR database. If a match is established, the coder follows a special tumor matching protocol to determine whether the tumor reported on the death certificate matches a previously reported tumor for that patient. If a tumor on a death certificate cannot be matched to anyone in the Registry’s database it becomes a DCO, and a follow-back is initiated with all applicable facilities (that in which the patient expired or was last treated).

Often the tumor reported on the Death Certificate reflects metastases from a previously reported tumor. Therefore, Death Certificate cases with common metastatic sites (lung, bone, etc.) are typically matched to previously reported tumors. Any death case matching a case on the registry database but containing a tumor that does not match a previously reported tumor, also becomes a DCO, with the appropriate follow-back procedures initiated.
6.3 DCO LISTS AS COMPLETENESS INDICATORS

DCO lists serve as a measure of the completeness of cancer reporting from individual facilities. The smaller the annual DCO list, the more complete the facility’s cancer reporting is. In addition to the overall number of cases on a particular DCO list, facilities should also consider the percentage of DCO cases with regard to their overall cancer caseload. Registrars can request their annual average caseload from their respective field rep. Additionally, the code on the DCO list that indicates the cause of death may provide insight regarding weaknesses in existing casefinding procedures. For example, if the number of leukemia, lymphoma and multiple myeloma cases is high, the facility might not be identifying cases diagnosed/treated solely by hematologists.

6.4 METHODS FOR REDUCING DCO LISTS

A proactive approach to reducing the number of DCOs at a facility involves determining how and where death certificates are processed. The individual responsible for reporting to the NYSCR can then establish a mechanism to ensure that they obtain copies of all death certificates for review.

6.5 RECONCILIATION OF DCO LISTS

It is imperative that reporting facilities reconcile all DCOs in a timely manner. Facilities are required to submit all reportable DCO cases and provide information for any non-reportable and/or missing cases within four weeks of receiving their DCO list. To meet this requirement, the individual responsible for reconciling DCOs should request the medical records for these cases as soon as the list is received. The facility’s field representative will contact the registrar if all cases are not received by the assigned date of completion.

Cases must be submitted electronically via the Health Commerce System. Specific abstracting instructions may vary from year to year, so it is important to read the instructions that accompany the DCO list carefully.

6.5.1 Reportable Cases

DCOs not previously reported that have been confirmed as reportable must be submitted via the facility’s cancer reporting software. The NYSCR recognizes that information related to DCO cases might be limited due to a brief admission during the terminal phase of their illness, or in the case of a patients who expire in the facility’s ED or are declared DOA. Information should be reported as it appears in the patient’s medical record, even though it may differ from that found on the death certificate.
6.5.2 “History Only” Cases

According to regular reporting guidelines, “History Only” cases of cancer are not reportable. However, when a patient presents to your facility with a history of cancer, AND, as a result, the patient subsequently is included on your annual DCO list, that case is reportable to the NYSCR. It is understood that the facility may have limited documentation related to the cancer and that many of the data fields may be submitted as “unknown”.

6.5.3 Non-Reportable Cases

If, after reviewing the medical record for a DCO case, it is determined that the patient did not have cancer or had been diagnosed with a non-reportable tumor, the registrar should inform his/her field representative. Cases deemed non-reportable will be deleted from the NYSCR database. To prevent a reportable case from being inappropriately deleted, supporting documentation showing the case is not reportable may be requested.

6.5.4 Previously Reported Cases

Registrars should contact their field representative if it is believed that a DCO case has been previously reported. The field representative can query the NYSCR’s database to confirm whether a report was received from the facility for that patient. If a report is found on the database, the field representative determines whether the malignancy reported on the death certificate is reflective of the primary site that was originally reported. If a report cannot be found on the Registry’s database, or if it is determined that the patient had been diagnosed with multiple primary tumors, the facility must report the case.

6.5.5 Patient Not in Database

If, after exhausting all available resources, a registrar cannot find any evidence that a patient on their DCO list was ever seen at their facility, the registrar should notify his/her field representative that the patient cannot be located within their facility’s patient database. Resources that should be checked include, but are not limited to, emergency room logs, review of actual death certificates, cancer treatment areas and pathology/cytology labs.

6.5.6 Medical Record Cannot Be Located

Registrars should notify their NYSCR field representative about any DCO case that cannot be completed due to a lost or misfiled medical record. These cases will remain on the facility’s outstanding DCO list until they are reconciled.
6.5.7 **Digital Storage**

If the medical record for a DCO case is being scanned for digital storage, the registrar should ascertain how long it could take for him/her to reconcile the case and notify their field representative.

6.6 **DEATH CLEARANCE LISTS (DCLs)**

The NYSCR, in conjunction with the NYSDOH Bureau of Vital Statistics, routinely prepares Death Clearance Lists (DCLs) to assist registrars with any patient follow-up activities conducted by their facility. Facilities with formal cancer registries that perform routine follow-up activities find the DCLs most useful. DCLs provide information on individuals who had a reportable condition mentioned on their death certificate or whose Cause of Death code was reflective of a reportable tumor. Facilities requesting DCLs receive lists that only contain information on those patients for which the facility previously submitted a reportable tumor to the NYSCR.

Electronic files are prepared for a given death year and upon request are sent to health facilities via the HCS. DCL files contain hospital-specific information regarding the death of individuals who were previously reported to the NYSCR by an institution (death clearance list) and cases reported by a facility that were subsequently seen somewhere else (non-death follow-up list). Instructions with information regarding the files are sent to the requesting facility by their assigned field representative, in a separate email.
Part Seven – Quality Assurance

7.1 INTRODUCTION .......................................................................................................................... 1
7.2 TERMINOLOGY ............................................................................................................................. 1
7.3 IMPORTANCE OF QUALITY DATA ............................................................................................... 1
7.4 TIMELINESS .................................................................................................................................. 2
   7.4.1 National Program of Cancer Registries (NPCR) ................................................................. 2
   7.4.2 North American Association of Central Cancer Registries (NAACCR) ............................... 2
   7.4.3 Surveillance Epidemiology and End Results (SEER) ......................................................... 2
   7.4.4 American College of Surgeons (ACoS) Commission on Cancer (CoC) ............................... 2
   7.4.5 How to monitor timely reporting ......................................................................................... 3
7.5 ACCURACY .................................................................................................................................. 3
   7.5.1 Computerized Edits ............................................................................................................... 4
   7.5.2 Visual Edits ............................................................................................................................ 4
   7.5.3 Cancer File Submission Reports .......................................................................................... 5
7.6 COMPLETENESS .......................................................................................................................... 5
7.7 MEASURABILITY .......................................................................................................................... 6
7.8 QUALITY ASSURANCE (QA) METHODS .................................................................................. 6
   7.8.1 Facility Accreditation ............................................................................................................ 6
   7.8.2 Central Registry Certification ............................................................................................... 6
7.9 AUDITS ........................................................................................................................................ 7
   7.9.1 Casefinding Audit .................................................................................................................. 7
   7.9.1.1 Central Registry ............................................................................................................. 7
   7.9.1.2 Facilities ........................................................................................................................ 8
   7.9.2 Re-abstracting Audits ........................................................................................................... 8
   7.9.2.1 Central Registry ............................................................................................................. 8
   7.9.2.2 Hospital Registry .......................................................................................................... 8
   7.9.3 Site-specific Audits .............................................................................................................. 9
   7.9.4 Accession Register Audits .................................................................................................... 9
   7.9.5 MRDI Audits ........................................................................................................................ 9
7.10 QUARTERLY FEEDBACK REPORTS ....................................................................................... 9
7.1 INTRODUCTION

Quality Assurance (QA) Measures and Continuous Quality Improvement (CQI) Procedures are used to achieve the highest quality cancer data. Good Quality Control (QC) Measures are necessary to assess registry data and identify areas of excellence, as well as opportunities for improvement.

These measures and controls allow registry professionals the benefit of a shared frame of reference, a common language, and a better understanding of the importance of QA Measures. By applying these techniques, cancer registries can improve the quality of their data, and create opportunities to improve communication within their facility and among those cancer data organizations with which they associate.

An effective cancer registry is staffed by individuals who have well-defined goals which are clearly documented. A registry can remain focused and maintain a sense of direction if staff has a clear understanding of the types of questions their registry can answer.

7.2 TERMINOLOGY

Quality Assurance (QA) – Webster’s defines “quality” as a degree of excellence. Terms with similar meaning, include:

- Quality Control / Quality Assessment – Assures data are useful. The processes may also ensure data and other information meet a previously defined standard.
- Continuous Quality Improvement (CQI) – A mechanism that ensures ongoing QA activities in an effective and efficient manner. One CQI method is to assess quality concurrently (i.e., in real time) rather than after the fact (retrospectively).

Concurrent assessment of information can reduce the amount of work needed to provide quality data, enhance the knowledge of the registrar, and improve the usefulness of the database, since it occurs as data are collected. Errors are immediately identified and corrected.

7.3 IMPORTANCE OF QUALITY DATA

Cancer registrars are a critical resource in the war against cancer as they are on the front lines, collecting vital information. To be effective, this information must be complete, timely and accurate. In the cancer registry field, data are the building blocks of information and they are measurable. Cancer registry professionals must always remain mindful that cancer data play an integral role in reducing the cancer burden on patients and society in general.

Registrars are familiar with numbers, reports, charts, and rates, but are often isolated from the patients who are affected by their work. Registry data, or information summaries based on the data, are used to assess risk, recommend therapies, and monitor patient outcomes. This information can also be used to educate cancer patients about the treatment decisions they face. Researchers use the data to increase public knowledge of the disease process. Public health officials use the data to monitor the burden of the diseases in populations – to plan, prioritize, implement, and evaluate cancer control interventions.
7.4 **TIMELINESS**

Timely data collection is important to both the hospital and Central Registry and comes with advantages and challenges. For example, in clinical trials; early patient and tumor identification assists in determining whether a patient is eligible for the trial. For the registrar however, this presents a challenge when determining stage and collecting treatment information, due to the lack of complete information at the time of abstracting. Different organizations have different timeliness standards. Most central registries have legislative mandates regarding the timing of data collection. NYS Public Health Law Section 2401 states: *Every physician, dentist and other health care provider shall give notice immediately but not later than one hundred eighty days of every case of cancer or other malignant disease coming under his or her care, to the department, except as otherwise provided.* (See Appendix A)

7.4.1 **National Program of Cancer Registries (NPCR)**

NPCR standards require that (1) within 12 months of the close of a diagnosis year, 90 percent of expected, unduplicated cases are available to be counted as incident cases and (2) within 24 months of the close of a diagnosis year, 95 percent of expected, unduplicated cases are available to be counted.

7.4.2 **Surveillance Epidemiology and End Results (SEER)**

SEER agreements with participating registries state that the registry must provide counts of new cases for a calendar year within 20 months of the end of a diagnosis year.

7.4.3 **North American Association of Central Cancer Registries (NAACCR)**

The NAACCR definition for timely reporting states that within 18 months of the close of a diagnosis year, the registry should contain 95 percent of expected cases.

7.4.4 **American College of Surgeons (ACoS) Commission on Cancer (CoC)**

CoC-approved programs are required to accession all eligible cases within six months of diagnosis or admission for treatment to the reporting facility. This is usually done retroactively since cancer is a disease for which treatment can be administered over many months. A patient may still be receiving first course of treatment and the medical record may be unavailable to the registry for review immediately upon discharge.

While these things may affect the reporting schedule, frequent data submission allows not only for a more even workload distribution, it also enhances data quality since errors may be caught and corrected early.
7.4.5 Monitoring Timely Reporting

There are several ways to monitor reporting for timeliness. Registrars can calculate the number of cases abstracted to-date for the current accession year as a percentage of the total number of cases expected for the current year. The expected number of cases can be determined by past reporting years, adjusted for changes in services delivered. This is then compared to the amount of time that has elapsed to-date in the current accession year, minus the allowable reporting time frame. For example, if the reporting time is six months, the number of cases abstracted by January 1st, should be 50 percent or more of the total number expected for the previous year. If so, the registry is within timeliness standards.

Another way to monitor timeliness is to have a computer generate the lag time. Lag time is the number of days between the discharge date or date of first contact (if there is no discharge date), and the date of submission to the central registry. If lag time is < 180 days, the registry is within timeliness standards.

7.5 ACCURACY

Data must be accurate. The consistent use of national standard data definitions allows for reliable comparison among all data collection agencies and facilitates the compilation of aggregate data.

Central and hospital registries share a common mission, albeit occasionally different goals and/or strategies. Viewing each registry as a stand-alone entity, however, minimizes the effectiveness of cancer registration as a system, and can lead to a lack of cohesion and cooperation. Central and hospital registries each report to various entities, including groups outside the cancer registry community, such as state legislatures, hospital administrators and the public at-large. Over the last several years, cancer registration standard setters have worked more collaboratively to minimize differences in data collection. They recognize that conflict in data standards and goals hampers reliable comparison studies. In addition, differing data collection standards place an undue burden on registrars in reporting facilities by requiring duplicate as well as differing data collection requirements. Most of the differences between central and hospital databases can be resolved through improved collaboration. It therefore behooves central and hospital registries to pursue the path of cooperation and collaboration by looking to the common goal and adopting methods that benefit everyone and facilitate success.

Data accuracy is also dependent upon a clear understanding of the goals of the registry. Knowledgeable and experienced individuals must oversee the design, collection, and dissemination of information. In the hospital setting, discrepancies in staging and other core data items must be resolved by interaction among the hospital registrars, the medical staff, and the central registry. To resolve discrepancies, abstracts can be shared with attending physicians to provide opportunities for discussion. The sharing of abstracts with medical staff is especially important as advances in therapies often evolve faster than many registrar’s ability to track them.

Open discussion among physicians and hospital and central registrars, provides excellent learning opportunities. Ongoing routine, as well as random, review of the data...
by multiple participants can provide an excellent system of checks and balances. Many registrars do not have access to the professional development opportunities that a multi-staff department can provide. Building a network of professional resources to act as mentors or sounding boards can enhance knowledge and confidence.

Central registries provide an objective check of data by assessing the quality and consistency of coding as it relates to supporting documentation. Without access to the patient's medical record, the central registry must rely solely on the supporting text narrative provided by the hospital registrar. Poor documentation contributes to inaccurate coding. Detailed documentation can reduce misunderstandings with the interpretation of rules and provide the opportunity to correct inaccuracies in a timely and objective manner. Clear, concise text which supports all coded fields is an essential component of any cancer abstract.

7.5.1 Computerized Edits

Standardized edits are one of the most important QA tools a cancer registry has at its’ disposal. Current cancer-reporting software, including SEER*Abs, provides computerized edit checks that are applied automatically to records as they are processed and submitted. The two (2) common types of computerized edits available in SEER*Abs, as well as commercial cancer-reporting software products, are:

- **Range Edit Checks** – which look for allowable values. If a value is outside the allowable range, the field cannot be populated (e.g., the acceptable range for ICD-O; C00_ - C80_).
- **Inter-Field Edit Checks** – which look at the relationship between variables within a single record to identify unlikely or improbable code combinations (e.g., a female with prostate cancer).

SEER*Abs also provides prompts, error messages, drop-down coding choice lists and online help (e.g., STORE Manual and SEER Program Coding and Staging Manual) to assist in making accurate coding choices.

7.5.2 Visual Edits

Although convenient, auto-coding should only be used in conjunction with a visual review of all text and codes. Computer-generated text should never be used when reporting information to the NYSCR. Text should always be entered into an abstract as it appears in the patient's medical record (i.e., in natural language). A visual review provides a check of the narrative text as it relates to the assigned codes and ensures that all information from the medical record is included in the abstract. The individuals involved in abstract review must be familiar with all data item requirements and coding instructions used by the NYSCR and be knowledgeable and well trained in abstracting cancer data from patient records.
7.5.3 Cancer File Submission Reports

As part of their QA procedures, reporting facilities should routinely review their NYSCR Cancer Case Submission Reports. These reports provide routine, detailed, and objective measures of the quality and consistency of coding. In addition to confirming receipt of batches by the NYSCR, the Cancer Case Submission Report provides a statistical breakdown of:

- the number of non-reportable tumors and early reported tumors;
- the number of records, including lab reports, within a batch that were rejected for errors and/or warnings; and
- the accepted number of records.

These variables – along with others such as percent of death certificate cases and percent of lab only cases – can be used to monitor patterns in reporting. The reporting facility should establish a procedure to retrieve, review and file all submission reports. All rejected cases and major errors identified on the submission report must be corrected and resubmitted to the NYSCR within 10 days of the original submission date. For more information on Submission Reports, see Part Eight of this manual (Electronic Reporting).

7.6 COMPLETENESS

Completeness can be assessed from two perspectives: completeness of individual abstracts and completeness of the registry’s overall database. Complete data within an abstract is necessary to avoid misleading or misconstrued conclusions regarding stage, treatment regimens or other factors that could affect the care of future patients. Obtaining all data elements is challenging for registrars given that patient care is often provided at many different facilities. Often, the cancer registry is the only place within a facility where the complete picture of a patient’s care is documented. Therefore, the cancer registry plays a crucial role in providing the facility with good QA information.

An important function in any registry’s operation is to ensure the completeness of the database. Hospital-based registries must ensure that casefinding sources such as disease indices are updated whenever ICD codes change. Caseloads from previous year(s) should be compared, to determine fluctuations. If the caseload appears to be decreasing, the registrar should check to determine whether all appropriate cases are being captured and if any major events occurred that would justify a reduction in caseload. Examples of potential reductions in caseload could be the loss of an oncologist or the termination of certain cancer-related treatment services. In such instances the registrar could expect to see a decrease in the number of cancer cases.

A casefinding audit can be performed to assess a facility’s completeness and determine if and where reportable cases are being missed. Obtaining complete treatment and follow-up information yearly from physician contacts can also assist in maintaining completeness.

At the central registry, DCOs are one method used to monitor case completeness. Inpatient facilities with incomplete casefinding may expect to see a higher DCO rate than similar facilities that are complete. For additional information regarding DCOs, refer to Part Six of this manual.
7.7 **MEASURABILITY**

For data collected by the NYSCR to be useful in research, public health planning and evaluation, it must be standardized, reliable and valid. Poorly documented, infrequently collected and/or non-standard data items are no less time-intensive to collect as are valid items. For example, quality of life and co-morbidity are topics of considerable interest. If all participants are not using the same measures, indicators, and definitions, the data are difficult to compare and difficult to interpret.

Use of this manual, as well as the SEER reporting manuals, and CoC’s Standards for Oncology Registry Entry (STORE) manual as the basis of data collection ensures that data collection is consistent among all facilities, in turn making data comparison more relevant.

7.8 **QUALITY ASSURANCE (QA) METHODS**

There are many methods available to monitor compliance of standards at both hospital and central registries. The cancer registry professional should understand the concepts of Continuous Quality Improvement (CQI) and be able to appropriately implement QA procedures.

7.8.1 **Facility Accreditation**

Obtaining and maintaining various forms of accreditation through a formalized survey process is one method healthcare facilities can pursue to ensure that QA mechanisms are in place and adhered to.

For example, the Joint Commission on Accreditation of Healthcare Organizations (JCAHO) provides standards on quality of services and data collection to which the facility must demonstrate compliance. The American College of Surgeons (ACoS), Commission on Cancer (CoC) provides standards specifically designed for quality of cancer services and data collection to which accredited facilities must demonstrate compliance. By receiving approval through a nationally accrediting body, a reporting facility’s cancer program is measured against a pre-defined standard of accountability, and quality of care. Communication is an essential component of applying for and maintaining various accreditation. Gaining accreditation is time consuming, costly, and requires cooperation and coordination of all those involved with the facility’s cancer related services.

7.8.2 **Central Registry Certification**

Central registries are affected by various standard setting organizations. Therefore, it is incumbent upon central registries to stay abreast of the reporting requirements for organizations such as NPCR, SEER, NAACCR and the CoC. This awareness is vital to the NYSCR when considering modifications to reporting requirements, and to provide the best possible communication and service to reporting facilities throughout New York State. Ongoing communication must be maintained among all accrediting organizations and central registries. This issue has become extremely important over the last few
years as there have been national efforts to collect data fields in all states and regions that are consistent, timely and meet high standards of quality.

The NAACCR Registry Certification Committee has established a process by which NAACCR Full Member Registries may annually receive an objective evaluation and confidential feedback of their achievement in case ascertainment, case linkage, completeness of information abstracted on critical variables, data accuracy and timeliness of cancer case reporting. When population-based cancer registries achieve excellence in all areas, they are certified. Certification enables each registry the opportunity to receive an objective and confidential report that identifies areas of strength and weakness. Central registries are encouraged to share their findings with appropriate partners and staff.

If used appropriately, the certification process can help a registry prioritize procedures to maximize the quality of data outcomes, achieve excellence and, ultimately, NAACCR certification.

7.9 **AUDITS**

The types of audits conducted by the NYSCR include:

- Casefinding
- Re-abstracting

The purpose of an audit is to ensure that all reportable cases are abstracted, and that the information contained in each abstract is complete and accurate. The NYSCR conducts casefinding and re-abstracting audits at reporting facilities to assess reporting completeness and monitor data validity in abstracting.

7.9.1 **Casefinding Audit**

Casefinding audits are conducted to determine whether all cases eligible for reporting have been reported for an established time period.

7.9.1.1 **Central Registry**

The goal of a central registry is to record a minimum of 95 percent of all cases of cancer or malignant disease, occurring among individuals within a designated geographic area (incidence). This involves receiving reports from all potential sources (hospitals, outpatient services, physician offices and death certificates) withing the designated geographic areas, as well as neighboring central registries and other central registries.

As previously stated, the NYSCR conducts regular, organized casefinding audits of reporting facilities. As part of a casefinding audit, field staff at the central registry review the MRDI, pathology reports, and all other applicable sources (e.g., oncology clinic logbook, radiation therapy logbook, outpatient clinics, etc.) for a specified period. Field staff make identify all reportable cancer cases within these sources, compare that list to the NYSCR’s database, and make note of any cases that do not appear in the Registry’s database.
Audits are conducted after the reporting deadline for the specified period has expired. All audit findings are clearly documented in writing to the applicable registrar(s), their supervisor, and any other appropriate facility staff, as well as to the director of the NYSCR.

### 7.9.1.2 Facilities

Complete casefinding by reporting facilities is not without its challenges, as it requires identifying reportable diagnoses from multiple sources. Cooperation and clear lines of communication with all applicable departments within the reporting facility (e.g., pathology, cytology, diagnostic radiology, and radiation oncology departments), as well as any satellite clinics and/or outpatient surgery centers which fall under the facility’s Operating Certificate, are essential to meet this goal. Requests for data that need to be forwarded to other departments can be accomplished more directly if registrars have good communication with the applicable department supervisors regarding the purpose and process of casefinding procedures.

Providing the validation and underlying principle for cooperation enhances the awareness, support, involvement and understanding necessary to capture all reportable cases. Because cancer patients are seen in multiple departments, it is necessary to look at all potential sources to accurately assess reporting completeness. Casefinding audits can identify areas where reportable cases are missed. Facilities should use this information as a tool to improve their routine casefinding procedures.

### 7.9.2 Re-abstracting Audits

Re-abstracting audits are intended to assess the quality of the data that are being reported to the NYSCR.

#### 7.9.2.1 Central Registry

With this type of audit, NYSCR staff select a random sample of abstracts the facility has previously reported. The NYSCR then provides a written request for corresponding medical records of the selected abstracts to be photocopied or scanned and sent to the NYSCR. Once received, NYSCR field staff review the medical records and create a cancer case abstract. Information collected from the documents that were received as part of the audit is then compared with the original abstract provided by the facility to identify discrepancies. Detailed reports of the results are then shared with the reporting facility. These audits are successful only when there is clear communication between the NYSCR and facility staff regarding the criteria, methods, standards, and findings. Trends involving abstracting errors, as well as any other significant coding/staging errors are regularly incorporated into NYSCR training workshops, without identifying either the patients or reporting sources involved.

#### 7.9.2.2 Hospital Registry

At the hospital/facility level, re-abstracting audits are a valuable measurement tool that can significantly contribute to data quality. For example, the cancer committee may choose to re-abstract 10 percent or more of the registry’s cases for a particular site or histology to assess agreement with abstracting guidelines.
7.9.3 **Site-specific Audits**

Periodic site-specific audits (e.g., colon, breast, lung, hematopoietic) are a valuable QA tool for both facility and central registries, as they allow registrars staff to identify potential errors and correct them quickly.

7.9.4 **Accession Register Audits**

This type of audit is undertaken to verify that all abstracted cases entered into a facility’s database have been successfully transmitted to the NYSCR.

7.9.5 **MRDI Audits**

MRDI audits consist of a review of a facility’s Medical Record Disease Index to determine whether all reportable cancer encounters have been reported for a designated period. Potentially reportable cases are identified by ICD diagnosis codes.

7.10 **QUARTERLY FEEDBACK REPORTS**

Quarterly feedback reports are used to evaluate specific data items based on predefined benchmarks. Registry data items and standards are set by the NYSCR, NPCR, SEER and/or NAACCR. One of the goals of NAACCR is to coordinate with the various standard setting organizations, so that cancer data in the US and Canada are collected in a cohesive manner, by applying unified standards.

To be successful and consistent in standardized data collection, it is recommended certain data items be evaluated regularly. It is important to know the data items that best meet the needs of local users or customers. The quarterly feedback report is a valuable tool that should be used to review data collection and improve the value of the cancer registry database.

The quarterly feedback report summarizes the reporting status of individual facilities. The time interval between diagnosis and/or discharge and transmittal of reports to the NYSCR is measured. A comparison is done on the number of unique tumors transmitted by a facility against an expected number of unique tumors, using historical reporting patterns. Completeness of reporting is determined by identifying the number of unique tumors submitted for a given year. Uniqueness is based on medical record number, social security number, date of diagnosis, ICD-O codes, and date of discharge. NYS Public Health Law stipulates that all cancers must be reported within six months (180 days).
8.1 CREATING AN EXPORT FILE
8.2 SUBMITTING TO THE NYSCR VIA THE HEALTH COMMERCE SYSTEM (HCS)
8.1 CREATING AN EXPORT FILE

The first step in preparing a file for submission to the NYSCR is the creation of an export file. Facilities using commercial software products should follow the instructions provided by their respective software vendor. Individual export files should be limited to a maximum of 500 abstracts each. Registrars should work with their software vendors to ensure that files do not contain more than 500 abstracts.

SEER*Abs users can export completed abstracts from SEER*Abs into an external file for submission to the central registry, through a direct database update.

8.2 SUBMITTING TO THE NYSCR VIA THE HEALTH COMMERCE SYSTEM (HCS)

All cancer abstracts are submitted to the NYSCR electronically via the HCS. Follow the steps below to transmit a file to the NYSCR.

1. Connect to the HCS.
2. Click CR Facility Reporting, found under the My Applications header, located to the left of the screen* (Figure 1).
3. Once on the Cancer Registry page, click Browse (Figure 2) and select the appropriate .xml or .txt file from the appropriate export folder (Figure 3).
4. Click Open (Figure 3) and the file name will appear in the Upload File box (Figure 4).
5. Click Upload (Figure 4).
6. Following completion of a successful file upload, the user should receive a message similar to that shown in Figure 5. Users should allow up to ½ hour for processing, after which the user will be able to view the file information in the same CR Facility Reporting application on the HCS website.

*If you do not have access to the CR Facility Reporting application, contact your HCS Coordinator and request s/he add the role of Facility Cancer Reporting Submitter to your HCS account. This role must be assigned separately through each facility a user submits cases for. If you have any questions, contact your NYSCR Field Services Representative at (518) 474-0971.
Figure 5
Page Left Blank Intentionally
New York State Cancer Registry Reporting Manual

Appendix A - NYS Public Health Law

Section 1. Short title.
This act shall be known and may be cited as the “Cancer Research Improvement Act of 1997”.

Section 2. Section 2401 of the public health law is amended to read as follows:

Article 24. Title 1.

§ 2401. Cancer; duty to report.

1. Every physician, dentist and other health care provider shall give notice immediately but not later than one hundred eighty days of every case of cancer or other malignant disease coming under his or her care, to the department, except as otherwise provided.

2. Whenever an examination of a tissue specimen in a laboratory discloses the existence of cancer or other malignant disease, the person in charge of such laboratory or the person making such examination shall immediately but not later than one hundred eighty days report the same together with all the facts in connection therewith to the department.

3. The person in charge of every cancer reporting facility shall immediately but not later than one hundred eighty days give notice of every case of cancer or malignant disease coming under the care of the institution to the department.

4. All abstracting work performed by a cancer reporting facility pursuant to the reporting provisions of this section shall be performed by a certified tumor registrar. Cancer reporting facilities may establish consortia to engage a certified tumor registrar to perform the reporting requirements of this section. A “certified tumor registrar” is an individual certified by a nationally recognized not-for-profit organization which certifies tumor registrars. The provisions of this subdivision shall not apply to any cancer reporting facility which renders services for one hundred or fewer cases of cancer and malignant disease per year as determined by the commissioner.

5. The department shall establish and update as necessary a manual designating which specific data elements shall be reported to the department pursuant to this section. The department shall make such manual available to every cancer reporting facility, physician, dentist, and other health care provider required to comply with the provisions of this section.
6. The department shall establish and update as necessary a data dictionary to standardize information interpretation of data elements reported by cancer reporting facilities and other health care providers. The department shall make such dictionary available to every cancer reporting facility, physician, dentist, and other health care provider required to comply with the provisions of this section.

7. The department shall, to the extent funds are made available, establish or contract for regional training programs to provide training to any cancer reporting facility, physician, dentist, or other health care provider required to comply with the provisions of this section. Such regional training programs shall provide training relating to the specific data elements which must be reported pursuant to this section, the data dictionary established pursuant to this section, and any other subjects which are intended to ensure quality, timely and complete compliance with this section.

8. The department shall, meet cancer registry goals established by a nationally recognized central cancer registry organization unless any such goal is contrary to any provision of law.

9. Where a cancer reporting facility fails to comply with the provisions of this section, the department may elect to perform registry services for such facility. Such cancer reporting facility shall reimburse the department for actual expenses incurred.

10. A physician, dentist, laboratory, cancer reporting facility or other health care provider which violates any provision of this section shall be subject to a civil penalty as provided in section twelve of this chapter.

11. The notices required by this section shall be upon forms supplied by the commissioner and shall contain such information as shall be required by the commissioner.

12. For the purpose of this section, a "cancer reporting facility" means a hospital as defined in article twenty-eight of this chapter, clinic or any organization certified pursuant to article forty-four of this chapter, or other similar public or private institution.

13. The commissioner shall have the power to promulgate any such rules and regulations as shall be necessary and proper to effectuate the purposes of this section.

§ 2401-a. Reporting.

1. Annual report. The commissioner shall, submit an annual report to the governor, the temporary president of the senate and the speaker of the assembly. The report shall include an evaluation of the cancer registry as it relates to timeliness, quality and completeness; an evaluation of the utility of the registry for scientific research; an evaluation of the access, timeliness and quality of reporting information to researchers and other similar individuals; an evaluation of the registry's data elements, including treatment, stage of disease, occupation and residence; an evaluation of the feasibility and utility of inclusion of occupational history and residence history; and an evaluation of integrating the registry with other data bases maintained by state agencies and departments, including the statewide planning and research cooperative system.
2. Quarterly report. The commissioner shall submit a quarterly report to the governor, the temporary president of the senate and the speaker of the assembly. The quarterly report shall include an evaluation of whether the registry is achieving cancer registry goals established by a nationally recognized central cancer registry organization, including numerical goals concerning timeliness, quality, and completeness.

3. Skin cancer reporting. The department shall annually submit a written report to the governor and the legislature on the incidence of skin cancer in the state of New York, by type and as a percentage of the overall number of reported cases of all types of cancer, as well as the associated causes of each type of skin cancer, if such causes are readily ascertainable. Such report shall be generated based on data gathered and reviewed pursuant to this title and shall provide information which is as current as practicable; provided, however, a retrospective of the past ten years of information collected pursuant to this title and predominant trends associated with such information, as concerns skin cancer and its associated causes, shall be a component of such report and each report submitted thereafter. At the discretion of the commissioner, such reports may provide additional information other than the information required by this subdivision. The first report created pursuant to this subdivision shall be submitted one year after the effective date of this subdivision. The reports generated pursuant to this subdivision shall be made available to the public on the department's website.

§ 2402. Cancer; reports confidential.

The reports of cancer cases made pursuant to the provisions of this article shall not be divulged or made public so as to disclose the identity of any person to whom they relate, by any person, except in so far as may be authorized in the sanitary code.
This information sheet has been prepared to clarify and confirm the authority of NYSCR staff to access patient medical records relating to the diagnosis and treatment of cancer. Access to this information is sought under NYSDOH authority, pursuant to Public Health Law 2401, which provides that “… every physician or other health care provider shall give notice immediately but not later than 180 days of every case of cancer or malignant disease coming under his or her care, to the Department of Health, except as otherwise provided.”

Such access has been determined by the NYSDOH/NYSCR to be the minimum necessary for protected health information for the state purpose in compliance with 45 C.F.R. s164.502. Please note that federal regulations permit reasonable reliance given attendant circumstances regarding requests for information made by public officials for stated purposes. [45 C.F.R. s164.514(d).]

The NYSDOH is a “public health authority”, as defined by the Health Insurance Portability and Accountability Act of 1996 (HIPAA). Federal regulations [see 45 C.F.R. s164.512] authorize disclosure without patient consent in a number of circumstances, including the following:

Disclosure is permitted to a public health authority authorized by law to access information to prevent/control disease, injury, disability, e.g., disease reporting, vital statistics reporting, public health surveillance, public health investigations, public health interventions and partner notification.

Because the NYSDOH is a public health authority and because cancer reporting and surveillance are required by state law, it is not necessary to complete a business associate’s agreement before providing the NYSCR with the requested personally identifiable information. The requested information is needed to conduct public health surveillance and will remain confidential.

If you have any questions with respect to the NYSCR’s authority to access protected health information, please contact Colleen Sherman, Director, NYSCR, at 518-474-0971.
Frequently Asked Questions and Answers
About HIPAA and Cancer Reporting

The below FAQs and answers about HIPAA were excerpted and revised by New York State from a document prepared by the North American Association of Central Cancer Registries (NAACCR). If you have any specific questions about HIPAA and cancer reporting that are not addressed below, please contact your NYSCR representative.

1. What is a ‘Public Health Authority’ under HIPAA?

Under HIPAA, a ‘Public Health Authority’ refers to “an agency or authority of the United States, a State or territory, a political subdivision of a State or territory, or an Indian tribe, or a person or entity acting under a grant of authority from or contract with such public agency, including the employees or agents of such public agency or its contractors or persons or entities to whom it has granted authority, that is responsible for public health matters as part of its official mandate.” 1 “...Such agencies are authorized by law to collect or receive such information for the purposes of preventing or controlling disease, injury, vital events such as birth or death and the conduct of public health surveillance, public health investigations and public health interventions.” 2 Central cancer registries are considered public health authorities because their duties are mandated by state laws.

1 C.F.R. 164.501
2 C.F.R. 164.512

2. What is a ‘Covered Entity’ under HIPAA?

A ‘Covered Entity’ is a health care plan, a healthcare clearinghouse, or a health care provider who transmits any health information in electronic form for financial and administrative transactions. A ‘health care provider’ is “a provider of medical or health services and any other person who furnishes, bills or is paid for health care in the normal course of business.” 1

1 C.F.R. 160.103

3. How does HIPAA impact the data collection of non–reportable/benign diseases (i.e., benign brain, CIN III, Co-morbid conditions)?

HIPAA does not obstruct any state law that supports or mandates the reporting of such cases.
4. Are private practice physicians still required to report new cancer cases?

Yes, reporting is required when in compliance with state reporting regulations. The central cancer registry has a reportable list that identifies which cancers are reportable and all reportable cancers should be reported, as required by state law.

5. What, if any, are the consequences of not reporting new cancer case information to the New York State Cancer Registry?

Penalties for failing to comply with state reporting are specified in the state law. A fine may be levied up to $2,000 per violation and if violation is willful, imprisonment of up to one year is possible. PHL § 12 and 12-b.

6. Doesn’t HIPAA nullify or preempt the state law for reporting cancer cases to central cancer registries?

No. Public health reporting under the authority of state law is specifically exempted from HIPAA preemption, per 45 C.F.R. § 160.203(c).